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Oral consumption is the most commonly used method of small molecule drug delivery due 
to its simple administration, flexible formulation design, cost-effectiveness and established 
production technology. The typical pathway for an orally ingested drug involves dissolution in the 
gastrointestinal fluid, followed by permeation across the gut membrane and systemic circulation 
until it reaches the point of action. The rate of dissolution is therefore of critical importance to 
ensure high drug adsorption and maximum efficacy. The Biopharmaceutical Classification System 
(BCS) classified active pharmaceutical ingredients (APIs) into 4 categories based on their 
solubility and permeability among which BCS class II APIs are defined as being poorly soluble 
but highly permeable. The share of BCS class II APIs of newly developed drugs has increased 
from 30% to 60% in recent years. Therefore, it is critical for the industry to incorporate effective 
formulation approaches for improving solubility and dissolution rates of these APIs. In this regard, 
a number of approaches have been investigated. Amorphous solid dispersion (ASD) is a successful 
approach for transforming and stabilizing crystalline drugs to amorphous form with higher 
solubility/dissolution rates. Spray drying (SD) is a solvent-based drying method that has been used 
for formulating ASDs with improved solubility and stability.  
Biopharmaceuticals are pharmaceuticals that are inherently biological in nature and 
manufactured using biotechnology. This broad definition includes any type of blood product, 
vaccines, antibodies, proteins and nucleic acids. Protein-based pharmaceuticals are among the 
fastest growing categories of therapeutic agents. Therefore, the development of stable protein-
based formulations with controlled physicochemical properties is of high interest. Reversible and 
irreversible aggregation in liquid protein formulations specifically at high concentrations is a 
challenging problem for biopharmaceutical producers. Spray drying is (SD) is a solvent-based 
technique in which solutions are atomized and dried using heat in a drying chamber. It is known 
for its high throughput and compatibility with continuous manufacturing. SD has previously been 
demonstrated as an effective technique for the preparation of ASDs and it has been used as an 
alternative method to freeze-drying for drying and stabilizing high concentration formulations of 
biopharmaceuticals. To date however, the development of spray drying processes for large 
biomolecules has proved challenging primarily due to protein/enzymatic inactivation caused by 
high drying temperatures and the shear stress induced by atomization. Overcoming this issue will 
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require a comprehensive understanding of the effect of formulation and process parameters on 
spray dried biological formulations.  
Chapter 1 reviews the fundamental principles of SD by explaining every individual step 
of the process from atomization to the drying chamber set up. It comprehensively covers the 
applications of SD in preparing ASDs and formulating stable biopharmaceuticals. The effect of 
process and formulation parameters on SD of biopharmaceuticals such as vaccines and proteins 
for pulmonary delivery applications are discussed. This follows an attempt to elucidate the 
systematic use of the Design of Experiment (DoE) approach for optimizing the SD process for 
different applications to conclude this chapter.  
Chapter 2 highlights the use of the DoE approach for formulating ternary ASD 
compositions of Ibuprofen (IBU) as a model BCS class II API. Based on the DoE approach a range 
of 16 formulations of IBU, HPMCP-HP55 and Kollidon VA 64 were spray dried. Statistical 
analysis was employed to decipher the interrelation of various SD process and formulation factors, 
namely solution feed rate, inlet temperature, API to excipients ratio and dichloromethane (DCM) 
/methanol (MeOH) ratio. The significance of composition (IBU:excipient) was shown as the 
determining factor in preparing stable ASD formulations. The effect of intermolecular interactions 
was investigated by Fourier-Transform Infrared spectroscopy (FTIR) and Carbon-13 Solid-State 
Nuclear Magnetic Resonance spectroscopy (ssNMR) analyses indicating that hydrogen bond 
formation between the carboxyl groups of IBU within the ASDs is highly likely. Studies show that 
the solubility of IBU in ASD formulations is improved relative to pure IBU. This was attributed 
to both the amorphous structure of IBU and of the existence of amphiphilic excipient, Kollidon 
VA64, in the formulation. This study indicates that ASD is an effective strategy for improving the 
dissolution rate of IBU as a BCS class II API.  
Chapter 3 investigates the influence of three different solvent-based techniques on the 
physicochemical properties and quality of ASDs of IBU. Solvent-based techniques of 
electrospinning (ES), spray-drying (SD) and rotary evaporation (RE), were used for formulating 
ASDs of IBU as a model BCS class II API with two cellulosic excipients, HPMCAS and HPMCP-
HP55 in an attempt to determine the effect of processing technique on the critical quality attributes 
(CQAs) of ASDs. Principal component analysis (PCA) of Raman spectra of crystalline and 
amorphous IBU was used for qualitative analysis of the homogeneity of ASDs as a determining 
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factor for the stability of ASDs during long-term storage. Results show that while ASD formation 
is solely dependent on API:excipient ratio, the ASD homogeneity is totally dependent on the 
processing technique. Samples produced by ES gave the least homogenous ASD compared with 
RE and SD samples potentially influencing long-term storage stability. Moreover, ES samples had 
the highest API release rate which was further confirmed to be due to the nanofibrous morphology 
and higher specific surface area of these samples. The presence of crystalline IBU in samples and 
the ASD forming strengths of each of the polymers was assessed by Differential Scanning 
Calorimetry (DSC). The higher melting point depression, higher glass transition temperature (Tg), 
and increased abundance of functional groups suitable for hydrogen bonding of HPMCAS proved 
it to be a significantly better ASD former relative to HPMCP-HP55. This chapter concludes by 
outlining the significance of the three solvent-based processing techniques (ES, SD and RE) on 
the physicochemical properties of ASDs such as dissolution rate, specific surface area and 
homogeneity, factors that could ultimately affect their stability and downstream processing 
capacity. 
Chapter 4 develops a rational approach towards the spray drying of biopharmaceuticals 
using lysozyme as a model biomolecule. A two-step approach is suggested towards a 
comprehensive understanding of the behaviour of large biomolecules during the spray drying 
process with a view to developing tailored spray drying protocols for biological molecules. A full 
factorial Design of Experiments (DoE) was employed to define the most critical process and 
formulation parameters. With respect to parameters such as feeding rate, outlet temperature (Tout) 
and feed solid concentration, Tout was determined to be the most statistically significant factor 
affecting the enzymatic activity of lysozyme based on screening analysis of the DoE. The second 
step of the study involved performing forced deactivation studies to identify critical points of 
potential enzymatic deactivation during the drying process. This was performed by investigating 
the inactivation of lysozyme both in solution and solid-state at wet-bulb (Twb) and outlet 
temperatures respectively. Results show that there is no substantial inactivation of lysozyme in 
solution at Twb (35-45 °C). However, lysozyme in solid form experienced a significant degree of 
inactivation when heated to temperatures similar to Tout (70-90 °C). This inactivation was fitted by 
an Arrhenius equation, where the inactivation energy and Arrhenius constant were estimated. The 
approaches and models presented herein provide a roadmap for improved understanding of the 
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critical process and formulation parameters required for the successful spray drying of large 
biomolecules.  
Chapter 5 summarises the additional contributions the author made during his Ph.D. 
period. It consists of a brief introduction to the results of three different projects on which the 
author is listed as a co-author:  
1. Particle engineering of lignin via spray drying as a potential excipient for the 
pharmaceutical industry.  
2. Co-crystal polymorphic control by nanodroplet and electrical confinement. 
3. A study on the effect of polymeric excipient on the downstream processing of hot-melt 
extruded cocrystals of ibuprofen.  
Chapter 6 provides a conclusive overview of the whole thesis.  
Chapter 7 discusses potential future directions in the field of spray drying of 
pharmaceuticals and biopharmaceuticals. If applied correctly spray drying as one of the leading 
continuous drying and formulating techniques in small molecule sector possess immense potential 
to become a major player in processing large molecule APIs as well. 
This thesis follows two main objectives: 
Firstly, developing novel ternary amorphous solid dispersions via spray drying for 
improving the dissolution and physicochemical properties of BCS class II APIs. In an attempt to 
meet this goal, the design of experiment (DoE) approach as part of the quality by design (QbD) 
strategy in pharmaceutical and biopharmaceutical industry was used for simultaneous analysis of 
interrelations of process and formulation techniques. Chapters three and four are focused on spray 
drying novel ternary amorphous solid dispersion of ibuprofen as a small molecule API with low 
aqueous solubility. 
Secondly, enabling the spray drying of biopharmaceuticals via a systematic understanding 
of the effect of process and formulation factors on the bioactivity and physicochemical properties 
of the large molecule API. The DoE approach was chosen as an approach with care for elucidating 
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Spray drying is increasingly becoming recognized as an efficient drying and formulation 
technique for pharmaceutical and biopharmaceutical processing. It offers significant economic and 
processing advantages compared to lyophilisation/freeze-drying techniques even though the 
optimisation of process parameters is often a costly and time-consuming procedure. Spray Drying 
has primarily been used in formulating small molecule drugs with low solubility however it is 
increasingly being applied to the processing of large biomolecules and biopharmaceuticals. This 
review examines the basics of the spray drying process, current technology and various 
components used in spray drying process. Moreover, it is focused on introducing critical 
formulation and processing factors in spray drying of small molecule drugs and large 
biomolecules, their similarities and differences. Finally, it provides an overview of the 
experimental optimisation strategies designed to achieve optimum spray drying results in the 
















1.1 Introduction  
Spray drying is the process of converting a solution, suspension or emulsion into dried 
powder in a single step by passing an atomized spray through a high-temperature gaseous medium, 
and was first developed in 1860 (Pency, 1872). The dairy (Schuck et al., 2016, Schuck, 2002) and 
food (Gharsallaoui et al., 2007, Truong et al., 2005) processing industries were the first examples 
of the industrial use of spray drying technology followed thereafter by the pharmaceutical industry. 
Despite the technological challenges of spray drying on an industrial scale, it has become an 
indispensable part of the pharmaceutical, food, ceramic, and dairy industries. Spray drying is 
known to offer the following advantages: (1) consistent powder quality throughout the entire 
drying process; (2) controllable continuous processing; (3) wide range of dryer designs for specific 
applications and capacities; (4) applicable to both heat-sensitive and heat-resistant materials; (5) 
suitable for various type of feedstocks including slurries, emulsions, pastes, or melts; (6) a low 
cost, scalable and consistent technique for formulating low solubility small molecule drugs via 
preparing amorphous solid dispersions; (7) significant time/cost savings in processing large 
biomolecules when compared to lyophilization. Despite many significant advances in the field of 
spray drying, the application of this technique to biologically complex, high-value therapeutic 
products such as biopharmaceuticals still requires extensive research that can only be achieved by 
a combination of experimental protocols, statistical analysis, and advanced computational 
modelling (Van Eerdenbrugh and Taylor, 2011).  
Experimental protocols are extensively used for optimising the process and formulation 
factors of spray drying specifically in pharmaceutical research. Statistical design of experiment 
(DoE) approaches are exploited in order to devise a sufficient number of experiments for defining 
the multidimensional relationship between factors and responses, and such approaches have played 
a significant role in the optimisation of spray drying operating parameters for a variety of products 
(Couto et al., 2013, Dufour et al., 2015, Liu et al., 2016) .  
Mathematical modelling and Computational Fluid Dynamics (CFD) based modelling 
techniques offer enormous potential when developing predictive models of the spray drying 
process, thereby potentially reducing the time required for process optimisation (Keshani et al., 
2015b, Straatsma et al., 1999). However, there are still significant gaps in understanding the real 
advantages of these modelling techniques in topics such as spray drying of biomolecules and 
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amorphous solid dispersions (ASDs) for formulating active pharmaceutical ingredients (APIs). 
Thus, other modelling techniques such as single-droplet drying models are required to effectively 
predict the critical attributes such as morphology, radial chemical composition and thermal 
deactivation of the biomolecules. 
This article reviews experimental considerations and techniques in relation to the spray 
drying of pharmaceuticals, biopharmaceuticals and optimisation techniques. The spray drying 
process itself is described in the first section of the review. Subsequent sections discuss the critical 
process parameters in relation to the spray drying of ASDs of poorly soluble small molecule drugs. 
The production of biopharmaceuticals suitable for pulmonary delivery and vaccine stabilization as 
two of the most recent and fastest expanding applications of spray drying are covered 
subsequently. Finally, an overview of different approaches to optimise the spray-drying process 
via experimental techniques is given.  
1.2 Background and Fundamentals of Spray Drying 
1.2.1 General principles of spray drying  
Figure 1.1 shows a schematic of a laboratory scale spray dryer. A typical spray dryer 
consists of four main components, namely the drying chamber, atomizer (nozzle), aspirator, and 
collection cyclone (Ameri and Maa, 2006). A standard spray drying process consists of the 
atomization of the prepared feedstock to produce droplets of a certain size. Various atomizers can 
be used depending on the required droplet size, solution viscosity and desired feed rate. Atomized 
droplets encounter a high-temperature gas stream (temperature depends on many factors such as 
type of solvent or solvents, materials degradation or denaturation temperature, glass transition 
temperature, etc.) resulting in solvent evaporation and the production of solid particles. Finally, 
the dried particles will be separated from the outlet gas stream, by cyclone. The whole process 
occurs in a timeframe of few seconds. The properties of the final powder can be altered by variation 








Figure 1.1; Schematic representation of spray drying without recirculation loop (BUCHI-290), (a) gas is sucked by 
aspirator; (b) gas is heated up to defined inlet temperature and flows into drying chamber; (c, d) feeding liquid is pumped into 
atomizer with predefined flow rate; (e) heated gas comes in contact with atomized feed and drying takes place in main chamber, 
(f) dried particles are separated from gas stream in the cyclone due to the pressure drop; (g) the final particles are collected 
(Ameri and Maa, 2006). 
 
1.2.2 Spray drying setup and configuration 
The modular characteristic of lab-scale spray dryers enables them to manipulate the particle 
properties. The process can be modified in terms of its cycle mode, types of atomizer and airflow 
pattern which are reviewed briefly in the following sections. However, this modularity becomes 
limited in industrial scale due to the financial and technological difficulties for instance, while 
changing atomizer or airflow are feasible in industrial-scale changing cyclone or drying chamber 
geometry might be very costly.  
Cycle mode 
Typical spray drying process can be done in one of two cycle modes, the choice of which 
is dependent on the type of solvent (organic/aqueous) entering the main drying chamber. In order 
to prevent the release of organic solvents into the environment, decrease the risk of explosion at 
high temperatures and reduce the vulnerability of the final product to oxidation, reduce cost and 
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recover solvents for reuse, a closed loop setup in combination with a condenser is preferred. During 
this process the outlet gas stream is directed to the condenser where organic solvent vapour is 
condensed and collected while the dried gas stream is returned to the drying chamber. In addition, 
an inert gas such as nitrogen is typically used as the gas flow stream to reduce the chance of organic 
solvent explosions at high temperatures. Moreover, closed loop may be preferred for aseptic 
formulation preparations even if the solution is aqueous. The open loop setup is employed in cases 
where an aqueous or water-based feedstock is to be dried. In this case, ambient air can be used as 
the drying gas stream without the necessity of using condenser as the outlet gas goes directly to 
exhaust (Aundhia et al., 2011). 
Atomization 
In terms of the spray-drying process, atomization is a critical step in the production of 
droplets with specific size distribution and desired morphology (Ledet et al., 2015). The 
atomization process influences the physical properties of the final product including particle size, 
drying chamber residence time and product morphology. Regardless of the type of atomizer used, 
the atomization process is affected by complex interrelated factors such as shearing and inertial 
forces, surface tension, droplet viscosity and droplet size distribution, all of which affect the angle 
and velocity of the atomized spray. The internal geometry of the atomizer is also highly influential 
in defining the final properties of the powders (Gaspar et al., 2014). There are several types of 
atomizer/nozzles used in the spray drying industry, the most prevalent of which are discussed 
below.   
Rotary Atomizer: Rotary atomizers are available in two categories: (a) atomizer wheel 
and (b) atomizer disc. Rotary atomization is based on centrifugal energy created by the atomizer 
motor. As the liquid feed passes across or through a rotating wheel or disk. The liquid feed breaks 
into droplets due to the centrifugal force of the rotating disc (Lefebvre and McDonell, 2017). With 
this type of atomizer, the range of possible droplet sizes is typically broader compared with other 
nozzles (10-500 μm) (Miller et al., 2016). Given that the evaporation rate is proportional to the 
diameter of the atomized droplet squared, larger droplets will require much longer drying time and 
a wider drying chamber to enhance the drying process. The average droplet and particle size is 
dependent on the size and diameter of the grooves within the nozzle core, speed of the wheel and 
feed rate. This atomizer is often preferred for viscous fluids where it has been shown to produce a 
relatively uniform droplet size. Also, high feeding capacities of wheel designs (up to 200 t/h) make 
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them a suitable choice for industrial applications (Figure 1.2) (Aundhia et al., 2011). Numerous 
equations are available for estimating median droplets size (D50), with an example being: 
𝐷50 = 0.008 ×  𝐹𝑓𝑒𝑒𝑑
0.15  ×  𝐷−0.18  ×  𝑁−0.05  ×  𝜔−0.75  × 𝜇𝑓𝑒𝑒𝑑
0.07    (1) 
where 𝐹𝑓𝑒𝑒𝑑 is feed flow rate, 𝐷 is the disk diameter, 𝑁 is the number of blades, 𝜔 is the 
blade speed and 𝜇 is the feed viscosity (Masters, 1985).   
 
Figure 1.2; Schematic representation of a rotary atomizer, (a) liquid feed goes through the spindle tube; (b) and (c) the 
spindle which is attached to the wheel/disc rotates with the defined rotation speed; (d) wheel/disc rotates with the defined speed; 
(e) due to the centrifugal force liquid feed is thrown out of the openings (Aundhia et al., 2011). 
 
Single-fluid (hydraulic or pressure) nozzle: single-fluid nozzles are operated by pumping 
the fluid through a die or orifice under pressure and are typically used when a narrow droplet size 
distribution (mean size 10-400 μm) is required (Miller et al., 2016). The feed swirls within the 
swirling chamber of the atomizer and departs the nozzle as a cone-shaped spray. The average 
droplet size is a function of feed rate, viscosity and pressure. For highly viscous feeds, pressures 
up to 800 atm are required for proper atomization (Figure 1.3). Equation 2 provides an estimation 
of D50 of droplets produced through pressure nozzles (Lefebvre and McDonell, 2017):  
𝐷50 = 4.0 × 𝐹𝑓𝑒𝑒𝑑
0.25  ×  ∆𝑃𝑓𝑒𝑒𝑑
−0.5  × (𝜎𝑓𝑒𝑒𝑑  × 𝜇𝑓𝑒𝑒𝑑)
−0.25 × 𝜌𝑓𝑒𝑒𝑑
0.07                (2)  
where, 𝐹𝑓𝑒𝑒𝑑 is feed flow rate, ∆𝑃𝑓𝑒𝑒𝑑 is the pressure, 𝜎𝑓𝑒𝑒𝑑 is the surface tension, 𝜇𝑓𝑒𝑒𝑑 is 




Figure 1.3; Schematic representation of single-fluid (hydraulic/pressure) nozzle; the feedstock enters the swirling 
chamber with high pressure and as it exits the tip of the nozzle it breaks into droplets (Aundhia et al., 2011). 
 
Pneumatic (multi-fluid) nozzle: In a pneumatic or multi-fluid nozzle the liquid feed is 
atomized by a gas stream (air or an inert gas such as nitrogen) which breaks up the feed stream 
into droplets at the tip of the nozzle (Figure 1.4). The average droplet size, in this case, is controlled 
by feed rate, atomizing gas rate and pressure. Pneumatic nozzles are used for making extremely 
fine droplet size (10-100 µm) and are widely used in the pharmaceutical sector (Miller et al., 2016). 
Lubanska presented the following equation for predicting D50 of the sprayed droplets via the two-
fluid nozzle as a type of multi-fluid nozzle:  








      (3) 
where 𝐾𝑑 is a constant, 𝐷𝑛 is the orifice diameter in the atomizer, 𝜂𝑓𝑒𝑒𝑑 and 𝜂𝑔𝑎𝑠 are the 
kinematic viscosities of the product and gas, 𝐹𝑓𝑒𝑒𝑑 and 𝐹𝑔𝑎𝑠 are the feed and drying gas flow rates 





Figure 1.4; Schematic representation of a two-fluid nozzle; the feedstock meets atomizing air at the tip of the nozzle and 
breaks up into droplets (Aundhia et al., 2011). 
 
Ultrasonic nozzle: An ultrasonic nozzle works by employing a high-frequency electrical 
signal to two electrodes that are placed between two piezoelectric transducers which then begin to 
vibrate (Figure 1.5). The final vibration is then amplified by a titanium nozzle tip (Cal and 
Sollohub, 2010). This type of nozzle produces more uniform and larger droplets and is less prone 
to clogging due to its self-cleaning ability. Moreover, it produces droplets with a relatively lower 
velocity which provides longer residence time in the drying chamber. Ultrasonic nozzle is capable 
of producing the widest range of droplets with a median size of 5-1000 µm (Miller et al., 2016).  
 
Figure 1.5; Schematic representation of ultrasonic nozzle; the liquid feedstock breaks up into droplets at the tip of the 




Overall, selecting the type of atomizer is dependent on the viscosity of the feed and the 
amount of energy available for atomization. In general lower viscosity liquids can be atomized to 
smaller droplets compared to liquids with higher viscosity at constant level of atomization energy 
(Wisniewski, 2015). Increasing the atomization energy leads to smaller droplet sizes. Droplet size 
affects final particle size which can be a critical quality attribute in applications such as pulmonary 
drug delivery. Selecting the proper atomizer depends on the feed properties (suspended particles, 
viscosity, rheological behaviour), particle size distribution requirements of the final product and 
feed flow capacity requirements (Miller et al., 2016).  
Airflow  
Spray dryers are classified based on the flow pattern within the drying chamber. This is an 
important factor defining the air-droplet interaction. It is based on the position of atomizer in 
relation to the inlet airflow. 
Figure 1.6 shows three types of airflow patterns that are commonly used, namely co-
current, counter-current and mixed flow. In the co-current arrangement, the drying air and droplets 
move in the same direction from the top of the drying chamber to the bottom (Figure 1.6a). This 
setup would be suitable option in the case of spray drying of heat sensitive materials (Masters, 
1985) however, they are in use for other types of materials as well. In this arrangement, the overall 
temperature of the droplet is lower compared with co-current and mixed flow arrangements during 
the most intense stage of drying where the droplet temperature is below the wet-bulb temperature 
(T < wet-bulb temperature). Thus, the droplet temperature does not rise markedly as it is in contact 
with lower temperature gas. In the counter-current arrangement (Figure 1.6b), the feed and drying 
gas, flow in opposite directions. As droplets encounter hot gas at the end of the drying chamber 
(at this stage droplets must be in the last stage of the drying process, i.e. wet-bulb temperature), 
their outlet temperature is higher compared with the co-current setup. Thus, the counter-current 
arrangement provides higher thermal efficacy for drying materials with a longer drying cycle 
(Masters, 1985). However, it might not be the best option for thermally sensitive materials (e.g. 
biopharmaceuticals) due to the higher outlet temperature compared with co-current arrangement. 
Moreover, final particle size is usually double the diameter of those in the co-current process 
because of the intensive agglomeration and as such is widely used in the production of detergents, 
fertilizers and certain food substances (Chhabra and Kreith, 2017).  
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Mixed flow is a combination of co-current and counter-current air flows. The atomizer is 
placed in the central part of the drying chamber and the solution is sprayed upward or downward 
(based on its thermal stability) while the airflow is downward. Mixed flow mode offers greater 
flexibility for drying materials with varying degrees of thermal stability. For drying powders with 
high thermal stability, the upward spraying direction may be used while for thermally sensitive 
materials the downward stream is used to decrease the air-droplet contact time (Masters, 1985). 
 
Figure 1.6; Types of airflow in spray dryer (a) mixed flow, (b) counter current, (c) co-current (Wisniewski, 2015). 
 
1.2.3 Critical Factors for Successful Spray Drying  
Particle formation 
Regardless of the application, control of the size and morphology of the particles is 
considered to be critical. Drug performance will be highly affected by its physical and chemical 
properties, namely aerodynamic properties, dissolution rate, flowability, compressibility and 
particle size distribution (Vicente et al., 2013, Liversidge and Cundy, 1995). In the last decade, the 
trend has been moving from the empirical design of particles to fundamental modelling of the 
underlying phenomena of particle formation (Vehring, 2008).  
(a) (b) (c) 
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The key factor in successful particle engineering strategies is understanding the underlying 
mechanisms and controlling the radial distribution of components during the spray drying process 
(Vehring et al., 2007). Surface activity and evaporation rate have been shown to be two of the most 
critical factors in defining the radial distribution of individual components. Surface activity may 
lead to the preferential orientation of the components on the surface while, by evaporation from 
the surface, the concentration of the components at the surface increases resulting in a flux of 
concentration away from the surface. Thus, understanding that evaporation is a coupled mass and 
heat transfer issue is essential. Various numerical models have been developed for multicomponent 
droplets drying (Chen, 2004, Adhikari et al., 2004). Vehring introduces a fundamental model for 
drying of droplets in the absence of internal convection i.e. the chemical components in an 
evaporating droplet can be described by the non-linear diffusion coefficient (Vehring, 2008, 
Vehring et al., 2007). Fick’s second law of diffusion for droplets with constant evaporation rate, 
at constant diffusion coefficients and negligible interactions between the solutes, has an analytical 
solution: 
𝑑2(𝑡) =  𝑑0
2 − 𝜅𝑡         (4) 
Where, d is the diameter of the droplet, d0 is the initial diameter of the droplet, 𝜅 is the 
evaporation rate and t is time.  
Based on this equation, drying time could be approximated as well as evaporation rate. 
Moreover, rearranging the solution of the diffusion equation, leads to the calculation of surface 
enrichment, Ei, which is the surface concentration of component i in proportion to its average 
concentration in the droplet:  






         (5) 
Where, 𝑐𝑠,𝑖 is the surface concentration of component i, 𝑐𝑚,𝑖 is the average concentration of 




          (6) 
The Peclet number is a dimensionless number showing the ratio of diffusional motion of 
the solutes to the radial velocity of the receding droplet surface (Vehring et al., 2007) where 𝜅 
represents the evaporation rate and Di is the diffusion coefficient of solute i.  
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A low Peclet number (Pe < 1) at a specific feed concentration leads to the droplet surface 
receding at a normal pace while solid particles have enough time to rearrange, leading to limited 
void space, a denser particle and, therefore, higher bulk density of the final powder. Compounds 
with a higher diffusion coefficient can keep up with the rate of shrinkage of the droplet surface so 
it will be distributed homogeneously throughout the final particle. In a solution containing several 
compounds, the compound with the lowest diffusion coefficient will most likely precipitate at the 
microsphere surface. The Peclet number can be affected by a mixture of material properties of 
solutes and solvents and process factors that determine the evaporation rate. Hence, surface 
enrichment could be manipulated by extremely high or low evaporation rates. The effect of solvent 
evaporation rate and solute diffusion coefficient on the final morphology of the spray dried 
particles has been reported elsewhere (Rizi et al., 2011, Vehring, 2008).  
The differential diffusion coefficient of various components of the solution affects the 
physical properties of the powder. At constant evaporation and feed concentration rates, a low 
diffusion rate/high evaporation rate (Pe > 1) denotes the slow diffusional movement of the solute 
compared to the receding speed of the droplet surface. Depending on the type of solute, different 
solidification scenarios may happen. Molecules with high initial saturation and fast crystallization 
kinetics may have crystalline phase separation while others may not have enough time for 
crystallization. This results in the formation of particles with decreased density since shell 
formation occurs earlier in the evaporation process. Large biomolecules such as peptides (Zijlstra 
et al., 2004, Ståhl et al., 2002) and proteins (Maury et al., 2005) are usually reported as forming 
hollow, wrinkled or dimpled particles. The diffusion coefficient can be expressed using the Stokes-
Einstein equation:  
𝐷 =  
𝑘𝐵𝑇
6𝜋𝜂𝑟
          (7) 
where D is the diffusion coefficient, 𝐾𝐵 is the Boltzmann constant, r is the hydrodynamic 
radius, T is the absolute temperature, and 𝜂 is the solution viscosity. The diffusion coefficient is 
inversely related to the viscosity of the solution and the hydrodynamic radius of the components 
in the droplet. 
As the diffusion coefficient and evaporation rate are not constant, thus the Peclet number 
is also not constant. It means that the Peclet number might vary as the droplet evaporation 
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progresses. This is in the co-solvent system where there are two different evaporation rates. 
Moreover, in cases where a phase transition e.g. crystallization might happen during the process, 
the Peclet number can change dramatically. Some of the low solubility peptides or amino acids are 
in this category (Vehring, 2008). The Peclet number could have a significant role in optimising 
the desired final particle properties. Therefore, it is necessary to be familiar with the process and 
formulation factors that influence it during the drying process. The next section will introduce 
these factors in spray drying of small and large molecules.  
1.2.4 Pre-requisites of producing amorphous solid dispersion with spray drying 
The influential factors in the spray drying process fall into two main categories: feed 
solution factors, and process factors. The former consists of the feed solution viscosity, surface 
tension, density, chemical stability and feed composition. The process factors are mostly machine-
related factors such as inlet/outlet temperature, feed rate, atomizing gas flow rate, atomizing gas 
type, nozzle type, airflow pattern and drying gas flow pattern. The interrelations of these factors 
make optimisation of the spray drying process a complex procedure. In an attempt to overcome 
this challenge, researchers have adopted a DoE approach thereby allowing effective interpretation 
of the interplay between different variants (Dufour et al., 2015, Liu et al., 2016, Cerpnjak et al., 
2015).  
Understanding the reasons behind the morphology of a particle, size, functional layers or 
aerodynamic properties requires a sound knowledge of a particle formation process. This leads to 
further research into physical and chemical mechanisms controlling the drying process and particle 
formation during spray drying process. Several experimental techniques have been devised for 
investigating these phenomena including suspending droplets from glass filaments (Lin and 
Gentry, 2003), levitating droplets using ultrasonic waves and moving chains of similar droplets.  
1.2.5 Feed solution properties 
Excipients 
Spray drying can be used for the production of ASDs. An ideal ASD is a one-phase system 
(i.e. molecularly dispersed) in which all molecules of the API are fully mixed with the carrier 
molecules (Van den Mooter, 2012). Melting point and enthalpy, thermal stability, constant of 
ionization, hydrogen bond (H-bond) donating/accepting nature, parameters of 
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solubility/interaction and partition coefficients are properties that could be helpful in identifying 
ideal poorly soluble candidates for ASD formulations. Active pharmaceutical ingredient, solvent 
and excipient are main components of a solution used for ASD. Thus, a combination of these 
components dictates the spray drying process factors required for specific final powder properties. 
With respect to excipient selection for spray drying, a key requirement is considerable 
solubility and chemical stability of solution state of the API and excipients in a regular volatile 
solvent or a mixture of solvents (Paudel et al., 2013b). Therefore, the solubility screening of the 
solid components is a necessary step prior to spray drying of formulations (Davis et al., 2016, 
Friesen et al., 2008). The role of the polymeric carrier is not only to stabilize the amorphous API 
but also to improve drug dissolution and absorption (Teja et al., 2013).  
Several factors need to be evaluated and established before excipient selection including 
glass transition temperature (Tg), nature of polymer (anionic/cationic), presence of functional 
groups, hygroscopicity of polymer, solubility in common organic solvents, polymer molecular 
weight and thermal stability (Baghel et al., 2016). Glass transition temperature is one of the most 
frequently used criteria to characterize amorphous solids and examine the interactions between 
API and excipients in ASDs. Moreover, it is one of the factors that should be considered before 
selecting input temperature for spray drying since high input temperatures may lead to wall 
deposition due to the softening of the particles and, subsequently, give low yields. Generally, 
amorphous systems with higher Tg are superior in order to improve the stability of the ASD 
formulation as they normally exist in a glassy state at room temperature with significantly higher 
viscosity (>1013 P) reducing API mobility and the risk of recrystallization (Chokshi et al., 2008). 
Thus, polymeric excipients with high Tg are exploited with APIs as they are capable of providing 
ASDs with Tgs of 75 °C or higher (at least 50 °C above the room temperature) (Shah et al., 2012). 
However, in some cases excipients with low Tg such as PEGs have been used for preparing ASD 
formulations due to the importance of the drug characteristics compared with the processing 
characteristics (Bolourchian et al., 2013).  
Intermolecular interaction between API molecules and the excipient is one of the most 
critical aspects that should be considered in developing new ASD formulations (Qian et al., 2010). 
The stronger the intermolecular interactions (hydrogen bonding, electrostatic, ionic or 
hydrophobic effect) the higher the miscibility between the API and the excipient. Excipient 
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screening based on structure is typically the first step in identifying the most favourable carriers 
for a drug with known chemical structure (Van Eerdenbrugh and Taylor, 2011). There are some 
systematic approaches to rationally predict and design ASD formulation (Korhonen et al., 2017). 
Calculating solubility parameters (Forster et al., 2001, Marsac et al., 2006), use of partition 
coefficients (Yoo et al., 2009), lattice-based solution models (e.g. Flory-Huggins theory) (Laitinen 
et al., 2014) and molecular modelling (Van Eerdenbrugh and Taylor, 2011) are examples of 
systematic techniques for studying ASD formulations. For instance, Greenhalgh et al. reported the 
miscibility of the API and polymer when the difference of their solubility parameter was less than 
7 MPa0.5, while samples with solubility differences above 10 MPa0.5 were immiscible (Greenhalgh 
et al., 1999).  
Additionally, hygroscopicity of the polymeric excipient is considered as another influential 
factor on the physical stability of amorphous products during storage and should, therefore, be 
considered in structure-based analyses. Unlike adsorption of water in crystalline materials which 
depends on the available surface area, water uptake in amorphous solids is mostly mass-dependent. 
Water weakens molecular hydrogen bondings and expands free volume of ASDs (Ahlneck and 
Zografi, 1990, Makower and Dye, 1956, Imaizumi et al., 1980, Andronis et al., 1997). This leads 
to lower miscibility of the drug in the polymer and decreased Tg of the formulation, thereby 
producing drug-rich phases that prompt phase separation and recrystallization (Shah et al., 2012). 
Moreover, water affects the viscosity of solids by lowering their Tg (Andronis et al., 1997). For 
instance, a decrease of about 150 °C in Tg of PVP K-12 after storage at a relative humidity of 53% 
was observed (Teng et al., 2010). Therefore in many cases, the use of a hydrophobic polymer such 
as Hydroxypropyl Methylcellulose Acetate Succinate (HPMC-AS) is recommended to provide 
enhanced stability (Chokshi et al., 2008). In addition, formulating spray-dried ternary ASDs with 
inclusion of a hydrophobic and a hydrophilic polymer has been tried. This approach has led to an 
increase in both the solubility and stability of ASDs (Davis et al., 2017, Six et al., 2004, Ziaee et 
al., 2017).  
Table 1.1 presents a comprehensive list of polymeric carriers most frequently used in the 







Table 1.1; Overview of typical carriers for ASD preparation and relevant physical properties (Teja et al., 2013, Paudel 




Tg (Tm) °C 
Solubility 
Parameter 
Hygroscopicity pH solubility 
Commonly used 
solvents 
HPMC 2910 10-1500 
148.2-
151.1 




acetone and water 







10-1500 152 - - 1-10 
Na-CMC 90-700 - - - - 
HPMC-P55 10-1500 138 28 7-8% >5.0 
Acetone 
HPMC-AS HG 55-93 117.9-120 - - - 
HPC (L-HPC) 50-1250 105 (220) - - - 
MeOH, Diluted, 
ammonia solution 
MCC 36 (260-270) - - -  






PVP K 25 28-34 - - 35-40% 1-10 DCM, IPA 
PVP VA64 45-70 
106.0-
110.0 





PVP VA37 - - - - 1-10  
Kollicoat IR 45 - - - - 
Water with or without 
HCl/ethanol, DCM 
PVA 22000 20 - - - - 
Hydroalcoholic or 
DCM, water 




Gelucire 50/13 - (50) - - - MeOH, DCM 
Compritol 888/ 
ATO 




Sterotex K NF - - - - - DCM 
PEG 4000 2.6-3.8 (50-58) - <25% 1-14 
DCM/MEOH, water, 
EtOH 
PEG 6000 7.3-9.3 
-22.71 
(55-63) 




PEG 8000 7-9 (60-63) - NH - 
PEG 20000 15-25 
-41 (60-
63) 
- NH - 
Poloxamer 407 9.84-14.6 - - - - 
Water, DCM or 
acetone 
Lactose 0.3423 (232) - - - Water 
Arabia gum - - - - - Water 
Stevia-G - - - - - EtOH/H2O 
Glucosyl 
hesperidin 





20 - - - -  
Eudragit E 100 47 48 19.3 - - 
EtOH, DCM, IPA, 
Ethyl acetate, THF 






- - - MeOH/DCM 




10-1000 203 - - -  




Appropriate solvent selection is as important as choosing a suitable excipient. Generally, 
the initial criteria for the selection of suitable solvents include: (1) high solubility of drug and 
excipients in the selected solvent (>50 mg.ml-1), (2) final solution viscosity, (3) low toxicity and 
environmental hazards, (4) high volatility for fast evaporation over the course of drying (5) 
chemical stability of the API and excipients in the solvent, (6) non-combustion in spray drying 
environments (Chokshi et al., 2008). Table 1.2 shows some of the most frequently used solvents 
in the spray-drying process and their physical properties.  
According to the International Council for Harmonization (ICH), all class II and III solvents 
are suitable to be used in the spray drying process (2009b). The relative volatility of the solvent 
should be considered as the primary criterion to achieve reasonable yield and reduce residual 
solvent in the final powder. Droplet viscosity and surface tension are crucial factors for effective 
feed atomization during the spray drying process (Lefebvre and McDonell, 2017). Dielectric 
constant and polarizability of the solvent are also significant in determining the crystallinity or 
amorphicity of the powder (Ansari and Sunderland, 2008). It is reported that the higher the 
dielectric constant and dipole moment, the higher the amorphicity of the final solid dispersion 
leading to higher equilibrium solubility (Ansari and Sunderland, 2008). The Hildebrand solubility 
parameter of the solvents can be an informative tool during solvent selection as it provides an 
estimation of the solubility of the drug and other excipients in the solvent. Kamlet-Taft (KT) 
solvent parameters that measure the hydrogen bond donor (α) and hydrogen bond acceptor (β) 
separately give understanding about the possibility of the presence of H-bond donor or acceptor 
pairs and the strength of H-bonding in the solutions (Kamlet et al., 1983). Solvents with higher (α) 
are efficient in dispersing drugs or polymers with H-bond acceptor functionality. The higher the β 
value of a solvent the more suitable it is for API or polymers with stronger H-bond donor groups 
(Paudel et al., 2013b). Solvent evaporation rate is another aspect that should be considered with 
respect to final properties of particle, specifically morphology and radial distribution of the 
components.  
Viscosity of the solution is dependent on the polymer concentration and its molecular 
weight, which is related to the polymer dispersity in the chosen solvent and non-covalent 
interaction between polymer-solvent-drug. Paudel et al. concluded that the use of a mixture of 
solvent and anti-solvent (e.g. acetone for PVP in a formulation of naproxen:PVP) leads to solid 
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dispersions with improved miscibility and physical stability (Paudel and Van den Mooter, 2012). 
Rheological properties of the feedstock (e.g. Newtonian/non-Newtonian liquids, shear-
thinning/shear-thickening) can also impact the droplet formation. 
 
Table 1.2; Solvent ICH limit relevant physical properties of commonly used spray drying solvents (Vasconcelos et al., 








P (Torr) η (mPas) γ (mN.m-1) ε δ (cal.cm-3)1/2 µ (D) 
Kamlet taft (KT) 
parameter 
α β 
Water - 100.0 40.7 17.5 0.89 71.690 78.4 23.4 1.84 1.17 0.47 
Methanol 3000 64.7 35.3 128 0.54 22.10 32.6 14.5 1.60 0.98 0.66 
Ethanol Class 3 78.3 38.7 59 1.08 22.00 24.3 12.7 1.70 0.86 0.75 
Isopropanol - 82.3 45.7 44 2.07 18.30 18.3 11.4 1.66 0.76 0.84 
DCM 600 39.8 28.0 475 0.42 27.20 8.9 9.7 1.60 0.13 0.10 
Acetone Class 3 56.3 29.1 240 0.30 22.68 20.7 9.6 2.70 0.08 0.43 
Methyl ethyl ketone Class 3 79.6 31.2 105 0.40 23.04 18.5 9.3 2.76 - - 
Dioxane 380 101.3 38.0 41 1.26 33.00 2.2 10.0 0.40 0.00 0.37 
Tetrahydrofurane 720 66.0 26.9 200 0.46 26.40 7.5 9.1 1.60 0.00 0.55 
Ethyl acetate Class 3 77.1 31.9 97 0.43 23.20 6.0 9.0 1.78 0.00 0.45 
Chloroform 60 61.2 30.8 210 0.54 26.60 4.7 9.3 1.01 0.20 0.10 
Acetonitrile 410 81.6 33.8 97 0.34 28.45 37.5 11.9 - 3.44 - 
B.P.: boiling point, ΔHv: enthalpy of vaporization, P: vapor pressure at 20 °C, η:  viscosity at 25 °C, γ: surface tension 
at 25 °C, ε: dielectric constant, δ: total solubility parameter, µ: dipole moment, α: KT hydrogen bond donor (acidity), 
β: hydrogen bond acceptor (basicity).  
 
1.2.6 Process factors 
Feed concentration 
The feed concentration is the solid particle fraction in the volume of the solution. Littringer 
et al. (Littringer et al., 2012) proposed that higher solution concentrations of mannitol aqueous 
solutions lead to particles with a rougher surface compared to low feed concentrations. They 
reported the formation of hollow spray dried particles with higher porosity and lower bulk density 
at high feed concentrations. A higher feed concentration corresponds to less solvent in each 
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droplet. This leads to higher Pe values, shorter evaporation times and porous particles with less 
density in the final stage. Higher feed concentrations increase the chance of agglomeration or 
formation of multimers between polymer chains or API molecules which result in more porous 
particles with lower density and rougher surfaces (Kim et al., 2003, Tomasko and Timko, 1999).  
Suhang et al. reported markedly lower residual moisture content in the final spray-dried honey 
powder at higher solid concentrations. This was attributed to the increase in feed solid content and 
decrease of total moisture to be evaporated (Suhag et al., 2016).  
Feed rate 
Feed rate in the spray-drying process is commonly reported as the mass of transferred 
powder per unit of time. It controls the amount of solvent and solid content entering the drying 
chamber. Thus, physicochemical properties such as solvent evaporation rate, morphology, particle 
size and density can be altered by varying the feeding rate. It has previously been demonstrated 
that higher feed rates result in higher moisture content in final particles (Tonon et al., 2008). 
Moreover, higher yields were also reported at decreased feed rates. Increased feeding rate of the 
feedstock at the same atomizing gas flow rate leads to enlarged droplets (i.e. particles) due to lower 
atomization energies (Stahl et al., 2002, Billon et al., 2000). Moreover, in terms of technological 
limitations, very high feeding rates might result in overloading the condenser in closed loop setup.  
Inlet/outlet temperature 
Inlet temperature has a direct effect on heat and mass transfer during the droplet drying 
process. Singh et al. have reviewed the effect of inlet temperature on the final properties of 
amorphous solid dispersions (Singh and Van den Mooter, 2016). Higher inlet temperatures 
influence the particle formation process due to the high rate of solvent evaporation. This process 
can lead to a pressure gradient inside and outside the droplet with subsequent effects on the final 
morphology of the powder such as surface roughness. A higher inlet temperature leads to the rapid 
formation of solid skin on the outer surface of the droplet which entraps the solvent vapours (Singh 
and Van den Mooter, 2016). Depending on the type of API and excipient polymer used, the solvent 
vapour pressure may collapse the whole particle, or result in a particle with a porous surface 
(Vehring et al., 2007, Vehring, 2008).  
Furthermore, faster drying due to higher temperatures is appropriate for the formation of 
ASDs with higher Tg, which in turn is more desirable for product stability. This is primarily due to 
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the rapid drying of the equilibrium fluid into a non-equilibrium glass form. In contrast, slower 
drying rates can result in low Tg products having stickier particles which reduce the final yield due 
to wall deposition. This will, in turn, increase the stickiness of the powders to the cyclone and 
lower the final yield of the spray-dried material (Singh and Van den Mooter, 2016).  
Atomization and drying gas (type and flow rate) 
Drying and atomization gas type and flow rate selection are crucial for defining the droplet 
size, density, velocity, and the properties of the final particles. Various atomization gases such as 
compressed air, N2 and CO2 have been used previously for spray drying. Atomization gas 
properties such as density and specific heat capacity are decidedly important in defining the final 
properties of spray dried powders. For instance, N2 with lower density (1.1233 kg.m
-3) has been 
shown to produce smaller particles with different surface morphologies compared to CO2 (1.7730 
kg.m-3) (Paudel et al., 2013a, Singh and Van den Mooter, 2016). Moreover, an inert gas such as 
N2 is typically used with non-aqueous solutions (organic solvents) and for solutions containing 
easily oxidized solutes. The differing morphology has been attributed to variations in heat and 
mass transfer of different drying mediums. The effect of atomization and drying gas type on 
crystallization has been studied by Langrish and co-workers (Islam and Langrish, 2010a, Islam 
and Langrish, 2010b). They stated that the crystallinity of the resulting spray dried lactose was 
affected by the drying and atomizing gas in the order of most crystallinity to least: N2 > air > CO2. 
A possible reason for this is due to the higher temperature and mass transfer of CO2 compared to 
N2 and air which in turn provides better conditions for the production of amorphous materials. 
Kudra et.al. reported higher efficiency in the drying process with CO2 compared to air due to its 
higher heat transfer rate. This leads to up to 20% faster drying which offers 4% energy savings on 
the heat input (Kudra and Poirier, 2007).  
Atomization device 
In addition to all aforementioned spray-drying process factors, the type of atomization 
device also affects the droplet size distribution, velocity, spray-cone diameter and incident angle. 
An overview of the various types of atomizers has been given in section 2.2. One-fluid nozzles 
can produce larger particles compared to the other types of atomizers as such particles produced 
using this method can often be used directly in tablet pressing without a granulation step (Dobry 
et al., 2009). However, these nozzles are not compatible with high-viscosity non-Newtonian 
feedstocks. The most common type of atomizer used in production and research of amorphous 
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solid dispersions is the two-fluid nozzle (Cal and Sollohub, 2010). In these systems, the atomizing 
gas and solution feed rate are the main factors in defining final particle size distribution thereby 
permitting a high level of control of the atomization process. Higher gas flow rates in tandem with 
lower feed rates typically result in smaller particle sizes (Mandato et al., 2012). In 2-fluid nozzle, 
droplet size decreases to a plateau with an increasing air (or gas):liquid ratio (ALR) (Snyder and 
Lechuga-Ballesteros, 2008b). The main drawback of two-fluid nozzles is the limitation in 
achieving high throughputs. Another disadvantage of two-fluid nozzles is that all formulation 
components are required to be solubilized in one type of solvent. However, in multi-fluid nozzles 
i.e. three-fluid (with two liquids and one gas channels) and four-fluid (with two liquids and two 
gas channels) nozzles, two solutions can be atomized simultaneously. Multi-fluid nozzles have 
previously been used for spray drying of amorphous solid dispersions (Kondo et al., 2014). The 
API indomethacin was successfully spray dried in amorphous form with a four-fluid nozzle and 
HPMC as polymeric excipient (Chen et al., 2007). In addition, the solubility of artemisinin was 
increased due to partial amorphization by employing a four-fluid nozzle in tandem with 
polyethylene glycol (PEG) as the polymeric excipient (Sahoo et al., 2011). 
Small molecule APIs are usually spray dried for multiple purposes among which, increasing 
the dissolution rate of BCS class II APIs with improved stability over time is the most important 
one. However, the spray drying of large biomolecules that are sensitive to thermal degradation is 
a significantly more complex process. In case of large molecule APIs, the main aim is preserving 
stability and bioactivity of biomolecules during and after spray drying process. In either of the 
cases, these properties can be controlled by understanding and optimising the interrelations of 
process and formulation factors during the spray drying process. The next section provides more 
insight into the critical quality attributes of spray drying process that should be considered during 
optimisation process.   
1.2.7 Critical quality attributes 
Based on ICH Q8 definitions, an important step in pharmaceutical product development is 
the identification of critical quality attributes (CQAs) in a way that those product characteristics 
having an impact on product quality can be studied and fully controlled (2009a). Moreover, it is 
recommended to use the enhanced product and process understanding along with quality risk 
management to establish an appropriate control strategy including a design space. A CQA is a 
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physical, chemical, biological or microbiological property or characteristic of a material that 
should be within an appropriate limit range or distribution to ensure the desired product quality. 
Critical formulation and processing factors of spray drying process were introduced, however 
depending on the application of spray dried powders, different CQAs are required to be screened. 
In the following section, CQAs of spray dried pharmaceutical powders are introduced.  
Particle size distribution 
Particle size distribution is critically important for formulating powders, especially where 
pulmonary delivery applications are concerned. (Baldinger et al., 2012). It has been recognized 
that the optimal aerodynamic particle size distribution for pulmonary delivery application is in the 
range of 1-5 µm (Hickey, 2016). Maltesen et. al. studied the effect of various processing and 
formulation factors such as nozzle gas flow rate, feed flow rate, inlet gas temperature aspirator 
capacity and solid concentration on final aerodynamic particle size distribution using near-infrared 
spectroscopy (NIR) (Maltesen et al., 2012). Moreover, LeClair et. al. found the significance of 
Peclet number, and solid content on particle size distribution (LeClair et al., 2016). Higher solid 
contents in tandem with higher Peclet number led to lower particle size distribution.  
Yield 
In order to have an industrially applicable spray drying process, the yield of the process 
should be in acceptable ranges depending on the value of the product. The process yield is highly 
affected by two main factors, namely loss due to the non-optimal process factors and the material 
formulation. This could be prevented by selection of an appropriate spray dryer with optimal 
design features such as wide drying chamber for rotary atomizers or high-efficiency collection 
cyclone in tandem with clearly defined and optimised processing factors. In addition, wall 
deposition during spray drying due to the low Tg of the sprayed formulation decreases the yield. 
This can be avoided by spray drying at lower outlet temperatures or introduction of polymeric 
excipients with higher Tg to the formulation. Low drying temperatures can cause incomplete drying 
of the particles (residual solvent in the particles) and stickiness of the particles to the drying 
chamber. Thus, optimising the drying conditions improves drying resulting in higher yields.  
Morphology  
The morphology of the spray-dried product is extremely significant, especially for 
biopharmaceutical applications whereby the product is to be delivered via oral inhalation (Prinn et 
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al., 2002, Paluch et al., 2012). Formulation factors such as solvent evaporation rate and diffusion 
rate of solute from the inner core to the outer crust of the particles have been shown to significantly 
affect the final morphology of the particles (see section 3.1.1.). It is well known that the higher the 
feeding rate, the larger the particle size. Moreover, lower solid contents and smaller nozzle tips 
(typically in 2-fluid nozzle) lead to smaller droplets and thus finer final particles. Paluch et al. 
introduced a new system of morphology classification for spray-dried biomolecules. In this 
system, the shape of particles was described as spherical or irregular, and the surface was 
categorized as smooth or crumpled (Paluch et al., 2012). This classification system is helpful in 
enhancing our understanding of the effect of morphology on aerosolization of spray dried particles. 
It has been reported that smooth and flat surface of particles results in increased adhesion forces 
between the particles. Moreover, the flat surface promotes the large contact area between the 
particles which leads to higher cohesive forces between particles (French et al., 1996, Steckel and 
Brandes, 2004). The effect of surface-active components such as amino acid L-leucine on the 
morphology and aerosolization of spray dried powders has been studied (Eedara et al., 2018). It 
was shown that its application leads to a reduction in surface cohesiveness and dimpled particles 
with reduced contact area (Sou et al., 2013, Vehring, 2008, Walton and Mumford, 1999).     
1.3 Applications 
1.3.1  Spray drying of poorly soluble small molecule drugs 
Spray drying has attracted significant interest in fields such as ceramics (Lukasiewicz, 
1989), pharmaceuticals (Paudel et al., 2013b, Baghel et al., 2016), biopharmaceuticals (Ameri and 
Maa, 2006, Ledet et al., 2015), dairy and food processing (Gharsallaoui et al., 2007). With respect 
to biopharmaceutical and pharmaceutical production, spray drying has been utilised as a method 
of enhancing bioavailability in addition to solubility enhancement of drugs via amorphous solid 
dispersion (Patel et al., 2015). Encapsulation of active pharmaceutical ingredients (APIs) within 
an inert protective matrix has been carried out by spray drying (I Ré, 1998). Spray drying is also 
employed in the production of dry powder vaccines offering significant advantages when 
compared with liquid formulations, due to increased stability against chemical and physical 
hydrolysis, particles aggregation, structural irreversible denaturation/degradation or fluctuations 
in pH (Ameri and Maa, 2006).  
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Based on the Biopharmaceutics Classification System (BCS) as depicted in Figure 1.7, 
drugs are classified according to their aqueous solubility and intestinal permeability as these 
factors are a key determinant of their oral bioavailability (Saluja et al., 2010). It is known that 40% 
of the newly developed drugs are poorly soluble or lipophilic in nature (Patel et al., 2015, Snyder 
and Lechuga-Ballesteros, 2008a).  
 
Figure 1.7; Biopharmaceutics classification system (BCS) (Saluja et al., 2010). 
 
In order to compensate for low solubility of pharmaceutical APIs, many physical and 
chemical techniques are employed such as: (a) salt formation of ionisable compounds (Huang and 
Tong, 2004), (b) particle size reduction (Liversidge and Cundy, 1995), (c) amorphous solid 
dispersions (ASDs) (Caron et al., 2011, Li et al., 2008, Chen et al., 2006, Leuner and Dressman, 
2000, Serajuddin, 1999, Teja et al., 2013, Sekiguchi and Obi, 1961), (d) crystal engineering 
approaches: co-crystallization, modification of crystal habits and polymorphs (Shan and 
Zaworotko, 2008, Hickey et al., 2007), (e) solution containing solvents, co-solvents, and lipids 
(Savjani et al., 2012), (f) micelle based approaches (Yu et al., 1998, Lee et al., 2007, Shin et al., 
2009), (g) complexation (Becket et al., 1999, Memişoğlu et al., 2003), salt formation (Savjani et 
al., 2012). 
Solid dispersion is historically defined as a dispersion of drug in a solid matrix where the 
matrix is either a small molecule or polymer. The dispersed state may include many forms such as 
eutectic mixture, crystalline/glass solutions, and amorphous/crystalline suspension (Sekiguchi and 
Obi, 1961, Chiou and Riegelman, 1971). Amorphous solid dispersion can now be more precisely 
defined as a dispersion of drug in an amorphous polymer matrix, preferably at molecular level 
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(Huang and Dai, 2014). Traditional methodologies such as rapid condensation of vapour, 
supercooling of melt, crystalline mass mechanical activation and fast precipitation from solutions 
have previously demonstrated ASDs with enhanced solubility (Angell, 1995). Disordered structure 
and higher Gibbs free energy of amorphous compared with crystalline state leads to improved 
solubility and higher dissolution rates (Zhang et al., 2012). However thermodynamic instability 
leads to structural relaxation, nucleation and undesirable crystal growth often during subsequent 
storage of amorphous formulations (Van den Mooter, 2012). Glass transition temperature (Tg) as 
one of the characteristics of amorphous materials is the temperature at which materials transform 
from a disordered glassy state to a softer rubber-like state (ISO, 2013). Thus, at temperatures higher 
than Tg adequate molecular motion is available for the phase transformation. As a basic rule of 
thumb storage of amorphous APIs at 50 °C below their Tg reduces the molecular motions leading 
to a lower chance of recrystallization of these compounds (Paudel et al., 2013b, Hancock et al., 
1995). Van den Mooter has mentioned phase instability as a function of time and/or storage 
conditions such as temperature and humidity as a primary reason for the low number of ASD 
formulations currently available in the market (Table 1.3) (Vasconcelos et al., 2016, Van den 
Mooter, 2012). However, this can be overcome by preparing a homogeneous amorphous 
dispersion of API with high Tg polymeric excipients (Li et al., 2008, Shen et al., 2011, Chan et al., 
2015). Due to high molecular weight and high entropy, polymers often inhibit mobility of 
individual API drug molecules thereby preventing subsequent crystallization. Thus, binary or 
ternary amorphous mixtures of drug and polymer-based excipients are often combined to form 
ASD (Taylor and Zografi, 1997, Davis et al., 2017, Kadir et al., 2011, Ziaee et al., 2017). To 
qualify a solid solution, the drug/polymer system should comply with two criteria: the formulation 
should depict a single glass transition temperature (Tg), and the drug should be in amorphous form 
(Goldberg et al., 1966). Taylor et al.  showed that the stability enhancement of the ASD 
formulations is due to the new assembly of bonding between API and polymeric carriers (Taylor 
and Zografi, 1997). Van den Mooter et al. refer to the anti-plasticizing effect of the polymers as 






Table 1.3;. Examples of commercially available pharmaceutical products using amorphous solid dispersion technologies. 
(Kawabata et al., 2011, Van den Mooter, 2012, Rumondor et al., 2016, Vo et al., 2013, Vasconcelos et al., 2016) 
Product name API Carrier Preparation 
method 
Year of approval 
Gris-PEGTM Griseofluvin PEG Melt extrusion 1975 (FDA) 
Isoptin® Verapamil HPC/HPMC N/A 1982 




Nabilone PVP N/A 1985 (FDA) 
Nivadil® Nivaldipine HPMC N/A 1989 
 PrografTM Tacrolimus HPMC Spray drying 1994 (FDA/MHRA) 
Nezulin® Troglitazone PVP N/A 1997 
Afeditab® Nifedipine  PVP/Poloxamer N/A 2001 
Cymbalta® Duloxetine HPMCAS N/A 2004 (EMA/FDA) 
Crestor® Rosuvastatin HPMC Spray drying 2004 (EMA), 2002 
(FDA) 






HPC Melt extrusion 
(metfotrmin) 
2007 (EMA) 
Fenoglide® Fenofibrate Poloxamer/PEG N/A 2007 
Intelence® Etravirine HPMC Spray drying 2008 (EMA/FDA) 
Modigraf® Tacrolimus HPMC Spray drying 2009 (EMA) 
Samsca® Tolvaptan HPMC Granulation 2009 (EMA/FDA) 




Everolimus HPMC Spray drying 2010 (EMA/FDA) 
OnmelTM Itraconazole HPMC Melt extrusion 2010 (FDA) 
FenoglideTM Fenofibrate PEG/Poloxamer 
188 
Spray melt 2010 (FDA) 







Telaprevir HPMCAS Spray drying 2011 (EMA/FDA) 
Kalydeco® Ivacaftor HPMCAS/SLS Spray drying 2012 (EMA/FDA) 
Zelboraf® Vemurafenib HPMCAS Co-precipitation 2012 (EMA) 2011 
(FDA) 






PVP-VA/TPGS Melt extrusion 2014 (EMA/FDA) 
Belsomra® Suvorexant PVP-VA N/A 2014 
Hravoni® Ledipasvir/Sofosb
uvir 
PVP-VA N/A 2014 
Orkambi® Lumacaftor/Ivacaft
or 
HPMCAS/SLS Spray drying 2015 (EMA/FDA) 
Envarsus® Tacrolimus Poloxamer/HPMC N/A 2015 
 
In addition to the traditional routes for the manufacture of ASDs, other technologies such 
as hot-melt extrusion (HME) (Douglas et al., 2016a, Douglas et al., 2016b, Albadarin et al., 2017), 
spray-drying (Paradkar et al., 2004, Paudel et al., 2013b, Janssens et al., 2008, Cho et al., 2017, 
Wlodarski et al., 2016), freeze-drying (Xu et al., 2016), milling (Wlodarski et al., 2016), melt-
quenching (Watanabe et al., 2004) and spray-congealing (Tong et al., 2011) have been employed. 
As can be seen from Table 1.3, spray drying is a leading technology among all solvent evaporation 
methods to produce commercialized ASD formulations. For spray drying to be considered an 
effective technique to produce ASDs, the dried product should enhance the absorption of poorly 
water-soluble drugs in gastrointestinal fluid (GI) and provide physical stability for the API 
(hindering crystallization and phase separation) leading to longer shelf-life, and easier shipment 
and storage (Friesen et al., 2008). Previous studies have shown that larger API molecules with low 
numbers of aromatic rings, a low level of molecular symmetry, branched carbon skeleton and 
electronegative atoms are capable of forming amorphous solid dispersions (Mahlin et al., 2011, 
Baird et al., 2010, Baird and Taylor, 2012, Baird et al., 2012). The following sections will be 
focused on presenting the most critical factors for the successful preparation of ASD formulation 
by spray-drying.   
30 
 
1.3.2  Spray drying of large molecule drugs (biopharmaceuticals) 
At ambient temperatures, many biopharmaceuticals such as proteins and peptide-based 
drugs are more stable in solid state compared to liquid state (Tan et al., 2019, Yamasaki et al., 
2019). Hence, for improved long-term storage and stability, the need for processing techniques 
capable of producing solid product free from moisture content is essential. Moreover, with the 
advent of new drug delivery systems such as long-acting microspheres , vaccine powders for 
intradermal delivery (LeClair et al., 2019) and fine powders for pulmonary delivery (Xu et al., 
2019), the biopharmaceutical sector will see increased demand for new powder formation 
techniques. However, the patient adherence to the correct required dosage should be considered 
specifically for powder formulations that require reconstitution in specific doses. In this case pre-
filled syringes with predetermined dosage of API are advantageous compared with solid state form 
of the drug.  
Lyophilization or freeze-drying is commonly used for powder preparation of many 
commercially available biopharmaceuticals (Wang, 2000). However, in addition to its denaturing 
effect, it requires a secondary procedure for breaking apart the freeze-dried cakes into finer 
particles. As a direct result of this requirement, there is less control over the particle properties 
such as particle size distribution, morphology, porosity, density, etc. Spray drying has shown huge 
promise as a single step liquid to powder conversion method which gives the user significant 
control over the final properties of the powder. A major difference between the two techniques 
which is often underestimated is the presence of different types of stresses. Ice formation stress, 
freeze concentration of the solutes and pH swing are some of the stresses due to the freeze-drying 
process while, spray-drying applies mostly thermal and mechanical stresses to the samples.  
Spray congealing has also been applied for processing particle engineering of 
biopharmaceuticals. It is a hybrid technology between spray drying and hot-melt extrusion, 
therefore, shares the advantages and disadvantages of both methodologies. It has been used for 
formulating controlled release formulations of proteins such as insulin (Maschke et al., 2007).  
Table 1.4 presents a comparison between freeze-drying and spray drying technologies for 




Table 1.4; Advantages and disadvantages of spray drying and lyophilisation techniques (McAdams et al., 2012). 
Technique Advantages Disadvantages 
Freeze Drying Established technology within the 
biopharmaceutical industry 
Large space and maintenance requirements 
Equipment widely available High power consumption 
Limited process losses Requirement for further processing to make 
final powder 
Straightforward aseptic processing Difficulty associated with scale-up 
Avoidance of high temperature, decreases the 




Highly controllable leading to the engineered 
particles properties (size, morphology) 
Process losses greater than freeze-drying (can 
be significantly reduced by proper process 
optimisation) 
Can be incorporated into continuous 
processing techniques 
Complex and interrelated process parameters 
Capacity to engineer particle morphology  Time consuming process optimisation 
Particles delivery routes can be tailored  
 
As regards spray drying of biopharmaceuticals, a clear limitation of the spray-drying 
process is the high temperature required for solvent evaporation which may destabilize or denature 
thermo-labile biopharmaceuticals. The drying process in spray drying consists of three steps 
outlined as follows (see Figure 1.8): (1) the droplet experiences initial heating (path 0-1) (2) at this 
stage evaporation starts and the solvent is readily available at the surface of the droplet. The mass 
of the droplet decreases while the temperature stays constant at the wet-bulb temperature of the 
solvent and the diameter of the droplet shrinks (path 1-2); (3) at this stage the droplet size has 
decreased and a solid outer crust has formed around a wet core and the droplet is treated as a wet 
particle with constant outer diameter (dp) The temperature of the droplet starts to rise as well (path 
2-3). The evaporation from the wet core continues and as a result, the thickness of the solid crust 
increases and wet core shrinks (di). The drying can be stopped at the desired residual liquid level. 




Figure 1.8; Typical temperature profile and morphology of a droplet during drying process containing solid. (the 
picture reprinted with permissions from (Mezhericher et al., 2008). 
 
The spray drying process often exerts certain thermal stresses on the product however with 
the appropriate process optimisation these can be minimized/controlled. For instance, outlet 
temperature is a key process parameter. If the outlet temperature is higher than thermal degradation 
temperature (depending on the degradation kinetics), the dried powder can undergo thermal 
degradation. On the other hand, if the outlet temperature is too low, the material experiences less 
thermal degradation but shorter shelf life due to residual water or lower yield due to wall stickiness. 
The challenge, therefore, is to optimise the process to produce a sufficiently dry powder, yet not 
incur unacceptable degradation 
Table 1.5 shows a number of biomolecules that have been spray dried and the 
corresponding spray drying conditions. This table shows the wide range of biomolecules that have 
been spray dried using various lab scale up to pilot scale spray dryers. The outlet temperature in 
all cases is well below 100 °C along with very low feeding rates. It is obvious that the researchers 
have tried to keep the outlet temperature as low as possible while maintaining a reasonable drying 
process. This clarifies the general optimisation conditions for spray drying of biomolecules. 
Irreversible denaturation happens during the dehydration process owing to the change in the 
secondary structure of the proteins (Hasija et al., 2013). This is attributed to the removal of 
hydration water molecules which are required to form hydrogen bonds to stabilize the protein’s 
secondary structure (Carpenter and Crowe, 1989, Prestrelski et al., 1995, Costantino et al., 1996). 
However, some proteins such as lysozyme experience both reversible and irreversible thermal 
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denaturation (Blumlein and McManus, 2013). To improve the stability of the spray dried proteins, 
it is advisable to use excipients including sugars (e.g. sucrose and trehalose (Ogain et al., 2011, 
Hulse et al., 2008)), and polyols (e.g. sorbitol (Maury et al., 2005)) that could function according 
to the water-replacement theory. Moreover, surfactants (e.g. pluronic F-127® (Haj-Ahmad et al., 
2013)), polymers (e.g. dextran and polyethylene glycol (S. Jacob et al., 2006)), antioxidants (e.g. 
ethylenediaminetetraacetic acid (Akers and DeFelippis, 2012)), amino acids (e.g. arginine and 
glycine (Ajmera and Scherließ, 2014)) and chelating agents (e.g. ammonium sulfate (Hiroyuki et 
al., 2009)) can be used as excipients for improving biomolecules stability during processing (Li 
and Mansour, 2011). Various mechanisms have been proposed to explain the role of excipients in 
protecting proteins from denaturation (Ajmera and Scherließ, 2014): 
(1) Increased preferential hydration around protein: proteins are usually bound to many water 
molecules in solutions. Excipients that form hydrogen bonds with proteins during water 
removal process, help to protect and strengthen the tertiary structure of proteins by creating 
a water-like environment for them (James and McManus, 2012). For instance, sucrose and 
trehalose (Ogain et al., 2011, Hulse et al., 2008)), and polyols (e.g. sorbitol (Maury et al., 
2005)) could function according to the preferential hydration theory.  
(2) Amorphous state stabilisation: the glass-forming excipients limit the molecular mobility of 
proteins and prevent aggregation by effective dispersion of protein molecules (Green and 
Angell, 1989).As an example, trileucine has been used for improving the physical stability 
of a wide range of drugs (i.e. asthma therapeutics such as albuterol and cromolyn) due to 
its high glass transition temperature (~104 °C) compared to room temperature which 
enables the long-term room temperature stability of the aerosols (Lechuga‐Ballesteros et 
al., 2008). 
(3) Surface adsorption reduction: the excipients acting as surfactant reduce the protein 
concentration at the surface because of their own surface activity thus preventing interfacial 
induced denaturation (Maa et al., 1998a, Yuh-Fun and Steven, 2000). For example, 
pluronic F-127® (Haj-Ahmad et al., 2013) could act as surfactant which occupies the 
surface of the droplets and protects proteins from air-liquid interface tension.  
Additionally, effects associated with high shear force during the spray drying process may 
lead to denaturation of protein-based biopharmaceutical materials. While it has been reported that 
shear force alone does not cause denaturation of biomolecules, in combination with the air-liquid 
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interface effect it may cause aggregation in some sensitive proteins (Ameri and Maa, 2006, Maa 
et al., 1998b).  Typically proteins are able to tolerate shear rates as high as 105 s-1 without protein 
aggregation or activity loss (Maa and Hsu, 1996). However, as most of the proteins are 
amphiphilic, in air-liquid interfaces their hydrophobic regions are exposed to the non-aqueous 
surface which results in denaturation (Ledet et al., 2015).  The sources of stress on 
biopharmaceuticals can be circumvented by optimisation of the process and formulation 
parameters. Parameters that are typically screened after spray drying are yield, morphology, 
chemical stability, therapeutic activity and flow properties of the final powder. The most 
significant factors affecting the powder properties are excipient type, protein/excipient ratio, feed 
solid concentration, instrument design, inlet/outlet temperature, liquid feed rate, type of atomizer 
and atomizing air pressure. All these parameters are interrelated, thus optimising one parameter 
often requires optimisation of many other parameters. However, many research groups have 
attempted to model spray drying process with different approaches. DoE, computational fluid 
dynamics (CFD), and heat-mass balance modelling has been used to understand the 
intercorrelations of the process and formulation factors in both lab-scale and industrial-scale spray 
dryers (Keshani et al., 2015a, Grasmeijer et al., 2013, Maltesen et al., 2008, Hennigs et al., 2001, 
Lin and Chen, 2006, Huang et al., 2004, Jamaleddine and Ray, 2010, Woo et al., 2008). Moreover, 
single droplet drying models in conjunction with experimental setups are another approach to 
studying the basic heat and mass transfer phenomena within one droplet (Perdana et al., 2015, 
Schutyser et al., 2012, Perdana et al., 2011).  
 
Table 1.5; Spray dried biomolecules and the corresponding spray drying conditions. 
Biomolecule Type of spray 
dryer/congealer 






Atomizing air flow 
(L.h-1) 
Lysozyme (Haj-
Ahmad et al., 
2016) 
Büchi B-290 mini 
spray dryer  
110 / 55  5 Two-
fluid  
600  
Plasmid (Lane et 
al., 2005)  
Büchi B-290 mini 
spray dryer  




(Wang et al., 2017)  
Spray dryer FT30 
MKII  






(Gaspar et al., 
2017) 
Büchi B-290 mini 
spray dryer  







et al., 2009) 
Büchi 190 mini spray 
dryer 









(Jensen et al., 
2010) 
Büchi 290 mini spray 
dryer 




(Seville et al., 
2002) 
Büchi B-191 mini 
spray dryer 






(Cordons et al., 
2003) 
LabPlant laboratory-
scale spray dryer 
100 / 52-62  10  Two-
fluid  
atomizing air 




antibody (Maa et 
al., 1999) 
Büchi 190 mini spray 
dryer 




1.3.3 Applications of spray drying of biopharmaceuticals   
Spray drying of biopharmaceuticals has been carried out by both academic research groups 
and the biopharmaceutical industry. Spray drying has been used for engineering specific particle 
sizes for pulmonary delivery applications e.g. insulin for treatment of diabetes. Stabilization of 
active biopharmaceuticals including vaccines with excipients is another field of immense interest 
(Hasija et al., 2013). The next section of this review gives a brief overview of the technological 
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requirements and final powder properties for vaccine stabilisation and pulmonary delivery 
applications.  
Pulmonary delivery 
Micronized APIs are the most common technology used for the production of inhalation 
powders (Seville et al., 2007, Chow et al., 2007). However, the micronization process itself offers 
limited control over final particle size and morphology as observed in jet milling (the typical 
approach for the production of micronized particles). Spray drying has been a promising technique 
for producing powders for inhalation since its first application as an alternative to milling processes 
in the 1980s (Fourie et al., 2008).  
A spray dried powder suitable for pulmonary delivery applications should satisfy the 
following properties: (1) aerodynamic particle diameter between 1-5 μm. The aerodynamic 
diameter of an irregular particle is defined as the diameter of the spherical particle with a density 
of 1000 kg.m-3 and the same settling velocity as the irregular measured particle (Hinds, Jan. 1999); 
(2) narrow particle size distribution; and (3) powder should be readily aerosolizable at relatively 
low aerodynamic dispersion forces (Chow et al., 2007); (4) the employed excipient should be able 
to protect the protein from destabilization/denaturation and improve its storage time/shelf-life at 
room temperature; (5) to ensure the biopharmaceutical product has not been denatured during the 
spray drying process therapeutic activity of the protein should be certified in ex vivo experiments 
(Zijlstra et al., 2009); (6) Finally, it is critical that particle properties (e.g. density, morphology, 
surface energy and composition, etc.) of an aerosol be maintained during manufacture, storage and 
administration (Lechuga‐Ballesteros et al., 2008). 
In line with the main mechanisms of particle deposition in lungs, namely inertial impaction, 
gravitational sedimentation and Brownian diffusion, the size of the inhalation particles is of 
extreme importance.  Large particles (larger than 5 µm) with high density and momentum travel 
in one direction only without the ability to change direction and collide on the airway’s wall in the 
respiratory tract. Particles smaller than 1 µm typically follow the Brownian deposition mechanism 
in the alveolar region where there is very low airflow. Gravitational mechanism in the central and 
peripheral regions of the lung is the dominant adsorption mechanism for particles with an 
intermediate size (1-5 µm). Therefore, 1-5 µm is the desired range of particle size for maximizing 
the absorption through pulmonary delivery. (Seville et al., 2007).  
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Insulin is suitable for pulmonary delivery. It has high permeability through the alveolar 
membrane and exhibits high thermal stability. In 2006 Pfizer and Inhale Therapeutic Systems 
received FDA approval for Exubera® spray-dried insulin for inhalation applications. It consists of 
recombinant insulin (60 %), sodium citrate, mannitol, glycine and nominal amounts of sodium 
hydroxide (for adjusting the pH to 7.2-7.4) (Ledet et al., 2015, McAdams et al., 2012, White et al., 
2005). However, it was withdrawn from the market after only one year in the market due to poor 
sales numbers (Heinemann, 2008). Lutz Heinemann has reviewed the main reasons behind the 
failure of Exubera and has attributed these to a number of reasons such as the size of the inhaler, 
which was large and cumbersome. Additionally, the procedure for preparing and activating the air 
pump was time-consuming and was reported to be annoying from the patients’ perspective. 
Moreover, the selection of specific doses was not possible using Exubera upon initial product 
introduction. (Heinemann, 2008). More recently, the MannKind Corporation has developed a new 
technology for pulmonary delivery of insulin (Technosphere®). Marketed as Afrezza, the 
formulation consists of a novel excipient fumaryl diketopiperazine (FDKP) and polysorbate 80 
which was approved by FDA in 2014 (2018). However, based on the market analysis four years 
after approval it is still experiencing low sales numbers.  
Excipients, such as sugars e.g. trehalose and raffinose and amino acids e.g. arginine and 
leucine have been investigated as protein stabilisers (Table 1.6) (Ogain et al., 2011). Using 
trehalose increases the cohesion tendency of the particles resulting in particle aggregation (Lo et 
al., 2004, Bosquillon et al., 2001b) and is, therefore, a suboptimal stabilizer. Lactose produces 
smooth, spherical particles with a narrow fine particle size distribution (Andya et al., 1999). It is 
efficient in increasing the shelf life of the spray dried powder though it has little effect on humidity 
resistance (Andya et al., 1999) whereas erythritol, a non-hygroscopic carbohydrate, has been 
shown to significantly improve the stability of the final powder against humidity. The 
concerns/risks of Maillard reactions of lactose, discourages its employment as an excipient to 
stabilise proteins (Bharate et al., 2010, Vinjamuri et al., 2017). Dextran and mannitol are two 
frequently used excipients (Chougule et al., 2006, Bosquillon et al., 2001a, Bosquillon et al., 2004) 
as stabilizing agents for proteins. Lechuga-Ballesterol et al. investigated the use of trileucine for 
improving the physical stability of a wide range of drugs (i.e. asthma therapeutics such as albuterol 
and cromolyn). Its high glass transition temperature (~104 °C) compared to room temperature 
enabled the long-term room temperature stability of the aerosols (Lechuga‐Ballesteros et al., 
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2008). Moreover, low aqueous solubility of trileucine led to the formation of corrugated particles 
and promoted the formation of trileucine coated particles with superior aerosol performance. Its 
high surface activity contributed to the formation of powders with reduced cohesiveness. Lastly, 
it competed with proteins on the air/water interface resulting in decreased surface tension in 
solution and less denaturation and aggregation in the solid state (Lechuga‐Ballesteros et al., 2008).  
 
Table 1.6; Excipients used for spray drying of biopharmaceutical powders for inhalation. This list is mostly compiled 
















Spray drying increases the stability of vaccines at ambient temperature (Plotkin, 2008). Dry 
vaccines are preferable to liquid because of the reduced risk of chemical and physical damage due 
to hydrolysis, aggregation, denaturation, degradation or pH fluctuations (McAdams et al., 2012). 
Most vaccines require storage between 2-8 °C. Improper storage conditions lead to denaturation 
of the API. This restriction inhibits the delivery of vaccines in developing countries that may have 
insufficient cold storage facilities. Table 1.7 outlines some examples of vaccines that have 
previously been spray dried as well as the drying conditions.  
A vaccine for cholera was spray dried using Eudragit® L 30 D-55 or Eudragit® FS 30D as 
excipients with 1:10 vaccine to excipient w/w ratio. Significantly, a lower yield was observed at 
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lower inlet temperature (60 °C) compared with 80 and 100 °C. However, the antigenicity of the 
samples produced with Eudragit® L 30 D-55 at the highest inlet temperature (100 °C) was only 
88% compared with 98% at 60 and 80 °C which was mainly due to the high processing temperature 
(Ano et al., 2011). 
Saluja et al. compared spray drying and freeze-drying of the influenza subunit vaccine for 
pulmonary delivery (Saluja et al., 2010). It was shown that spray drying produces smaller particles 
(mass median size 2.6 μm) compared with spray freeze drying (mass median size 10 μm) at the 
same processing conditions. Live, attenuated measles virus vaccine was also spray dried and 
freeze-dried (Ohtake et al., 2010). Different stabilizing excipients have been employed to enhance 
vaccine stability at room temperature; sucrose-trehalose (17% w/v) were employed for 
stabilization against dehydration;  L-arginine (4% w/v) to prevent the protein to protein interaction 
and aggregation; human serum albumin (4% w/v) to stabilize the vaccine by a combination of 
enhanced Tg, increased viscosity and surfactant effect, glycerol (1.25 wt.%) as plasticizer to 
increase the interaction between glassy sugar matrix and the vaccine molecule. Moreover, 
potassium phosphate buffer (50 mM) was used in conjunction with divalent cations (CaCl2 and 
ZnCl2) to reduce process loss and maintaining the virus structure during processing, respectively.   
 
Table 1.7; Spray-dried vaccines. 
Vaccine Spray Drying Conditions Excipients Applications and 




et al., 2011) 
Büchi 191 Mini Spray Dryer 
Two fluid nozzle, 0.7 mm tip 
Feed rate: 5 L/min, Atomizing 
airflow: 600 L/h, Inlet 






vaccine (Saluja et al., 
2010) 
Büchi 190 Mini Spray Dryer 
Two fluid nozzle, 0.5 mm tip 
Feed rate: 5 mL/min , atomizing 
airflow: 800 Ln/hr, inlet 








temperature: 50-55 °C, aspirator 
air flow: 1000 L/min. 
Attenuated measles 
virus vaccines 
(Ohtake et al., 2010) 
Büchi B-190Mini Spray Dryer 
Feed rate: 0.5 mL/min, 
Atomizing nitrogen pressure: 15 
psi, Inlet temperature: N/A, 
Outlet temperature: 40 °C.  
Sucrose, Trehalose, 
Mannitol  
Enhancing stability at 
ambient temperature. 
Aluminium-salt for 
hepatitis B virus 
(Chen et al., 2010b) 
-Polysacharide-
protein conjugate 
vaccine for meningitis 
A (Chen et al., 2010b) 
 TMGEA Niro Mobile Minor
pilot plant 
Feed rate: 520 g/h, Atomizing 
gas flow: 6kg/h, Nozzle pressure: 
1.9 bar, Inlet temperature: 90-95 
°C, Outlet temperature: 61 °C.   
Sucrose, Trehalose  Thermostability 
Insulin (Exubera, 
Pfizer) (White et al., 
2005)  
Büchi B-190Mini Spray Dryer 
Feed rate: 5 mL/min, Atomizing 
airflow: 600 L/h, Inlet 
temperature: 110 – 200 °C, 





amounts of sodium 
hydroxide (for 
adjusting the pH to 
7.2-7.4) 
Pulmonary delivery of 
insulin.  
AERAs-402, live virus 
vector (Jin et al., 
2010) 
Inlet temperature: 65-125 °C, 
drying gas flow: 439-538 L/h, 
Outlet temperature: 34-50 °C, 




Pulmonary delivery  
Newcastle disease, 
live virus (Huyge et 
al., 2012) 
Büchi B-290Mini Spray Dryer 
Feed rate: 7.5 ml/min, Inlet 
temperature: 150 °C, Outlet 




Pulmonary delivery  
Hep B, alum-
adjuvanted subunit 
(Maa et al., 2003, 
Cape et al., 2008, 
Chen et al., 2010a) 
GEA Niro pilot plant Trehalose Freeze sensitive 
Vibrio cholera, killed 
cell (Esquisabel et al., 
2011) 




Feed rate: 5 L/min, atomization 
gas flow: 600 L/min, Inlet 
temperature: 60, 80 and 100 °C.  
 
1.4 Optimisation of the spray-drying process 
Optimising spray drying as a multivariate process with interconnected effective factors is 
highly challenging for process optimisation engineers and scientists. Traditionally, experimental 
approaches were focused on one factor at a time studies. However, by introduction of the Quality 
by Design (QbD) philosophy (Juran, 4 May 1992) into the pharmaceutical industry, the 
significance of statistical methods for designing and analysing the results of experiments was 
emphasized by regulatory authorities (FDA, EMA) (2009b). QbD has been defined as “a 
systematic approach to development that begins with predefined objectives and emphasizes 
product and process understanding and process control, based on sound science and quality risk 
management.” by ICH Q8(R2) (2009b). DoE is a structured and organized method for determining 
the relationship between factors affecting a process and the output of the process. The application 
of QbD in the pharmaceutical product development process is based on analyzing multivariate 
experiments using process analytical technology (PAT) and DoE to identify the CQAs and 
working environment of the process. DoE is recognised as the main toolbox for employing QbD 
in drug formulation and process development. In this section, a brief overview of recent 
developments in optimising spray drying via experimental procedure based on DoE is given.  
DoE is a method for clarifying and optimising the effect of process and formulation factors 
on final powder with decreased number of experiments and lower amount of required materials. 
The interactions between factors is estimated systematically using DoE. Additionally, it gives 
experimental information in a larger region of the factor space (CZITROM, 1999). Employing 
DoE approaches for mapping the effect of interrelated parameters and their interactions on multiple 
responses are highly recommended by pharma and biopharma regulatory agencies (2009b). Note 
that users of DoE as a process optimisation technique need to be aware of all process and 
formulation factors, their possible effects and interrelations on the spray-drying process. 
Otherwise, the designed DoE might not lead to a comprehensive understanding of the process. 
DoE has two main drawbacks as well. First, its complexity and dependency on statistics. 
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Moreover, the number of runs of the experiment required for getting the statistically significant 
factors especially in case of high-value therapeutics can be highly costly.  
Several DoE approaches and software packages have been used in the literature for 
optimisation of the spray-drying process in either pharma or biopharma applications. Vinjamuri et 
al. used a two-phase DoE for optimising spray dried ipratropium bromide microspheres for oral 
inhalation. In phase I, a 27-3 fractional factorial design was used to evaluate the individual 
formulation and process parameters and their possible effect on yield (%), particle size, particle 
size distribution and Tout. A screening design is informative in terms of defining the approximate 
working environment and determining the most critical factors affecting the output responses. 
Phase II was based on a response surface design to identify the critical individual, interaction and 
nonlinear effects of input factors (i.e. the factors that were found to be significant in the screening 
design) (Vinjamuri et al., 2017). The effect of five input variables (solution pH, solid content, inlet 
temperature, atomizer gas flow rate and feedstock feeding rate) on final yield and aerodynamic 
properties of spray dried antibiotic (ciprofloxacin hydrochloride) and nutrient dispersion 
compound (glutamic acid) was studied. A central composite design with 32 runs revealed that final 
yield is primarily controlled by variables that determine cyclone efficiency i.e. atomizer gas and 
feedstock flow rate and solid content. It would be informative if the authors could study the effect 
of drying air flow rate on the final yield of the process, as this effect is missed in this study (Ross 
et al., 2017).  
In our research group, we used a custom design with JMP® Pro Version 13.0 (SAS Institute 
Inc., Cary, NC) for formulating an amorphous solid dispersion of ibuprofen via spray drying (Ziaee 
et al., 2017). The effect of solid content, feedstock flow rate, inlet temperature and formulation 
factors such as API/excipient and composition of solvents on physical and chemical properties of 
the final powders were studied. Contours and empirical equations were derived by post analysis 
of 16 runs revealing the intercorrelations between the process and formulation factors. For 
instance, higher yield was achieved at formulations with higher excipient contents and solid 
contents between 5-10 wt.%. 
Mao and co-workers used a central composite design to identify the optimal drug:excipient 
ratio and spray drying temperature. Using Design-Expert® software (Stat-Ease, Inc., Minneapolis, 
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MN) they managed to figure out 4:5 and 120 °C as mannitol:itraconazole optimal ratio and inlet 
temperature, respectively(Sun et al., 2015).  
Table 1.8 describes pharmaceutics and biopharmaceutics that have previously been 
optimised for spray drying. This table summarizes the input factors and output responses, the DoE 
methods and the software used for statistical analysis. It provides helpful information on the most 
critical factors of spray drying of biomolecules that have been addressed so far by other 
researchers. More interestingly, in some cases a two-step DoE has been used for an initial 
screening of critical factors and subsequent analysis of the intercorrelations of factors and 
responses. It should be noted that a sound understanding of various DoE methodologies and their 
applications is a must for concise analysis of the results.  
 
Table 1.8; DoE methods, software packages, optimised input parameters and output responses. 
Input factors Output responses DoE method Software 
Atomizer gas flow rate, solid 
content, aspiration rate, 
feedstock feeding rate, inlet 
temperature  
Yield, volume median 
diameter, span, outlet 
temperature  
Two phases: 
1) 27-3 factorial, 
2) response 
surface 
JMP® Pro Version 
10.0.2 (SAS Institute 
Inc., Cary, NC) 
(Vinjamuri et al., 2017) 
pH, solution concentration, 
inlet temperature, atomizer 
gas flow rate, feedstock 
feeding rate 






(Warrenton, VA) (Ross 
et al., 2017) 
solid content, feedstock flow 
rate, inlet temperature, 
API/excipient and 
composition of solvents 
Yield, residual solvent, 
density, crystallinity, 
dissolution rate, particle size, 
morphology of ASD 
formulation of ibuprofen 
Custom design, 
16 samples 
JMP® Pro Version 13.0 
(SAS Institute Inc., Cary, 
NC) (Ziaee et al., 2017) 
Inlet temperature, 
mannitol:drug ratio 
Particle size Central 
composite design 
Design-Expert® 
software (Stat-Ease, Inc., 
Minneapolis, MN) (Sun 
et al., 2015) 
Water:organic solvent ratio, 
feedstock feed flow rate, solid 
content, atomizing air flow 
rate, type of organic solvent  
Dissolution rate, yield, actual 
drug load, particle size and 






software (Stat-Ease Inc., 
Minneapolis, USA) 
(Kauppinen et al., 2018) 
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Inlet, aspiration rate Yield, α-Tocopherol recovery 
rate 
Central 
composite design  
Stat Graphics 
5.0, Statistical Graphics 
Corporation, MD, USA 
(Bonferoni et al., 2018) 




Size of redispersed nano 
crystals of hesperidin 
Two phases: 





MODDE 9 software 
(Wei et al., 2018) 
Acetalated dextran 
nanoparticles wt. %, total feed 
concentration of mannitol and 
nanoparticles, inlet 
temperature,  
drug loading, encapsulation 
efficiency, water content, 
mass median 
aerodynamic diameter, 
geometric standard deviation, 
fine particle fraction, 
respirable fraction, emitted 
dose, percent size change, and 




Design Expert (Version 
8 Stat-Ease, Inc.)(Wang 
and Meenach, 2017) 
 
1.5 Conclusions 
Spray drying is increasingly being used in the biopharmaceutical sector and is currently 
being used in the pharmaceutical industry for producing amorphous solid dispersions and 
improving the solubility of low solubility APIs. As the biopharmaceutical sector continues to 
expand with new products, there is increased demand for new single-step processing techniques 
such as spray drying. This paper reviewed the fundamentals of the spray drying process and its 
application in the pharmaceutical and biopharmaceutical sectors. The highly influential process 
and formulation factors were reviewed with respect to their effect on final powder products, and 
an overview of the interrelation between these parameters was explained. Examples of 
commercially available spray dried pharmaceuticals and biopharmaceuticals were also 
highlighted.  
Formulating ASDs via spray drying has progressed immensely however, there are still 
numerous challenges to be addressed. Low solubility of small molecules in organic solvents, very 
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low Tg and stickiness, low flowability and compressibility of spray dried powders are some of the 
current challenges. Moreover, the need for precise experimental analytical methods for examining 
the radial distribution of components in spray dried particles is of extreme importance to particle 
engineering. There is still a need to address the gap in the literature on examining the effect of 
downstream processing on the stability of ASDs.  
Spray drying of biopharmaceuticals remains a developing area of research. The emergence 
and subsequent withdrawal of Exubera® from the market highlighted both technical and non-
technical challenges. Despite the challenges for spray drying of pharmaceuticals and 
biopharmaceuticals, this technology is highly promising in terms of its wide range of applications 
and versatility. Moreover, increasing interest in advancing continuous manufacturing has put 
technologies such as spray drying at the centre of focus for formulation processing of 
pharmaceuticals and biopharmaceuticals. Thus, the research in this field is increasingly expanding 
with exploring new opportunities for spray drying and more fundamental understanding.  
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A design of experiment (DoE) approach was used to investigate the critical formulation and 
processing parameters in spray drying ternary amorphous solid dispersions (ASDs) of ibuprofen. 
A range of 16 formulations of ibuprofen, HPMCP-HP55 and Kollidon VA 64 was spray dried. 
Statistical analysis revealed the interrelation of various spray drying process conditions and 
formulation factors, namely solution feed rate, inlet temperature, Active Pharmaceutical Ingredient 
(API)/excipients ratio and dichloromethane (DCM) /methanol (MeOH) ratio. Powder X-Ray 
diffraction analysis (PXRD) showed that all the samples with the lowest API/excipient ratio (1:4) 
were amorphous, while others were crystalline. Moreover, differential scanning calorimetry (DSC) 
analysis was employed to investigate ASD formulation more in-depth. The glass transition 
temperatures (Tg) of all ASDs were in the range 70-79 °C, while crystalline formulations displayed 
an endothermic peak of melting of crystalline ibuprofen in the range of 50-80 °C. The high Tg of 
ASDs was an indication of highly stable ASD formulations as verified via PXRD at day zero and 
afterward at 1, 1.5, 3 and 6 month intervals. The intermolecular interactions between ibuprofen 
molecule and excipients were studied by Fourier transform infrared spectroscopy (FTIR) and 
solid-state nuclear magnetic resonance (ssNMR) spectroscopy. FTIR and Carbon-13 ssNMR 
analysis indicated that hydrogen bond formation involving the carboxyl group in ibuprofen within 
the ASDs is likely. More importantly, the solubility of ibuprofen in ASD formulations is improved 
compared to pure ibuprofen. This was due to both the amorphous structure of ibuprofen and of the 












Approximately 40 % of newly developed drugs are poorly water-soluble or lipophilic in 
nature (B.B. Patel et al., 2015). Poor solubility of newly developed Active Pharmaceutical 
Ingredients (API) is one of the major challenges that the pharmaceutical industry has been facing 
over the last two decades. Sekiguchi et al. (K. Sekiguchi and N. Obi, 1961) reported the 
development of solid dispersions by incorporating highly soluble phase or carrier (hydrophilic) for 
enhancing the dissolution of poorly water-soluble drugs (hydrophobic). Since then, the use of solid 
dispersions (SDs) has been under investigation as one of the key strategies for improving the 
dissolution rate of poorly water-soluble API. Amorphous solid dispersions (ASDs) depict high 
dissolution rates due to their highly disordered structure and higher Gibbs free energy compared 
to crystalline materials (M. Zhang et al., 2012). However, the inherent thermodynamic instability 
of the amorphous materials often leads to the relaxation, nucleation and crystal growth of the API 
during storage (G. Van den Mooter, 2012, A.T.M. Serajuddin, 1999). Thus, inclusion of 
amorphous polymeric carriers can enhance the stability of the ASD formulations by either 
assembling new bonds with API molecule (L.S. Taylor and G. Zografi, 1997) or exerting an anti-
plasticizing effect due to their high glass transition temperature (Tg) (G. Van den Mooter et al., 
2001).  
Several technological approaches have been introduced for preparing ASD formulations 
including spray drying (SD) (D.W. Bloch et al., 1983, V. Caron et al., 2011) and hot-melt extrusion 
(HME) (R.J. Chokshi et al., 2005). Spray drying is one of the most commonly used techniques due 
to its advantageous capability in continuous, rapid, scalable and controllable particle 
manufacturing when compared to other technologies (A. Paradkar et al., 2004, A. Paudel et al., 
2013, A. Sosnik and K.P. Seremeta, 2015).  
Ibuprofen is a BCS class II anti-inflammatory drug with poor solubility being widely used 
in the market for more than 30 years. Binary ASDs of ibuprofen have been studied in the literature 
(M. Newa et al., 2007, N.M. Najib et al., 1986), however ternary ASDs have previously been 
reported to be superior to binary systems of other APIs in regard to their solid-state stability and 
dissolution rate (M.T. Davis et al., 2017, K. Six et al., 2004, D. Prasad et al., 2014). To date ternary 
ASDs of ibuprofen, their stability and dissolution properties have rarely been reported upon in the 
literature. This is possibly due to the low Tg of pure ibuprofen (-44.10 °C) thereby making it 
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significantly more challenging to formulate as a stable ASD (C. Wiranidchapong et al., 2015). 
Although there are reports available for spray drying of ibuprofen with other excipients such as 
mesoporous SBA-15 (S.C. Shen et al., 2010) or silica (S.C. Shen et al., 2011a) to enhance its 
solubility, none of these studies use a systematic approach to study physical and chemical 
properties of the final product. Thus, Design of Experiment (DoE) approach can be used to 
systematically screen, optimize and identify the critical and non-critical process and formulation 
factors (G. Kanojia et al., 2016).  
This study aims to develop and optimise the spray drying process for producing a novel 
ternary ASDs of ibuprofen with Kollidon VA64 and HPMCP-HP55. This novel formulation is 
designed to improve the stability and dissolution rate of the ASD formulation. Moreover, their 
presence could lead to controlled release of IBU during its passage through stomach and upper 
intestine as HPMCP-HP55 is only soluble at pH over 5.5. The DoE approach was employed to 
optimise the effect of formulation and process parameters on the final properties of the ASD 
powders. It reveals a systematic approach to the optimised spray drying strategy of ternary ASDs 
using a comprehensive DoE. This methodology is helpful in optimizing the formulation, process 
factors and characterizing ASDs and can be implemented in formulating other ternary ASDs.  
2.3 Materials and methods 
HPMCP-HP55® [Hydroxypropyl methylcellulose phthalate], Kollidon VA 64® 
[vinylpyrrolidone-vinyl acetate] were donated by, Shinetsu, Ashland and BASF, respectively and 
racemic mixture (RS)-ibuprofen was purchased from Phion chemicals Co. Dichloromethane 
(DCM) and methanol (MeOH) were both purchased from Sigma Aldrich.     
2.3.1 Design of experiments (DoE) 
 A design of experiments (DoE) was used to investigate the effect of various formulation 
and process parameters on the final properties of the powders. In this regard, a JMP® custom DoE 
module was used to devise a set of experiments. Five factors were selected to be studied, namely, 
solid content (5-15 w/v%), feed rate (2-10 mL/min), inlet temperature (70-85 °C), DCM:MeOH 
(1:3, 1:1 and 3:1) and API/excipients ratio (1:4, 1:2 and 2:3). It should be mentioned that the ratio 
of the excipients (HPMCP-HP55 and Kollidon VA 64) was kept at 1:1 for all compositions. Final 
62 
 
yield, residual solvent content, particle size distribution, density, phase structure and morphology 
were analysed after spray drying. Table 2.1 shows the experimental design matrix. 
 
Table 2.1; Experimental design matrix which shows the input parameters that were set for spray drying different 




Feed flow rate 
(%) /(ml/min) 
Inlet temperature (oC) DCM/MeOH API/Excipient 
1 5 10/3 70 1:3 2:3 
2 5 40/12 70 3:1 2:3 
3 10 25/7.5 77.5 1:1 1:2 
4 15 40/12 85 3:1 1:4 
5 5 40/12 70 3:1 2:3 
6 15 40/12 85 1:3 2:3 
7 5 10/3 85 3:1 1:4 
8 15 10/3 70 1:3 1:4 
9 10 25/7.5 77.5 1:1 1:2 
10 5 10/3 85 1:3 1:4 
11 5 40/12 85 1:3 1:4 
12 15 10/3 70 3:1 2:3 
13 15 10/3 85 3:1 2:3 
14 5 10/3 85 1:3 2:3 
15 15 40/12 70 1:3 1:4 
16 5 40/12 70 3:1 1:4 
 
2.3.2 Spray drying 
The solubility of all components in different solvent ratios (DCM/MeOH; 1:1, 1:3 and 3:1) 
was checked visually to confirm the homogeneity of the solution. All samples were spray dried by 
a Büchi B-290 mini spray dryer. The inert loop was enabled in conjunction with a condenser at -
20 °C to facilitate the use of organic solvents. The solid particles were collected by a high-
efficiency cyclone. A 2-fluid nozzle with a 0.7 mm cap was employed for atomizing the solution 
of ibuprofen and excipients. Due to the volatile nature of organic solvents nitrogen was selected 
as the atomizing gas with flow rate of ~473 NL/h (P = 1013.25 mbar and T = 273.15 K) and the 
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aspirator was set to 100% (35 m3.h-1) for circulating nitrogen as drying gas. Collected powders 
were transferred to a desiccator immediately after production until further analyses.   
2.3.3 Thermal analysis 
The residual solvent of all spray dried samples were analysed using a TGA-4000 
Thermogravimetric Analyser (Perkin-Elmer Instruments, Beaconsfield, Bucks, UK) using heating 
rate of 10 °C.min-1. Nitrogen was used with 30 mL.min-1 flow rate as instrument and balance purge 
gas.  
A PerkinElmer DSC 8500 equipped with a refrigerated cooling accessory (PerkinElmer, 
Workingham) using helium (30 mL.min-1) as the purge gas was used to study the solid-state of the 
spray dried samples. The instrument was calibrated at heating rates of 20 and 100 °C.min-1 using 
high purity indium and zinc to standardise the temperature and heat flow signals. Samples (~5.0 
mg) were weighed and placed in crimped DSC pans, then ramped from 20 to 200 °C at either 20 
°C.min-1 to check for crystallinity or 100 °C.min-1 to study the glass transition regions. Analysis 
was carried out using PE Pyris Thermal Analysis software, version 10.1. 
2.3.4 Powder X-Ray diffraction (PXRD)  
Spray dried powders were analysed using an X’pert PRO X-Ray diffractometer 
(PANalytical, Almelo, the Netherlands) with monochromatized Cu Kα radiation (λ = 0.15405 nm) 
attached to a computer running High Score Plus. The employed X-Ray generator setting was 40 
kV and 40 mA. Data were collected over the 2θ range of 5-50°, with a step size of 0.02 degrees/step 
and a step time of 40 s/step.  
2.3.5 Scanning electron microscopy (SEM) 
The morphology of the spray dried particles was investigated by high resolution field 
emission electron microscopy (SEM, Hitachi SU-70) operating at 5 kV with 15 mm working 
distance. To avoid overcharging of the samples they were coated with gold-palladium for 2 
minutes with 20 mA current.   
2.3.6 Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectrum of the samples was measured at ambient temperature using a Perkin-
Elmer Spectrum 100 FTIR spectrometer. The spectrum was collected at wavelengths of 4000-650 
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cm-1 using an attenuated total reflection (ATR) accessory with a ZnSe crystal. Samples were placed 
on the crystal with a pushing arm and 128 scans were collected for each sample at a resolution of 
4.00 cm-1. 
2.3.7 Solid-State Nuclear Magnetic Resonance (ssNMR) spectroscopy 
Carbon-13 NMR spectra were acquired on a Bruker Avance III HD NMR spectrometer 
operating at B0 = 9.4 T, with corresponding 
1H and 13C resonance frequencies of ν0(
1H) = 400.1 
MHz and ν0(
13C) = 100.6 MHz.  Samples were packed in 4 mm o.d. zirconia rotors with Kel-F 
caps under ambient atmosphere, and experimental 13C NMR spectra were acquired at natural 
abundance using a 4 mm double channel (X/H) Bruker MAS probe.  NMR spectra were referenced 
to TMS at δiso = 0 ppm by setting the high-frequency 
13C resonance in adamantane to 38.48 ppm 
(C.R. Morcombe and K.W. Zilm, 2003). The 13C NMR spectra were acquired in a single spectral 
window using the cross-polarization pulse sequence, with a magic angle spinning (MAS) rotor 
frequency of 12 kHz, a 1H 90° pulse width of 5 μs, and 50 kHz 1H decoupling during acquisition.  
Proton decoupling was carried out with the SPINAL64 (B.M. Fung et al., 2000) decoupling 
sequence.  A contact time of 4 ms was optimized using a crystalline sample of ibuprofen and was 
used for the acquisition of all 13C CP/MAS NMR spectra.  Recycle delays were 6 s; for each 
sample, the 1H T1 relaxation time(s) were checked using the saturation recovery pulse sequence to 
ensure that the recycle delay allowed for adequate relaxation between the collection of subsequent 
transients.  The NMR spectra of the pure samples of ibuprofen, HPMCP-HP55, and Kollidon VA 
64 consisted of 1.5k, 2k, and 1k transients, respectively. Carbon-13 CP/MAS NMR spectra of the 
ibuprofen-containing solid dispersions consisted of 10k transients each. Simulations of the 13C 
CP/MAS NMR spectra were carried out with DMfit (D. Massiot et al., 2002). 
2.3.8 Density Measurements 
True density of all spray dried samples was measured at ambient temperature using the 
Accupyc II gas displacement pycnometry system (Micromeritics®, Nocross, GA, USA) based on 
USP 699 standard procedure. Helium was purged into the sample chamber to determine its volume.  
True density is the mass of a substance divided by its volume, excluding open and closed (or blind) 
pores.  
2.3.9 Particle Size Distribution 
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Particle size distribution (PSD) was measured by Microtrac S3500 laser diffraction analyser 
(Microtrac®) with wavelength 780 nm. The instrument is coupled with a Turbotrac dry powder 
dispersion device.  
2.3.10 In Vitro Drug Release Studies 
The dissolution studies were performed following USP29 procedure for ibuprofen 
solubility studies. USP II apparatus was employed with paddle rotation speed at 50 rpm for 60 
minutes. The dissolution flasks were filled with 900 mL of prepared 0.1 M phosphate buffer with 
pH 7.2. They were immersed in a water bath to provide fixed and approved temperature at 37±0.5 
°C before starting the experiment. The paddles were then assembled and rotated with 50 rpm for 
15 minutes to equilibrate the dissolution media.  
After the equilibration process, the paddles were stopped and a fixed amount of each spray 
dried formulation containing 50 mg equivalent of ibuprofen was added to each dissolution media. 
The paddles were then immediately rotated at 50 rpm. Samples of 5 mL were collected from the 
media and filtered by using Nylon 0.45 µm filters at specified intervals of 5, 10, 15, 20, 30, 45 and 
60 minutes. The samples were then analysed using a UV spectrophotometer at 221 nm for 
ibuprofen. The readings were then translated to the amount of ibuprofen using a calibration graph 
derived from the standard solutions of ibuprofen in phosphate buffer.  
 
2.4 Results and discussions 
2.4.1 Polymer selection 
In this study, hydroxypropyl methylcellulose phthalate (HPMCP-HP55®) and 
vinylpyrrolidone-vinyl acetate (Kollidon VA 64®) were used as polymeric excipients. HPMCP-
HP55 is insoluble in gastric fluid but swells and dissolves in the upper intestine (T.K. Giri et al., 
2012). It has proved to be a proper hydrogen bond acceptor due to the presence of carbonyl groups 
in its structure. Moreover, it is an effective anti-plasticizer required for stabilizing the ASD 
formulations at room temperature due to its high glass transition temperature (Tg = 165 °C). On the 
other hand, Kollidon VA 64 is an amphiphilic compound readily soluble in both polar and nonpolar 
solvents. Thus, its application can enhance the solubility of the formulated API. 
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Application of one slow-dissolving polymer with high stabilizing properties along with a 
fast-dissolving one to improve the API dissolution properties has been proved to be a promising 
approach in ASD formulations (M.T. Davis et al., 2017).  
2.4.2 DoE analysis 
The collected powders were fluffy, white and electrostatically charged in some cases. The 
investigated process and formulation factors were X1: solid content, X2: feed flow rate, X3: inlet 
temperature, X4: DCM/MeOH ratio and X5: API/excipient ratio. The studied responses were A: 
residual solvent (wt.%), B: particle size [D50] (µm), C: density (g/cm3) and D: yield (%). Table 
2.2 summarizes the results of the analysed responses for all spray dried formulations.  
Table 2.2; Analysed responses of the spray dried powders.  
 
Residual Solvent (wt.%) Particle size [D50] (µm) Density (g/cm3) 
Crystallinity or 
Amorphicity  
1 0.55 3.59 1.19 C 
2 0.53 4.99 1.19 C 
3 0.53 6.95 1.19 C 
4 0.39 11.23 1.24 A 
5 0.60 5.39 1.19 C 
6 0.54 9.97 1.18 C 
7 0.28 3.78 1.22 A 
8 0.33 7.48 1.23 A 
9 0.45 6.20 1.19 C 
10 0.19 3.73 1.22 A 
11 0.21 5.46 1.23 A 
12 0.50 6.62 1.20 C 
13 0.18 6.51 1.18 C 
14 0.34 5.02 1.20 C 
15 0.20 8.06 1.25 A 
16 0.23 7.31 1.26 A 
2.4.3 Yield after spray drying 
A standard least squares model was used to generate quadratic equations for each response 
variable. The influence of the spray drying process parameters on the final yield was assessed. 
Some experimental runs led to yields as low as 20 % while others gave yields as high as 91 %. 
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Samples with lower API/excipient ratio (1:4) showed the highest yields. A higher proportion of 
excipients in the spray dried formulations seem to increase the process yield. This is most likely 
due to the higher glass transition temperature of these compositions compared to formulations with 
higher API/excipient ratios which results in lower wall deposition. The statistical analysis depicts 
the significance of the solid content and API/excipient ratio on the final yield (P-value < 0.05). 
Equation 1 depicts the fitted mathematical model (R2 = 0.79) for the interrelation of the final yield 
with solid content and API/excipient ratio.  
51 12.10542.198.121 XXD −−=        (1) 
This equation quantifies the effect of process and formulation parameters on the final 
process yield.  Figure 2.1 illustrates the contour map of the yield versus these factors. The highest 
yields were achieved at the values between 5-10 wt%.  
 
Figure 2.1; Contour plot of the effect of API/excipient ratio and solid content on the final yield of the spray drying 
process. 
 
2.4.4 Residual solvent content  
The influential spray drying factors on the residual solvent content were investigated. 
API/excipient ratio (𝑋5), solid content (𝑋1) and interaction effect of API/excipient ratio and solid 
content (𝑋5 × 𝑋1) were the most significant factors (P-value < 0.05) based on the statistical 
analyses. Residual solvent is an indication of a high drying efficiency. In addition, high amounts 
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of residual solvent may act as a plasticizer to facilitate recrystallization of the amorphous API (K. 
Alexander and C. Judson King, 1985, M. Maury et al., 2005, E.M. Littringer et al., 2012). Residual 
solvent of all samples was < 1 wt.% (Table 2.2). Moreover, it was observed to be lower in 
amorphous samples compared to crystalline samples. This was attributed to the proper drying 
process for these samples due to the presence of more excipients with higher Tg values compared 
to crystalline formulations. Equation (2) shows the fitted model to the factors (R2 = 0.90). This 
equation is significantly helpful in quantifying the residual moisture content of the final powders 
based on the formulation and process factors.  
2
55151 05.202.085.201.066.1 XXXXXA −−++−=      (2) 
 
Figure 2.2; Contour plot of the effect of API/excipient ratio and solid content on the final residual solvent content of the 
spray drying process. 
 
Figure 2.2 shows the effect of API/excipient ratio and solid content on the final residual 
solvent of the spray drying process. Analysis of the contour plot and fitted model equation shows 
that the API/excipient ratio is predominant influencing factor in defining the final residual solvent 
compared to the effect of solid content. 
2.4.5 Particle size (D50) 
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The particle size [D50] of all samples was revealed to be < 12 µm (Figure 8.1). Statistical 
analysis was employed to clarify the effective factors on the final particle size of the spray dried 
powders. 
Solid content (𝑋1), feed flow rate (𝑋2), inlet temperature (𝑋3), DCM/MeOH ratio (𝑋4) and 
interaction effect of feed flow rate and DCM/MeOH ratio (𝑋2 × 𝑋4) were the most significant 
factors (P-value < 0.05) based on the statistical analyses.  
424321 03.075.008.002.041.078.4 XXXXXXA +−+++−=     (3) 
Particle size was shown to be affected by multiple factors including solid content, feed flow 
rate and inlet temperature, all of which have synergistic effect on final particle size. The 
DCM/MeOH solvent ratio is the only parameter with negative effect on the final particle size (see 
Figure 2.3). Equation (3) is the fitted model (R2 = 0.95) showing the interrelation of the effective 
factors with final particle size.   
 
Figure 2.3; The contour maps of the effect of (a) solid content and feed flow rate on the particle size (D50), (b) inlet 
temperature and DCM/MeOH on particle size (D50). 
 
2.4.6 Morphology and particle size distribution  
The morphology of the dried powders was investigated using Scanning Electron 
Microscopy (SEM). Most of the samples consist of dimpled, raisin-like particles which is most 
likely due to the high Peclet number (Pe > 1) and rapid solidification of the particles (Rizi et al., 
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2011, R. Vehring, 2008). This is because of the high solvent evaporation rate or low diffusional 
rate of solutes in solvents. On the other hand, samples with spherical morphologies have 
experienced slower drying processes due to either lower evaporation rates or a faster diffusional 
rate of solutes. (Sample 12 (feed rate: 10%, inlet temperature: 70 °C, API/excipient ratio: 2:3, solid 
content: 15 wt.%, DCM/MeOH ratio: 3:1) and sample 13 (feed rate: 10%, inlet temperature: 85 
°C, API/excipient ratio: 2:3, solid content: 15 wt.%, DCM/MeOH ratio: 3:1)). These samples were 
spray dried at the lowest possible feed rate (5%) leading to the very slow solvent evaporation. 
Moreover, the high amount of smaller API molecule compared to heavier polymeric molecules 
(API/excipient ratio: 2:3) results in higher diffusional rate within solvents for these samples. Thus, 
solutes have sufficient time to redistribute and form dense solid particles with spherical 
morphology. Figure 2.4 illustrates the SEM images of some of the spray dried samples.  
 
Figure 2.4; Scanning electron microscopy (SEM) of (a) sample 15, (b) sample 13, (c) sample 10 and (d) sample 12.  
 
2.4.7 Analysis of crystallinity, PXRD  
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The phase structure of all samples was analysed with Powder X-Ray Diffraction (PXRD) 
technique. Figure 2.5 shows the XRD graphs of the 16 spray dried samples. The PXRD analysis 
was done at day zero and afterward at 1st, 1.5, 3rd and 6th month intervals. Characteristic peaks of 
crystalline Ibuprofen were present in the spectra of 9 samples. On the other hand, no peaks could 
be detected at any time frame for other 7 samples. Thus, it was concluded that these samples are 
amorphous. Investigating the correlation between the PXRD results and process/formulation 
factors, it was revealed that the common factor among all amorphous samples is the API/excipient 
ratio. These samples are composed of the lowest API/excipient ratio (1:4). Hence, it can be 
concluded that the most significant factor in designing amorphous solid dispersions of ibuprofen 
is the formulation factor (API/excipient ratio) rather than process parameters.  
 
Figure 2.5; Powder X-Ray diffraction (PXRD) patterns of all samples after 6 months storage in desiccator at room 
temperature. 
 
2.4.8 Thermal properties, DSC 
Differential scanning calorimetry (DSC) was used for more in-depth analysis of the effect 
of formulation on the phase structure of the spray dried samples. In the first step, a modified 
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version of the Gordon-Taylor equation (M. Gordon and J.S. Taylor, 1952) was employed to 
































=           (6) 
 
Where, x  is the mass fraction of each component. Calculated Tg of three different 
formulations with various API/excipient ratios are presented in Table 2.3. As expected, the 
composition with the lowest API content (composition 1) has the highest Tg. Conversely, the 
remaining two compositions show a lower Tg which does not favour the development of stable 
amorphous solid dispersions.  
Table 2.3. Calculated glass transition temperatures of the different spray dried formulations. 
 
Formulation 1  Formulation 2  Formulation 3  
Kollidon VA 64 (wt.%) 40 34 30 
HPMCP-HP55 (wt.%) 40 34 30 
IBU (wt.%) 20 32 40 
Theoretical T
g 
(°C) 76.60 46.04 27.97 
Kollidon VA64: Tg: 107 °C (K. Kolter et al., 2012), ρ:1.2 g.cm-1 (2017), HPMCP-HP55: Tg: 145 °C (Augsburger and 
Hoag, 2016), ρ:1.28 g.cm-1(Lei et al., 2016), ibuprofen: Tg: -44.1 °C (Dudognon et al., 2008), ρ:1.03 g.cm-1 (M. J. O'Neil, 2001).  
Following the theoretical calculations, DSC analysis was performed on all spray dried 
samples. As expected, based on the Gordon-Taylor calculations, samples with 20 wt.% ibuprofen 
(amorphous samples based on PXRD analysis) revealed Tg ~70 - 79 °C. Figure 2.6 shows the DSC 
graph of the amorphous spray dried samples. The absence of endothermic melting peak of 
ibuprofen confirms full amorphicity of these samples. Moreover, high Tg of the amorphous 
samples can be another reason for the high process yields of these compositions due to their low 





Figure 2.6; DSC thermograms of the PXRD-amorphous spray dried samples. (Heating rate: 100 °C.min-1.)   
 
On the other hand, no Tg was observed during DSC analysis of samples with API content 
higher than 20 wt.%. However, these samples showed an endothermic peak at ~50-80 °C due to 
the presence of crystalline ibuprofen. Pure crystalline ibuprofen has a sharp melting endothermic 
peak at 72 °C. Thus, the proportion of the area under the endothermic peak of these compositions 
to the one of pure crystalline ibuprofen was used as a measure of percentage of crystallinity in 
these samples. A portion of amorphous ibuprofen was present in all crystalline samples. However, 
the amount of amorphous ibuprofen was highly dependent on the API/excipient ratio. Thus, 
samples 3 and 9 with API/excipient ratio of 1:2 have lower crystalline ibuprofen content compared 
to samples with 2:3 ratio. This further highlights the critical influence of formulation composition 
on the phase structure on final product (Figure 8.2).  
2.4.9 Intermolecular interactions 
Fourier Transform Infrared Spectroscopy (FTIR) 
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The significant effect of hydrogen bonding in the formation and stability of ASDs has been 
reported earlier (M. Vasanthavada et al., 2005, L.S. Taylor and G. Zografi, 1997). Therefore, to 
recognize the possible molecular interactions between ibuprofen and the two excipients, all 
samples were analysed by FTIR. Figure 2.7 shows the FTIR spectra for ibuprofen and contains 
characteristic stretches at 1720 cm-1 (due to carbonyl stretching of isopropionic acid group) and 




Figure 2.7; ATR-FTIR spectra of ibuprofen, Kollidon VA 64, HPMCP-HP55, formulation 1 (crystalline spray dried 




Furthermore, the characteristic IR stretch of ibuprofen at 1720 cm-1 is completely omitted 
from the spectra of ASDs however a small shoulder of this peak is present in crystalline spray 
dried samples. This is in accordance with what Xu et al. has reported for the hydrogen bond 
formation between carboxyl group of ibuprofen and amide group of Kollidon VA64 (L. Xu et al., 
2007). Moreover, Sekizaki et al. revealed the mechanism of interaction between ibuprofen and 
polyvinylpyrrolidone (PVP) (H. Sekizaki et al., 1995). They mentioned the C-H stretching for 
ASD compounds of ibuprofen and PVP to be in the range of 2940-2960 cm-1 with a broad baseline 
stretched from 2400-3500 cm-1. This has also been observed in our ASD formulations (sample 4) 
which indicates the presence of hydrogen bonding between ibuprofen and Kollidon VA64. 
Moreover, they observed the broadening of both peaks of 1720 cm-1 of ibuprofen and the 1670 cm-
1 of cyclic amide C=O stretch of PVP in spectra of ASD formulations. This is clearly visible in the 
spectrum of sample 4 in Figure 2.7. Bogdanova et al. have studied the intermolecular interactions 
of ibuprofen with Kollidon VA64 comprehensively elsewhere (S. Bogdanova et al., 2005). They 
observed that the intensity of the peaks at 2633 and 2731 cm-1 (these bands are attributed to the 
stretching vibrations of the cyclic dimerized hydroxyl groups) was decreased and finally 
disappeared due to the dimerized OH groups by increasing the PVP content. This disappearance 
of these peaks in the IR spectra of sample 4 is observed. This is due to the absence of ibuprofen 
crystal structure. Moreover, the characteristic sharp peak of crystalline ibuprofen at 779 cm-1 is 
present in all crystalline formulations but absent in amorphous formulations as expected 
(Previously confirmed to be amorphous by PXRD).   
 
Solid State Nuclear Magnetic Resonance (SSNMR) Spectroscopy  
Carbon-13 CP/MAS NMR spectra of bulk ibuprofen, HPMCP-HP55, Kollidon VA64, and 
samples 1 and 4 are shown in Figure 2.8.  A detailed assignment of the 13C NMR spectrum of solid 
ibuprofen was reported by Geppi et al. in 2005 (M. Geppi et al., 2005). Note that our 13C CP/MAS 
NMR spectrum of bulk ibuprofen is consistent with that previously published in the literature;(M. 
Geppi et al., 2005) peak assignments are reported in Table 8.1 (see Figure 8.3 for atom labels). As 
multiple peaks from the excipients overlapped with those from ibuprofen in the 13C CP/MAS NMR 
spectra of samples 1 and 4, the program DMfit (D. Massiot et al., 2002) was used to simulate the 
spectra.  A representative simulation is shown in Figure 2.8. 
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In the NMR spectrum of sample 1, narrow, sharp peaks like those observed in the 13C NMR 
spectrum of bulk ibuprofen are present; these are notably absent in the 13C NMR spectrum of 
sample 4.  This is consistent with our powder X-Ray diffraction data, which indicate that 
crystalline ibuprofen is present in sample 1 and absent in sample 4.  Broad peaks with chemical 
shift(s) approximately corresponding to those of crystalline ibuprofen in the 13C NMR spectra of 
both samples 1 and 4 are indicative of the presence of amorphous ibuprofen (see Figure 2.8, Table 
S1).  The 13C NMR data indicate that amorphous ibuprofen is likely interacting with another 
moiety in the ternary solid dispersions. The sharp peak at δiso = 183 ppm indicates that the 
crystalline ibuprofen in sample 1 is not interacting with the excipient molecules; the chemical shift 
of this peak agrees with what we obtained in the bulk.  However, in the 13C NMR spectra of both 
1 and 4, broad peaks assigned to amorphous ibuprofen are observed at δiso = 178 and 177 ppm, 
respectively.  The difference in chemical shift between these peaks and that in the bulk sample of 
ibuprofen are evidence of a structural change at the carboxyl carbon atom in the amorphous solid.  
Shifts in the 13C NMR resonance frequency of the carboxyl carbon atom similar to this have been 
reported for solid dispersions of ibuprofen and polyvinylpyrrolidone (PVP) (H. Sekizaki et al., 
1995) as well as for ibuprofen in functionalized organic nanotubes (N. Liu et al., 2016). In the 
research of Sekizaki et al., (H. Sekizaki et al., 1995) a shift in resonance from δiso = 181 ppm in 
the bulk form to 178 ppm in the solid dispersion was attributed to the carboxyl group in ibuprofen 
interacting with the excipient, PVP, via hydrogen bonding.  In the research of Liu et al., (N. Liu et 
al., 2016) a shift in carboxyl carbon resonance frequency from the bulk value of δiso = 183.0 ppm 
to 179.0 ppm was attributed to ibuprofen monomers undergoing intermolecular interactions with 
hydroxyl groups on the outer surface of the functionalized nanotubes.  
In this research, the shift in carboxyl carbon resonance frequency from δiso = 183 to 177 or 
178 ppm is most likely attributed to hydrogen bond formation involving the carboxyl group in 




Figure 2.8; Experimental and simulated 13C CP/MAS NMR spectra of bulk ibuprofen, HPMCP-HP55, Kollidon VA 64, 
and samples 1 and 4.  Experimental 13C NMR spectra were acquired at B0 = 9.4 T.  Simulations were generated using DMfit. 
Individual peaks used in the simulation are shown under the lower trace in the insert (top left).  
2.4.10 In-vitro dissolution  
From the dissolution profile, it was observed that dissolution rate of ibuprofen from all 
spray dried samples increased markedly compared to pure untreated ibuprofen. All amorphous 
samples showed burst release with over 80 % of the drug released in less than 10 min compared 
to the control pure ibuprofen with less than 20 % released at the same time (Figure 2.9). There are 
two possible explanations for the improved dissolution rate of these samples. First, this can be 
rooted in the fully amorphous structure of ibuprofen in these samples (A.A. Elkordy and E.A. Essa, 
78 
 
2010). The lower dissolution rate in other samples is due to the slower dissolution kinetics of 
crystalline ibuprofen compared to its amorphous form (S.C. Shen et al., 2011b). This effect is more 
obvious when comparing the dissolution profile of ASDs (e.g. sample 4) with crystalline spray 
dried samples (e.g. sample 1).  
Additionally, the overall increase in the amount of dissolved API can be attributed to the 
presence of polymeric entities such as Kollidon VA64 with amphiphilic nature which increases 
the wettability of the API and dissolution rate (S.Y. Chan et al., 2015).   
 
Figure 2.9; In-vitro dissolution profile of the pure ibuprofen and spray dried samples; formulation 1 (crystalline spray 
dried formulation) and formulation 2 (amorphous spray dried formulation).  
 
2.5 Conclusions 
In summary, we have successfully spray dried ternary amorphous solid dispersions of 
ibuprofen. Moreover, the capability of a DoE approach in formulating ternary ASDs of ibuprofen, 
enhancing their stability and engineering the particles properties was verified. Statistical analyses 
uncovered the critical process and formulation factors on the final yield, residual moisture content 
and particle size [D50]. API/excipient ratio was revealed to be the most critical factor in 
formulating ASD samples. It was shown that all samples with 20% API content were in the 
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amorphous form, while others were partly crystalline. In-vitro dissolution studies showed higher 
dissolution rate for amorphous samples compared to crystalline samples further highlighting the 
effect of amorphous phase structure on API dissolution relative to amorphous polymeric 
excipients. The DSC and FTIR analyses shed more light on the improved dissolution rate of the 
amorphous samples. DSC thermograms of amorphous samples depicted Tg in the range of 70-79 
°C range due to the presence of ASDs of ibuprofen. Moreover, shifted or absent peaks in the FTIR 
spectra in addition to shifts in the 13C NMR resonance frequency of the carboxyl carbon atom are 
most likely due to hydrogen bonding between the excipients and the ibuprofen molecules. This 
research reveals the potential of a DoE approach in developing successful spray drying strategies 
which can enhance our knowledge of the optimisation of both formulation and process factors, 
simultaneously. 
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Amorphous solid dispersion (ASD) is one of the most promising strategies for improving 
the solubility of active pharmaceutical ingredients (APIs) with low aqueous solubility. Solvent-
based techniques such as electrospinning (ES), spray-drying (SD) and rotary evaporation (RE), 
have been used for formulating ASDs. To date however, the effects of these processing techniques 
such as the different drying kinetics and presence of electrical charge on the physicochemical 
properties and quality of ASDs has remained mainly unexplored. Therefore, this paper uses 
ibuprofen (IBU) as a model BCS class II API with two cellulosic excipients, HPMCAS and 
HPMCP-HP55 to produce ASDs employing ES, SD and RE techniques and study their impact on 
the physicochemical properties of ASDs such as morphology, crystallinity, dissolution rate, 
specific surface area and the homogeneity of formulations. It was shown that while ASD formation 
is only dependent on API:excipient ratio, the ASD homogeneity is totally dependent on processing 
technique. Principal component analysis (PCA) of Raman spectra of crystalline and amorphous 
IBU was used for qualitative analysis of the homogeneity of ASDs as a determining factor for the 
stability of ASDs over long-term storage. ES sample was the least homogenous ASD compared 
with RE and SD sample which could potentially influence its long-term storage stability. 
Moreover, the electrospun samples had the highest API release rate which was further confirmed 
to be due to the nanofibrous morphology and higher specific surface area of these samples. The 
presence of crystalline IBU in samples and the ASD forming strengths of each of the polymers 
were assessed using Differential Scanning Calorimetry (DSC). The higher melting point 
depression, higher Tg, and increased abundance of functional groups suitable for hydrogen bonding 
of HPMCAS proved it as a better ASD former compared with HPMCP-HP55. This paper studied 
the significance of three solvent-based processing techniques (ES, SD and RE) on the 
physicochemical properties of ASDs such as dissolution rate, specific surface area and 








Enhancing the solubility of poorly water-soluble drugs is currently one of the major 
challenges facing the pharmaceutical industry (Albadarin et al., 2017, Kalepu and Nekkanti, 2015, 
Van den Mooter, 2012, Baghel et al., 2016). Over 40 % of newly developed drugs never reach 
patients due to low or reduced solubility (Takagi et al., 2006, Ziaee et al., 2019, Ziaee et al., 2017). 
According to the Biopharmaceutical Classification System (BCS), the majority of newly 
developed drugs are classified as class II and exhibit low solubility despite being highly permeable. 
Solubility is, therefore, a significant limiting factor in drug development and the rationale for 
formulating advanced drug delivery systems with improved dissolution and bioavailability profiles 
is clear (Lipinski et al., 2012).  
Formulating amorphous solid dispersions (ASDs) is one of the most promising strategies 
for improving the solubility of active pharmaceutical ingredients (APIs) with low aqueous 
solubility (A.T.M. Serajuddin, 1999, Singh and Van den Mooter, 2016, Leuner and Dressman, 
2000). ASDs can be specifically defined as the dispersion of a drug/API, preferably at molecular 
level, in an amorphous polymeric matrix (Huang and Dai, 2014) and was first introduced by 
Sekiguchi and Obi in 1961 by formation of a eutectic mixture of sulphatiazole with water-soluble 
excipients (Sekiguchi and Obi, 1961, G. Van den Mooter, 2012, Chen et al., 2018, Bhardwaj et al., 
2018). Since then multiple ASDs have received FDA-approval and been introduced to the market 
(Ziaee et al., 2019). The choice of excipient, API/Excipient ratio and processing technique have 
previously been shown to be critical factors in developing a successful ASD formulation (Ziaee et 
al., 2017). At certain API concentrations, polymeric excipients with elevated glass transition 
temperatures (Tg) have been shown to enhance antiplasticization thereby hindering nucleation and 
subsequent growth of crystals. The ASD formulation processing technique has also been shown to 
alter the final solid-state properties such as stability, dissolution rate and morphological 
appearance. Techniques including spray drying and electrospinning have recently been 
investigated with a view to improving final properties, in particular particle morphology for 
subsequent downstream processing (Padrela et al., 2019, Solomon et al., 2019). Nagy et al. 
investigated the effect of different processing techniques in terms of final products dissolution rate 
(Nagy et al., 2013, Nagy et al., 2015a). Final product dissolution rate is a significant consideration 
when formulating ASDs as in addition to low aqueous solubility, the absorption of most poorly 
soluble drugs is dissolution rate limited resulting in the API passing the absorption site even before 
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complete dissolution (Baghel et al., 2016). Therefore, a comprehensive understanding of the effect 
of processing technique and physicochemical properties with respect to dissolution rate is of 
crucial importance.  
Spray drying (SD) is a solvent based technique in which solutions are atomized and dried 
using high heat in a drying chamber and is known for high throughput and compatibility with 
continuous manufacturing (Ziaee et al., 2019). SD has previously been demonstrated as an 
effective technique for the preparation of ASDs (Patterson et al., 2007, Davis et al., 2017, Ziaee et 
al., 2017). In addition, techniques such as rotary evaporation (RE) (Wegiel et al., 2013, Frizon et 
al., 2013) and electro-spinning/electro-spraying (ES) (Nagy et al., 2015a, Nagy et al., 2012, Yu et 
al., 2010) have attracted attention from both industrial and academic communities as potential 
processing techniques for new ASD formulations (Wang et al., 2017, Vigha et al., 2017, Nagy et 
al., 2015b). Electrospinning/Electrospraying is a versatile, flexible and one-step process for 
producing nano/micro sized particles and fibres from liquid feedstocks and operates by utilising 
electric force to draw charged threads of solution onto a grounded collector (Yang et al., 2016, 
Pamudji et al., 2013, Vigha et al., 2017, Browne et al., 2019). Rotary evaporation is a relatively 
fast solvent evaporation technique that has been adopted for ASD production (Tominaga, 2013, 
Bennett et al., 2015) however formulations produced by this method often require further 
processing steps when compared those produced by SD or ES. Z. K. Nagy et al. studied the effect 
of SD, film casting and ES on formation of ASDs of itraconazole and their subsequent dissolution 
properties. They observed higher dissolution rates for ES compared to SD samples which was 
attributed to the higher specific surface area of the electrospun fibres (Nagy et al., 2015a).  
This work focusses on examining the impact of three different solvent-based processing 
techniques i.e. ES (electrospinning), SD (spray drying) and RE (rotary evaporation) on the final 
physiochemical and dissolution properties of ASD formulations of Ibuprofen (IBU) with the 
excipients HPMCAS and HPMCP-HP55. This work explores the effect of different factors such 
as electrical charge involved in ES, slow drying kinetics of RE and fast evaporation rate of SD on 
the final composition and formation of ASD and the physicochemical properties of ASDs. 
Ibuprofen, a BCS class II anti-inflammatory drug was selected as a model API due to its low Tg 
and high propensity to crystallise. The t50 (time taken for a 50% recrystallisation from amorphous 
to crystalline) for pure IBU is in the order of minutes and as such it is a challenging API to 
formulate as a stable ASD composition (Wiranidchapong et al., 2015, Rehder et al., 2013).  
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3.3  Materials and methods 
Hypromellose phthalate HPMCP-HP55® and hypromellose acetate succinate (also known 
as hydroxypropyl methylcellulose acetate succinate) HPMCAS® were donated by Shin-Etsu and 
Ashland, respectively. A racemic mixture of (RS)-ibuprofen (IBU) was purchased from Phion Ltd. 
(UK). Dichloromethane (DCM) and methanol (MeOH) were both purchased from Sigma Aldrich. 
Figure 3.1 shows the molecular structure of HPMCAS and HPMCP-HP55. Water absorption 
resistance of HPMCAS and HPMCP-HP55 enhances the stability of ASDs due to their high Tg 
even at high relative humidity (Huang and Dai, 2014). All the excipients were used from the same 
batch provided by supplier in order to prevent the effect of variability between different batches.  
 
Figure 3.1; Molecular structure of excipients (a) HPMCAS, (b) HPMCP-HP55. 
 
3.3.1 Preparation of Solid dispersions  
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Solid dispersions of IBU with HPMCAS and HPMCP-HP55 as the polymeric carriers were 
prepared via spray drying (SD), electrospinning (ES) and rotary evaporation (RE) at differing 
compositions as outlined in Table 3.1. DCM:MeOH at a ratio of 3:1 was used as the solvent for 
all formulations. Previous work has demonstrated the suitability of this solvent ratio for both IBU 
and the aforementioned excipients (Ziaee et al., 2017).  
 
Table 3.1; Composition of the samples prepared via spray drying, electrospinning and rotary evaporation techniques. 
Sample composition IBU : HPMCAS or HPMCP-HP 55 
1 1 : 9 
2 3 : 7 
3 5 : 5 
4 7 : 3 
5 9 : 1 
 
Spray drying (SD): All spray drying experiments were performed on a Büchi B-290 mini 
spray dryer in inert loop mode in conjunction with a condenser at −20 °C to facilitate the use of 
organic solvents. A high efficiency cyclone was used to trap the spray dried particles once formed. 
The 2-fluid nozzle utilised in this study had a 0.7 mm cap and an atomization gas flow rate of ~357 
NL/h (P = 1013.25 mbar and T = 273.15 K). An inlet temperature of 55 °C and feed rate of 4.5 
ml.min-1 was used for all samples. For spray drying, the process parameters were selected based 
on the work done by Ziaee et al. and our observations during spray drying process (Ziaee et al., 
2017). However, applying the inlet temperatures as high as 70 °C for samples with over 20 wt.% 
ibuprofen led to high levels of stickiness. Therefore, a lower temperature of 55 °C was selected as 
inlet temperature with lowest stickiness and highest achievable yield for all samples. Due to the 
volatile nature of organic solvents, nitrogen was selected as the atomizing gas. The aspirator was 
set to 100% (35 m3·h−1) for circulating nitrogen as the drying gas. Dried powders were transferred 
to a desiccator immediately after production and stored until further analyses.  
Electrospinning (ES): Electrospinning was carried out under ambient conditions (24 ± 1°C 
and relative humidity of 36.5 ± 3%). Samples were electrospun based on the optimized parameters 
studied by L. Padrela et al. (Padrela et al., 2019). The solutions were sprayed using a custom-built 
electrospinning device containing a plastic syringe with a metallic needle. The needle was 
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connected to a high voltage supply (Bertan, Series 230). Samples were collected on grounded 
aluminum foils positioned 14 cm from the needle. The solution was pumped at a flow rate of 15 
ml.hr-1 at voltage of 15-20 kV. Deposited samples were removed from the foil and stored in a 
desiccator until further analyses.  
Rotary evaporation (RE): A Buchi R-100 rotary evaporator with a water bath temperature 
of 60 °C (based on the combined evaporation temperature of DCM and MeOH) was used for all 
evaporation experiments. Samples were placed in a round bottomed flask and lowered into the 
water bath with a rotational speed of 75 rpm. For all RE experiments the vacuum pump was set to 
722 mbar. After the majority of the solvent had been removed as indicated by the lack of formation 
of droplets on the condenser rings, the vacuum was decreased to 500mbar, followed by 250mbar, 
50mbar and 5 mbar before the vacuum was released. Samples were placed in a vacuum oven at 40 
°C for 24 hours to remove any residual solvents. Samples were milled and sieved by a 100 µm 
sieve and stored in a desiccator until further analyses.  
3.3.2 Powder X-Ray diffraction (PXRD) 
Samples were analysed using an X’pert PRO X-ray diffractometer (PANalytical, Almelo, 
the Netherlands) with monochromatized Cu Kα radiation (λ=0.15405 nm) attached to a computer 
running High Score Plus. The employed X-ray generator was set to 40 kV and 40 mA. Data were 
collected over the 2θ range of 5–50°, with a step size of 0.02 °·step-1 and a step time of 40 s·step-
1. 
3.3.3 Thermal analysis 
The residual solvent of all samples was analysed using a TGA-4000 Thermogravimetric 
Analyser (Perkin-Elmer Instruments, Beaconsfield, Bucks, UK) at a heating rate of 10 °C·min−1 
and a nitrogen purge gas flow rate of 30 mL.min-1. 
A PerkinElmer Pyris I Differential Scanning Calorimeter (DSC) equipped with a 
refrigerated cooling accessory (PerkinElmer, Workingham) using nitrogen as the purge gas (30 
mL·min−1) was employed to evaluate the thermal transitions of the samples. Samples (∼5.0 mg) 
were weighed and placed in crimped DSC pans, then ramped from 20 to 200 °C at a heating rate 
of 10 °C·min−1. Percentage crystallinity was calculated using the ratio of the area under the 
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endothermic melting peak in all processed samples and the area under the melting peak of pristine 
IBU. Analysis was carried out using PE Pyris Thermal Analysis software, version 10.1. 
In order to investigate the amorphous and crystalline content of IBU in samples, the area 
under the melting peak of IBU was calculated and used to quantify the amount of crystalline IBU.  
3.3.4 Scanning electron microscopy (SEM) 
The morphology of all samples was investigated by high resolution field emission electron 
microscopy (SEM, Hitachi SU-70) operating at 5 kV with 15 mm working distance. Samples were 
coated with gold-palladium for 1 min with 20 mA current to avoid over-charging. 
3.3.5 Spectroscopic analysis 
Fourier transform infrared spectroscopy (FTIR): FTIR spectra were recorded at ambient 
temperatures using a Perkin-Elmer Spectrum 100 FTIR spectrometer at wavelengths of 4000–650 
cm−1 using an attenuated total reflection (ATR) accessory with a ZnSe crystal. Samples were 
placed on the crystal with a pushing arm and 128 scans were collected at a resolution of 4.00 cm−1. 
Confocal Raman spectroscopy: Raman spectroscopy was carried out using a LabRAM HR 
Evolution (HORIBA UK Ltd., Stanmore, UK) in a backscatter configuration with 785 nm 
excitation, laser power 499 mW and exposure time of 10 s for 2 accumulations. Spectra were 
collected using a 100x objective at a 4 cm−1 resolution from 717 to 1418 cm−1 using a grating of 
600 gr.mm−1. Spectral range was selected in the region which exhibited the greatest variation for 
IBU-HPMCAS solid dispersions. 
Hot stage Confocal Raman spectroscopy: Amorphous IBU was created in-situ on a 
THMS600 microscope hot stage (Linkam Scientific, UK) by heating Form I crystalline IBU at 
10 °C.min-1 up to 80 °C and allowing cooling under ambient conditions. 
Raman Mapping: Three dispersions of IBU-HPMCAS, prepared by ES, SD and RE were 
analysed by Raman mapping on two separate days. For each map 160 spectra were collected in an 
8 by 20 rectangular arrangement with a spacing of 1 µm between points in both the x and y axis. 




Raman Spectral analysis: The full set of spectral data was analysed using R: A Language 
and Environment for Statistical Computing (Team, 2013). Spectra were imported using a 
customised import routine for the HyperSpec package followed by pre-processing including 
transformation by Extended Multiplicative Signal Correction. Spectral variation was illustrated 
using principal component analysis with consideration for the first five components. 
3.3.6 Density measurements 
True density of all samples was measured at ambient temperature using the Accupyc II gas 
displacement pycnometry system (Micromeritics®, Nocross, GA, USA) based on USP 699 
standard procedure. Helium was purged into the sample chamber to determine its volume. True 
density is the mass of a substance divided by its volume, excluding open and closed (or blind) 
pores. 
3.3.7 In vitro drug release studies 
The dissolution studies were performed in sink condition following USP29 procedure for 
IBU solubility studies in order to keep the results comparable and relevant to other work in 
literature. USP II apparatus was employed with a paddle rotation speed of 50 rpm for 60 min. 
Equivalent of 50 mg of IBU was added to each dissolution flask. Dissolution rates were recorded 
in 900 mL of 0.1 M phosphate buffer with pH 7.2 (simulated gastrointestinal fluid) which was 
equilibrated to 37 ± 0.5 °C. 5 mL samples were collected from the media and filtered using Nylon 
0.45 μm filters at specified intervals of 5, 10, 15, 20, 30, 45 and 60 min.  
Preparation of standards and calibration curve 
Stock solution of IBU (1 mg/mL) was prepared in 1:1 (v/v) acetonitrile:0.1% (v/v) 
orthophosphoric acid. Calibration curves (0.122 µg/mL – 250 µg/mL) were prepared by 
subsequent dilution in the mobile phase. 
Sample preparation  
An aliquot of 500 μL of mobile phase was added to the same volume of each collected 
dissolution sample. Diluted samples were then vortexed, filtered through 0.25µm syringe filters 
and transferred to glass vials for analysis by HPLC. 
HPLC analysis and quantification 
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HPLC was performed with an Agilent 1260 Infinity Series system (Agilent Technologies, 
Waldbronn, Germany) equipped with a temperature-controlled column compartment and DAD 
VL detector. The mobile phase consisted of 1:1 (v/v) acetonitrile and 0.1% (v/v) orthophosphoric 
acid. Separations were performed on a Kromasil C18 5 μm, 4.6 d 250 mm column (MZ-
Analysentechnik GmbH, Mainz-Germany) at a flow rate of 1.0 mL/min.  An isocratic mobile phase 
(total run time 15 min) was used for the separation of IBU with an injection volume of 10 μL. IBU 
was detected at a retention time equivalent to 7.805 min at a wavelength of 195 nm with a limit of 
quantification (LOQ) of 0.122 µg/mL. Chromatography data was collected and analysed by 
Agilent OpenLAB 2.2 chromatography data systems (CDS) software. 
3.3.8 N2 Adsorption 
Nitrogen adsorption/desorption isotherms were measured at -196 °C using an Autosorb-1C 
gas adsorption unit (Quantachrome Instruments, Boynton Beach, FL). Each sample was degassed 
at 100 °C for 16 h under vacuum before starting the analysis. The linear part of Brumauer-Emmett-
Teller (BET) plots was used for determining the specific surface area of samples. The adsorption 
of N2 adsorption/desorption isotherms was used for calculating the pore size distribution using the 
conventional Barrett-Joyner-Halenda (BJH) method (Barrett et al., 1951).  
 
3.4 Results and discussion 
3.4.1 Analysis of crystallinity 
Figure 3.2 shows the PXRD patterns of all IBU-HPMCAS and IBU-HPMCP-HP55 
samples produced. Regardless of the processing techniques and type of excipient used, samples 
with IBU:excipient ratios of 1:9 were all PXRD-amorphous, as no crystalline IBU peaks were 
present. Alternatively, samples with excipient content <90 wt.% (3:7, 5:5, 7:3 and 9:1 
IBU:excipient ratio) were partially crystalline. This was further investigated by DSC to determine 
the percentage crystallinity of IBU in samples with different IBU:excipient ratios. The stability of 
the spray dried samples was tested by PXRD analysis after 9 months of storage in closed vials at 





Figure 3.2. Powder X-ray diffraction (PXRD) patterns of samples prepared by Electrospinning (ES), Rotary 
Evaporation (RS) and Spray Drying (SD).  
 
Pristine IBU has a single endothermic peak (melting point) at 75.45 °C as shown in Figure 
3.3 (a) and (b). (Friesen et al., 2008, Ghosh et al., 2011). No melting peak was observed in RE, SD 
and ES samples with 10 wt.% IBU, further highlighting the absence of any crystalline IBU in these 
samples. Glass transition temperatures of HPMCAS and HPMCP-HP55 have been reported at 120 
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°C and 138 °C, respectively. The Tg of the amorphous IBU-HPMCAS-1-9 was between 71-79 °C 
regardless of the processing technique used (Figure 9.5 and Figure 9.6). In amorphous samples of 
IBU-HPMCP-HP55-1-9 the detected Tg was observed between 62-64 °C. The large deviation in 
Tg between samples with differing excipients can be attributed to the increased branching of 
HPMCAS in comparison with HPMCP-HP55. The crystalline samples displayed melting points 
with onset temperatures from approximately 51 °C to 72 °C (increasing with the percentage of 
IBU present in the samples). The presence of both hydrogen bonding donor and acceptor groups 
in IBU molecule improves its hydrogen bonding propensity with both of the polymers. However, 
a larger melting point depression in samples prepared with HPMCAS highlighted the superior 
miscibility of IBU with HPMCAS relative to HPMCP-HP55 (Donnelly et al., 2015). Based on 
research by Taylor and co-workers on the evaluation of hydrogen bonding strengths in polymers, 
HPMCAS has very strong hydrogen bonding donor strength, while HPMCP-HP55 has only strong 
hydrogen bonding donor strengths (Van Eerdenbrugh and Taylor, 2011, Wegiel et al., 2013). The 
larger melting point depression in samples containing HPMCAS could thus be correlated to the 






Figure 3.3; DSC thermograms of samples (a) electrospun IBU-HPMCAS samples and (b) electrospun IBU-HPMCP-
HP55 samples (c) percentage of crystallinity of IBU present in formulations prepared via electrospinning, (d) percentage of 
crystallinity of IBU present in formulations prepared via spray drying, (e) percentage of crystallinity of IBU present in 
formulations prepared via rotary evaporation.  
 
Figure 3.3 (c, d and e) shows the percentage of crystallinity for all samples and each 
processing technique. The increase in the percentage of crystalline IBU at higher IBU contents 
was observed in all samples. The solid dispersions which contained HPMCAS as the excipient 
presented a lower crystalline content of IBU compared with the samples prepared by HPMCP-
HP55 as the excipient. This effect was only significant in samples with 5:5 and 7:3 IBU:excipient 
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ratio. This is in accordance with the larger melting point depression observed in these samples due 
to the more efficient and homogeneous distribution of IBU in the presence of HPMCAS excipient. 
At low excipient contents i.e. 10 wt.% there was no significant difference between excipients as 
the properties were mostly influenced by the percentage of IBU present. Similarly, with 90 wt.% 
of excipient, no difference between the amorphization strength of excipients was observed as the 
properties of samples were mainly influenced by excipient concentration. Moreover, the lower Tg 
of HPMCAS compared with HPMCP-HP55 and the presence of multiple hydroxyl and carboxyl 
functional groups as hydrogen bond donor and acceptors led to a more homogeneous mixing with 
IBU during processing. 
Figure 3.4 shows the FTIR spectra of all samples and highlights the intermolecular 
interactions between IBU and the respective excipients whereby the presence of specific 
interactions is often used to infer miscibility and potential ASD formation (Marsac et al., 2006). 
Shifting of FTIR vibrational peaks in ASD formulation spectra relative to pristine API and 
excipient, is typically associated with intermolecular interactions due to hydrogen bonding.  
The intense peak at 2955 cm-1 in the spectra of IBU is attributed to CH3 asymmetric 
stretching. O-H and C=O of carboxylic acid and C-C stretching were assigned to the peaks at 2971 
cm-1, 1721 cm-1 and 1231 cm-1, respectively. Moreover, the strong bond at 779 cm-1 corresponded 
to the rocking vibration of CH2. (Ramukutty and Ramachandran, 2012, Matkovic et al., 2005, Ray 
et al., 2010). The sample with an IBU:excipient ratio of 1:9 presented the broadest peaks due to 
the presence of amorphous IBU irrespective of processing technique. The narrow peaks at 1231 
cm-1 and 1721 cm-1 in the samples containing 3:7, 5:5, 7:3 and 9:1 IBU:excipient ratios, 
corresponds to the presence of crystalline IBU. Moreover, the shifting in the position of the 
carboxyl peak at 1721 cm-1 to higher wavenumbers by decreasing the IBU:excipient ratio, 
indicated the presence of hydrogen bonding between the carboxylic acid group of IBU and the 





Figure 3.4; FTIR spectra of samples produced via electrospinning (ES) using HPMCAS (a) and HPMCP-HP55 (b) as 
excipient. 
 
3.4.2 Morphology  
Figure 3.5 shows the morphology of samples with 1:9 API to excipient ratio prepared via 
ES, SD and RE. For each of the electrospun samples, fibres with diameters in the range of 1-3.5 
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µm were observed regardless of the type of excipient used (Figure 3.5 (a) and (b)). However, 
samples produced with HPMCP-HP55 displayed increased beading relative to those produced with 
HPMCP-HP55. This can be attributed to the differences in viscosity and surface tension of the 
respective processing solutions. The fibrous morphology was gradually shifted to a more 
crystalline appearance as the IBU content increased from 10 wt.% to 90 wt.% (see Figure 9.5 and 
Figure 9.6). Samples prepared via RE showed irregularly shaped particles for all compositions 
(Figure 3.5 (c) and (d)) with IBU crystals clearly visible at higher IBU concentrations (Figure 9.7 
and Figure 9.8). Dimpled and corrugated spherical particles were observed in spray dried samples 
with up to 30 wt.% IBU (Figure 3.5 (e) and (f)). Needle-shaped crystals were present in samples 
with more than 50 wt.% IBU (Figure 9.9 and Figure 9.10). These observations suggest the effect 
of polymeric excipient on the formation of spherical particles. Moreover, the low Tg and its 
subsequent stickiness at high temperatures during spray drying led to the formation of large 
agglomerates in samples with >70 wt.% IBU, with particle sizes ranging from 5-15 µm. Particle 
morphology is a key consideration in optimizing the downstream processing of ASDs specifically 
as solid oral dosage forms such as tablets.  
 
Figure 3.5; SEM images of samples with 1:9 API to excipient ratio: (a) ES-IBU-HPMCP-HP55, (b) ES-IBU-HPMCAS, 
(c) RE-IBU-HPMCP-HP55, (d) RE-IBU-HPMCAS, (e) SD-IBU-HPMCP-HP55, (f) SD-IBU-HPMCAS. 
 
3.4.3 In vitro dissolution  
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Figure 3.6(a) shows the dissolution rate profile of the samples with the same composition 
(10 wt.% IBU) in a simulated gastrointestinal fluid (phosphate buffer, pH~7.2). Results show that 
the dissolution rate of IBU in all samples was increased regardless of the preparation technique 
used when compared with pristine IBU. The fastest release profile was observed for each of the 
electrospun samples. Over 65% of the drug was released from electrospun samples in the first 5 
minutes while only 50 % and 40 % was released from spray dried and rotary evaporated samples, 
respectively. In order to check the statistical significance of the difference between the dissolution 
rate of samples after 5 minutes, a t-Test was performed. A P-value of 0.047 (P-value<0.05) 
revealed the meaningful difference in the dissolution rate values. Despite the slow initial release 
in SD and RE samples, all samples released over 65 % of the API after 50 minutes. The enhanced 
dissolution properties of samples prepared by ES has previously been observed and can be 
attributed to the presence of micro and nano-scale fibres (Nagy et al., 2015a). To further investigate 
the enhanced dissolution profile of the electrospun samples the specific surface area of each sample 
was recorded.  
 
Figure 3.6. (a) Dissolution rate profile of ES/RE/SD-IBU-HPMCCP-HP55 and ES/RE/SD-IBU-HPMCAS samples 
(API-excipient 1:9 ratio), (b) Adsorption/desorption isotherms of ES/RE/SD-IBU-HPMCP-HP55-1:9 samples.  
 
Figure 3.6(b) shows the N2 adsorption/desorption isotherms of three samples of ES/RE/SD-
IBU-HPMCP-HP55 with an IBU:excipient ratio of 1:9. The calculated specific surface area of 
each sample is reported in Table 3.2. The specific surface area of ES sample was 2 and 15-fold 




dissolution rate. The direct correlation of dissolution rate and surface area of solute was previously 
explained by the well-known Noyes-Whitney equation (Noyes and Whitney, 1897). 
Table 3.2; Specific surface area of samples prepared via ES, SD, and RE containing 10 wt.% IBU. 





3.4.4 Intermolecular Interactions 
Raman spectroscopy 
To investigate the effect of processing techniques on the solid-state form of IBU, hot stage 
Raman was used to prepare samples of amorphous IBU in situ (Rehder et al., 2013). Form I 
crystalline IBU melted in line with the reported melting point of IBU of 79 °C (Figure 3.7 (a)). 
When the liquid form was allowed to cool under ambient conditions, the collected spectrum 
matched that of amorphous IBU which was previously reported by Rehder et al. and Hédoux et al. 
(Rehder et al., 2013, Hédoux et al., 2011). The glassy form of IBU was extremely unstable at room 
temperature and started to re-crystallise in less than an hour thereby further highlighting the 
challenges of preparing stable ASDs of IBU.  
The Raman spectrum of amorphous IBU was used for tracking its dispersion in each of the 
different samples. The spectra collected from each ASD of IBU-HPMCAS with a 1:9 ratio were 
averaged point by point to provide a representative spectrum of the whole dispersion and are shown 
in Figure 3.7(b) along with the spectra of pure crystalline and amorphous IBU and HPMCAS. The 
spectrum of the dispersion is mostly similar to that of HPMCAS apart from two regions marked 
in grey (Figure 3.7(b)) between 775-875 cm-1 and 1160-1235 cm-1, respectively. Specifically, the 





Figure 3.7; (a) Raman spectra of (i) Form I IBU at 30 °C, (ii) Form I IBU at 70 °C, (iii) Melted IBU at 80 °C, (iv) 
supercooled glassy IBU at 50 °C, (v) Form I IBU which recrystallized from the glass in under one hour at room temperature, (b) 
Raman spectra of form I IBU, amorphous IBU, HPMCAS and the spray dried, electrospun and rotary evaporated samples. 
 
Influence of processing technique on homogeneity of solid dispersions 
The differentiation of ASDs with similar overall amorphous content, but different 
stability/dissolution qualities has previously been investigated by Benes et al. (Beneš et al., 2017). 
Analysis techniques such as PXRD and DSC are well established for the measurement of bulk 
ASD properties (Nollenberger et al., 2009). However, the determination of homogeneity on a 
localised scale is required for a comprehensive understanding of the influence of processing 
technique on the stability of ASDs over long-term storage (Lauer et al., 2013). Confocal Raman 
Spectroscopy was employed to determine the homogeneity of samples that contained the same 






Figure 3.8. Plot of the spread of Raman spectra collected from three similarly composed but differently prepared solid 
dispersion. 
 
Principle component analysis (PCA) was performed on the spectral window between 
775-875 cm-1 and 1160-1235 cm-1 where the spectra are different than that of HPMCAS. The K-
mean clustering analysis was employed to group the spectra according to their similarity, forming 
clusters with each one representing the identical molecular properties. Thus, a wider spread of the 
clusters could be a clear sign of heterogeneity in sample. PC2 represents 4.8 % of the variance 
whereas PC3 represents 1.7% of the variations thereby permitting easier sample differentiation on 
the PC2 scale. Figure 3.8 shows the spread of Raman spectra collected from three similarly 
composed but differently prepared ASDs. 95% confidence ellipses are added to aid visualisation 
based on the scaled and mean centred scores of the second and third principal components. This 
plot shows that the greatest variation is in the spectra collected from the electrospun samples, 
followed by the spray dried dispersions, with the least variable dispersion produced by rotary 
evaporation. Although the electrospun samples had substantially higher dissolution rate due to 
their larger specific surface area, low compositional homogeneity could significantly affect their 





Three different solvent-based ASD processing techniques, spray drying, electrospinning 
and rotary evaporation were evaluated for the preparation of ASDs of IBU with polymers of 
HPMCAS and HPMCP-HP55. Results show that the complete transformation of crystalline to 
amorphous IBU is exclusively composition dependent regardless of the processing technique used. 
Electrospun ASD samples displayed higher dissolution rates compared with samples produced via 
RE and SD. Morphological analysis revealed the significant effect of specific surface area on 
dissolution rate. Moreover, HPMCAS was defined as a relatively stronger ASD former compared 
with HPMCP-HP55 due to its higher Tg, higher melting point depression and increased abundance 
of appropriate functional groups suitable for hydrogen bonding. Confocal Raman spectroscopy 
was employed to assess the homogeneity of ASDs as a critical factor for their stability. The highest 
inhomogeneity in samples was observed in samples produced via ES followed by SD and RE 
which should be considered for assessing the long-term stability of ASDs. The comprehensive 
characterization techniques used in this study showed the significance of preparation technique in 
altering the critical properties of ASDs such as dissolution rate, specific surface area and 
homogeneity. Enhancing these physicochemical properties could lead to more robust and 
improved downstream processing strategies.  
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Spray drying of large biomolecules has been attracting interest from the biopharmaceutical 
industry as it is a continuous and a single step process to generate dry powder formulations. To 
date however, the development of spray drying processes for large biomolecules has proved 
challenging primarily due to protein/enzymatic inactivation caused by high drying temperatures 
and the shear stress induced by atomization This paper suggests a two-step approach towards a 
comprehensive understanding of the behaviour of large biomolecules during the spray drying 
process with a view to developing tailored spray drying protocols for biological molecules. Using 
lysozyme as a model biomolecule a full factorial Design of Experiments (DoE) was employed to 
define the most critical process and formulation parameters. With respect to parameters such as 
feeding rate, outlet temperature (Tout) and feed solid concentration, Tout was determined to be the 
most statistically significant factor affecting the enzymatic activity of lysozyme based on screening 
analysis of the DoE. The second step of the study involved performing forced deactivation studies 
to identify critical points of potential enzymatic deactivation during the drying process. This was 
performed by investigating the inactivation of lysozyme both in solution and solid states at wet-
bulb (Twb) and outlet temperatures, respectively. Results show that there is no substantial 
inactivation of lysozyme in solution at Twb (35-45 °C). However, lysozyme in solid form 
experienced a significant degree of inactivation when heated up to temperatures similar to Tout (70-
90 °C). This inactivation was fitted by an Arrhenius equation, where the inactivation energy and 
Arrhenius constant were estimated. The approaches and models presented herein provide a 
roadmap for improved understanding of the critical process and formulation parameters required 










The global market of biopharmaceutics was valued at US$ 228 billion in 2016 (Moorkens 
et al., 2017). The proven efficiency and safety of these drugs has led to both increased development 
and increased acceptance of newly developed drugs by regulatory agencies (Moorkens et al., 
2017). In 2017, 12 new biologics were approved by the US Food and Drug Administration (FDA). 
This number has been steadily increasing since 1998 when the first biologic received FDA 
approval and is expected to grow significantly over the coming years (de la Torre and Albericio, 
2018). Of the 12 new biologics approved in 2017, nine are antibodies, one is an antibody-drug 
conjugate (ADC), and two are enzymes (de la Torre and Albericio, 2018). One of the major 
challenges that drug developers face during the development phase of protein-based 
biopharmaceutics is to maintain their chemical and physical stability during manufacturing, 
transportation and subsequent shelf life. Factors such as temperature, pH, interface exposure (shear 
stress at the air-liquid interface) and mechanical stress have been shown to significantly impact 
the stability of biomolecules (Ameri and Maa, 2006). 
Drying of protein-based therapeutics is a widely established stabilising technique for liquid 
formulations with low stability. This is especially relevant for high concentration formulations 
with an increased chance of self-interactions and a high risk of irreversible aggregation (Lee, 2002, 
Batens et al., 2018). Removal of water improves formulation stability by limiting protein 
conformational mobility, and thereby decreasing the rate of protein self-interactions (Cicerone and 
Douglas, 2012). Freeze drying is currently the leading technology for the industrial production of 
stable dry powders of biologics however it is regarded as a time consuming and expensive batch 
process technique that requires significant capital investment due to the cryogenic facilities (Horn 
et al., 2018, Wang, 2000). Spray drying is a one-step process for converting a liquid feedstock into 
a dried powder and is capable of continuously drying liquids with higher efficiency and reduced 
cost relative to freeze-drying (Ziaee et al., 2017, Grenha et al., 2005, Mumenthaler et al., 1994, 
Ziaee et al., 2019). In addition, spray drying is compatible with continuous manufacturing systems 
widely recognised as the future of the pharmaceutical and biopharmaceutical industries. The 
exploitation of spray drying as a tool to engineer particles of specific size and morphologies has 
also been recognised (Vehring, 2008). Spray dried powders exhibit properties suitable for 
pulmonary inhalation and can be used as an inhalable form in dry powder inhalers (DPI) (Seville 
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et al., 2007, Maa et al., 1999, Hou et al., 2018), or simply as a bulk powder storage alternative to 
freeze-drying (Moayyedi et al., 2018, Ji et al., 2016).  
Spray drying is considered a gentle drying process, however, due to the amphiphilic nature 
of proteins, they are often exposed to high gas-liquid interface tensions post atomization (Maa et 
al., 1998). The shear stress applied to the liquid feedstock during the atomization process can 
potentially damage the structure of large biomolecules, leading to aggregation and denaturation 
(Abdul-Fattah et al., 2007). It should be noted that only less than 1 % aggregation is acceptable by 
regulatory authorities in biopharmaceutical industry. Depending on the outlet temperature used 
(Tout), the particles generated by spray drying also experience moderate to high drying 
temperatures. Therefore, Tout has previously been reported as one of the critical factors during 
spray drying of protein-based biologics (Ghilzai, 2006, Ji et al., 2017).  
Spray dried particles are subjected to a number of thermal changes at various stages of the 
drying process. At the early stages, the atomized feedstock rises to wet bulb temperature (Twb) 
before being rapidly heated to Tout, however, it has been previously demonstrated that the core of 
the droplet experiences temperatures of 10-15 °C lower than the surface (Masters, 1990). In 
addition, it has also been reported that spray dried powders may experience elevated temperatures 
while residing in the dryer collection chamber during the latter phases of the drying process. With 
respect to protein-based biologics, it is not clearly understood at which stage of the spray drying 
process the most significant protein degradation occurs and this has subsequently limited the 
application of spray drying to such materials. This ambiguity can be resolved by devising forced 
deactivation studies of proteins even before spray drying takes place (Wang and Roberts, 2013). 
In addition, the Arrhenius equation can be used to predict the activation energy of chemical 
interactions including those that contribute to protein inactivation. J. Schaefer et al. have 
previously demonstrated the feasibility of using Arrhenius equation for describing the effect of 
temperature on the stability of spray dried catalase with a high degree of accuracy (Schaefer and 
Lee, 2015b, Schaefer and Lee, 2015a).  
This work aims to provide a better understanding of the behaviour of protein-based 
biologics at various stages of the spray drying process using lysozyme as a model complex, with 
a view to developing tailored spray drying protocols for large biomolecules. This is achieved by 
implementing a full factorial DOE to screen factors affecting the bioactivity of lysozyme. 
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Lysozyme was selected as a model biological molecule as it is a well-studied enzyme with a 
straight-forward and reproducible assay for measuring its enzymatic activity (Rodrigues et al., 
2009, Ji et al., 2017, Choi et al., 2017, Ji et al., 2016, Elkordy et al., 2004). The deactivation energy 
of lysozyme in the solid and liquid states was calculated by employing forced deactivation studies 
the results of which were verified by actual spray drying experiments. Furthermore, the effects of 
two different types of nozzle (2-fluid and ultrasonic) on enzymatic activity were investigated.  
4.3 Materials and methods 
Lysozyme (14 kDa) was purchased from Huisun Pharma, China. Ultra-pure type II 
Millipore water from a Milli-Q water purification system was used in all studies.  
4.3.1 Design of experiment (DoE)  
A three-factor full factorial design of experiments (DoE) was used to define the critical 
factors affecting the properties of spray dried lysozyme (Figure 4.1). The full factorial design 
identifies the effect of individual factors and their interactions on the studied response. A full 
factorial DoE is an appropriate screening DoE when fewer than five factors are being investigated 
as is the case in this study. The factors included in this DoE were the feeding rate (Ffeed) of the 
liquid feedstock, outlet temperature (Tout) and solids concentration. All samples were spray dried 
using both 2-fluid (Figure 10.1) and ultrasonic nozzles (Figure 10.2). JMP® pro software (JMP®) 
was used to fit a standard least-squares model to investigate the significant factors affecting the 
enzymatic activity of lysozyme, particle size distribution (D50) and residual moisture content. The 
model was fitted to the Tout, feed rate and solid concentration of spray dried samples as variable 
factors for both ultrasonic and 2-fluid nozzles. To facilitate the interpretation of the most critical 
parameters results are presented as scaled parameter estimate plots (Batens et al., 2018). The 
models provided herein are data-driven models that can only be applied on the same type of 
material. For further modification of the formulation, the model needs to be modified to meet the 




Figure 4.1; Schematic representation of the design of experiments (DoE) for the stability study of lysozyme during 
spray drying. The DoE was implemented with both ultrasonic and 2-fluid nozzles. 
 
4.3.2 Spray drying  
All liquid feedstock solutions were prepared using ultra-pure type II Millipore water. All 
drying studies were conducted on a Büchi B-290 mini spray dryer in open loop mode in 
conjunction with a dehumidifier at -4 °C, capable of condensing water vapour within the air stream. 
A high-efficiency cyclone was used to trap the spray dried particles. The 2-fluid nozzle utilised in 
this study had a 0.7 mm cap and an atomization gas flow rate of ~473 NL/h (P = 1013.25 mbar 
and T = 273.15 K). The ultrasonic nozzle was employed with power set at 1 W and feed flow rates 
as per DoE (Table 4.1). The aspirator was set to 100% (~35 m3/h) for circulating nitrogen as the 
drying and atomizing gas for both nozzles. The spray drying process was started by spraying 
ultrapure water at the same conditions of the sample, until equilibrium Tout was reached. The 
feedstock was then pumped to the drying chamber and all spray dried powders were removed from 
the sample collection chamber after 20 minutes of drying. This short spray drying time eliminates 
the effect of post-chamber deactivation on the final activity of lysozyme (Schaefer and Lee, 
2015b). To reduce the effect of reversible unfolding the collected samples were immediately 
removed from the drying chamber and stored in a fridge at 5 °C for 24 hours prior to testing 
enzymatic activity. It should be noted that during spray drying with each of the respective nozzles, 
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the feed rate was kept constant as per the DoE. Droplet size and hence particle size were not 
controlled on either nozzle and are widely varied due to the different atomization mechanisms.  
4.3.3 Enzymatic activity testing  
The enzymatic activity of samples post spray drying was evaluated by continuous 
monitoring of turbidity changes in a suspension of Micrococcus lysodeikticus by UV-Vis 
spectrophotometry (Bergmeyer, 1983). A suspension of freeze-dried bacteria in phosphate buffer 
(pH 6.24) with an absorbance of 0.700-0.850 at 450 nm was prepared as substrate.  Samples of 
spray dried lysozyme were prepared in fresh phosphate buffer at 5 °C with a concentration of 400 
units/mL. Blank sample was prepared by pipetting 2.5 mL of substrate into a cuvette with 0.1 mL 
of phosphate buffer and the decrease in A450 was monitored continuously for 5 minutes. Activity 
testing was performed by pipetting 2.5 mL of the substrate to a cuvette and adding 0.1 mL of 400 
units/mL enzyme solution with A450 being recorded for 5 minutes. Equation 1 was used to calculate 
the unit/mL lysozyme.  
𝑢𝑛𝑖𝑡𝑠 𝑚𝐿⁄  𝑒𝑛𝑧𝑦𝑚𝑒 =
(∆𝐴450 𝑚𝑖𝑛⁄ 𝑇𝑒𝑠𝑡−∆𝐴450 𝑚𝑖𝑛⁄ 𝐵𝑙𝑎𝑛𝑘)(𝑑𝑓)
(0.001)(0.1)
    (1) 
where, df is dilution factor, 0.001 is change in absorbance (ΔA450) as per the unit definition 
and 0.1 is volume (mL) of lysozyme solution.  
Equation 2 was used to calculate the units per milligram solid of the enzyme: 
𝑢𝑛𝑖𝑡𝑠 𝑚𝑔 𝑠𝑜𝑙𝑖𝑑⁄ =
𝑢𝑛𝑖𝑡𝑠 𝑚𝐿 𝑒𝑛𝑧𝑦𝑚𝑒⁄
𝑚𝑔 𝑠𝑜𝑙𝑖𝑑 𝑚𝐿 𝑒𝑛𝑧𝑦𝑚𝑒⁄
      (2) 
4.3.4 Forced deactivation studies 
To replicate the potential enzymatic deactivation processes occurring at exhaust 
temperature (Tout) as-received solid lysozyme powders were placed in individual vials and heated 
in a water bath with a temperature similar to Tout at 60, 70, 80 and 90 °C. Samples were taken at 
time intervals of 10, 20, 30, 40, 50 and 60 minutes and evaluated for enzymatic activity. In order 
to evaluate potential enzymatic deactivation occurring at Twb, lysozyme solutions of 1 and 10 wt.% 
solid concentration (as per the DoE) were heated at different temperatures close to Twb. The Twb 
temperature was calculated based on the empirical correlation: 
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log(𝑇G) − 45       (3) 
where, TG is the drying gas temperature and Tb is the boiling temperature of the solution 
(Vehring, 2008, Miller et al., 1998). Aliquots were removed for activity testing at 5-minute 
intervals up to 45 minutes from the commencement of the heating process. 
4.3.5 Estimation of kinetic parameters 
Lysozyme deactivation has been reported to be a first-order reaction (Nohara et al., 1999) 
which can be described by: 
𝐴
𝐴0




 is the residual enzymatic activity after treatment for time 𝑡 (min), and 𝑘 (min-1) 
is the inactivation rate constant at a specific temperature. The inactivation rate constant can be 
estimated by linear regression analysis of the natural logarithm of the residual enzymatic activity 
versus heat treatment time.  
Decimal reduction time (D-value) is the time needed for a 10-fold reduction of the initial 
activity at a given temperature (Espachs-Barroso et al., 2006). It can be determined based on the 




          (5) 
Arrhenius equation was fitted to the inactivation rate constant versus temperature to 
estimate the inactivation energy as follows: 




𝑇⁄ )         (6) 
where, k is the inactivation rate constant, T is the absolute temperature, A is a constant, Ea 
is the inactivation energy and R is the universal gas constant.  
4.3.6 Moisture content analysis 
A Perkin-Elmer 4000 TGA (Thermal gravimetric analysis) analyser was used to measure 
the residual moisture content of all samples. Samples were heated under nitrogen atmosphere from 
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room temperature to 200 °C at a heating rate of 10 °C.min-1. The residual moisture content was 
calculated based on the weight loss of the sample up to 150 °C.  
4.3.7 Scanning electron microscopy (SEM)  
The morphological configuration of the as-received solid lysozyme powder as well as 
lysozyme after spray drying with 2-fluid and ultrasonic nozzles was studied using high resolution 
field emission electron microscopy (SEM, Hitachi SU-70) operating at 5 kV with a 15 mm 
working distance. All samples were coated with gold-palladium for 1 min with 20 mA current to 
avoid overcharging. 
4.3.8 Particle size distribution (PSD)  
Particle size distribution (PSD) was measured using Microtrac S3500 laser diffraction 
analyser (Microtrac®) with a detection wavelength of 780 nm. The instrument was coupled with 
a Turbotrac dry powder dispersion device. 
4.3.9 Thermal imaging 
An IR thermal camera (FLIR E6, FLIR Systems, OU, Estonia) was used to monitor the 
temperature of both nozzles during cold spray drying (without heated gas) for a 30-minute period 
with refractive index set at 0.8 for polished stainless-steel surface of nozzles.  
 
4.4 Results and discussions 
4.4.1 Screening the critical factors  
The effect of process and formulation factors with respect to the spray drying of lysozyme 
were investigated using a full factorial DoE. For this purpose, the physicochemical properties i.e. 
particle size, residual moisture content and enzymatic activity of powders dried using both 2-fluid 
and ultrasonic nozzles were studied. 
4.4.2 Residual moisture content  
The residual moisture content of all samples after spray drying was determined using TGA 
(see Table 4.1). Samples spray dried with an ultrasonic nozzle showed markedly higher residual 
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moisture content compared to those sprayed with a 2-fluid nozzle. This could be attributed to the 
larger droplets produced by the ultrasonic nozzle that subsequently required increased drying times 
compared to the smaller droplets produced by the 2-fluid nozzle. The larger droplet size can be 
inferred from the D50 values of particles sprayed with each nozzle (Table 4.1). Spray dried powder 
had a residual moisture content in the range of 3-12 wt.% depending on the type of nozzle used. 
Data obtained for various DoE parameters was used to fit regression models for each response, i.e. 
residual moisture content (wt.%), particle size (D50) and retained activity of lysozyme (%). 
Neither including the residual moisture content as a response or using it as an uncontrolled factor 
in linear regression models showed a correlation between or a significant influence on the different 
responses. Thus, it was omitted from the linear regression models.  
 
Table 4.1; The initial process and formulation configurations of spray drying process. 
 DoE Inputs  DoE Outputs 





Moisture content (wt%) Particle size D50 (µm) 
 ultrasonic 2-fluid    ultrasonic 2-fluid ultrasonic 2-fluid 
1 73 70 50 1.5 1 5.6 5.9 6.8 4.8 
2 138 101 50 6 1 7.9 4.7 9.3 2.6 
3 139 97 70 1.5 1 6.7 2.9 7.4 3.9 
4 142 130 70 6 1 11.8 3.9 9.7 3.9 
5 70 70 50 1.5 10 9.3 4.2 16.8 8.1 
6 115 96 50 6 10 7.6 5.1 20.7 5.5 
7 97 99 70 1.5 10 10.8 3.6 16.8 7.9 
8 140 132 70 6 10 7.1 4.5 19.8 2.9 
9 104 97 60 3.75 5.5 8.1 3.0 13.7 4.4 
 
4.4.3 3.1.2. Particle size distribution  
Results show a significant difference in the particle size distribution (PSD) of the powders 
produced by each nozzle with those produced by the ultrasonic nozzle exhibiting a significantly 
higher D50 value. Figure 4.2 shows SEM image of sample 3 as per Table 4.1. In addition to being 
larger in size, the surface of the particles produced by the ultrasonic nozzle is noticeably roughened 





Figure 4.2; SEM images of sample 3 spray dried with (a) 2-fluid nozzle and (b) ultrasonic nozzle. The samples spray 
dried with ultrasonic nozzle are prominently larger than samples spray dried with 2-fluid nozzle. 
 
This can be attributed to the initial droplet size post atomization. Drying with the ultrasonic 
nozzle results in larger droplets that experience slower drying rates. This leads to a smaller Peclet 
number and a softer outer crust that can deform more easily due to the internal pressure or diffusion 
of the particles (Schaefer and Lee, 2015a, Schaefer and Lee, 2015b, Vehring, 2008). Alternatively, 
droplets produced by the 2-fluid nozzle have a higher surface to volume ratio and therefore 
experience faster drying rates and higher Peclet number leading to less deformations occurring 
during the spray drying process. Note that Tout was meant to be kept constant at specific values as 
per DoE during spray drying with both nozzles. However higher inlet temperature was required to 
maintain the Tout in the case of the ultrasonic nozzle.  
 Figure 4.3 shows the estimated parameters with respect to particle size (D50) of the spray 
dried formulations with 2-fluid and ultrasonic nozzle (Batens et al., 2018). Feed rate and solid 
concentration (shaded bars) are the two significant factors affecting the PSD of the spray dried 
powders with 2-fluid nozzle (P-value < 0.05). The estimated coefficients show the extent and the 
type of effects of the factors on the particle size. The predictions are quantitative and material 
dependent. Particle size is negatively correlated to feed rate while positively correlated to solid 
concentration as suggested by the model for 2-fluid nozzle. The interactions between these factors 
were statistically non-significant. In the case of the ultrasonic nozzle, feed rate and solid content 
were the significant factors while in this case they were both positively correlated to the D50 of 




Figure 4.3;  Scaled parameter estimates plot with respect to the particle size (D50) of the spray dried formulations with 
(a) 2-fluid nozzle (intercept estimate = 5.44 ± 0.34); and (b) ultrasonic nozzle (intercept estimate =   ±13.44 0.08). Open bars 
identify non-significant factors. Shaded bars are the statistically significant factors. Error bars show the estimated standard 
error for each estimated parameter.  
 
4.4.4 Retained enzymatic activity  
Figure 4.4 shows the percentage of retained enzymatic activity of spray dried lysozyme 
samples relative to the activity of the as-received lysozyme material. The results show that with 
respect to the activity of lysozyme samples dried using 2-fluid nozzle, those that were sprayed at 
higher Tout (70 °C) experienced major loss of their initial activity when compared to samples 
processed at lower Tout (50 °C). For example, sample 2, dried using a high feed rate and low Tout 
(50 °C), experienced minimal decrease in its activity. Similarly, sample 5 which was processed 
with a high solid concentration (10 wt.%) but low Tout (50 °C) also displayed minimal decrease in 





Figure 4.4; Comparative graph of the retained activity of lysozyme after spray drying with ultrasonic nozzle (black) 
and 2-fluid nozzle (red). 
 
Figure 4.5 shows the scaled parameter estimates plot of the model fitted to the retained 
activity of lysozyme after spray drying with both the ultrasonic and 2-fluid nozzles. With respect 
to the ultrasonic nozzle, the standard least-squares fit showed the crossover interaction of solid 
concentration and outlet temperature to be the most significant factor that was negatively 
correlated to the activity of samples. It has been previously reported that at higher solid 
concentrations i.e. higher viscosities, the residence time of the liquid on the atomizing surface 
increases. This causes the atomizing liquid to rise to temperatures greater than the inlet temperature 
due to vibrational energy dissipation and in turn, leads to enzymatic deactivation (Dalmoro et al., 
2013). However, for samples atomized by a 2-fluid nozzle the only factor with a significant effect 
on enzymatic activity was Tout with a P-value of 0.03 which was in line with our expectations. The 
effects of feed rate and solid concentration were statistically negligible (P > 0.05). Outlet 
temperature was revealed to be the most significant factor affecting the activity of lysozyme during 
spray drying with the 2-fluid nozzle. The negative correlation suggests loss of activity after spray 





Figure 4.5; Scaled parameter estimates plot of the model fitted to the retained activity (%) of the spray dried 
formulations with (a) 2-fluid nozzle (intercept estimate =87.5 ± 1.77 and (b) ultrasonic nozzle (intercept estimate = 46.87 ± 1.03. 
Open bars identify non- significant factors. Shaded bars are the statistically significant factors. Error bars show the estimated 
standard error for each estimated parameter. 
 
4.4.5 Effect of nozzle type 
All samples spray dried with an ultrasonic nozzle had significantly lower activities when 
compared to samples sprayed with a 2-fluid nozzle. Typically, an ultrasonic nozzle is more 
advantageous than a 2-fluid nozzle as it applies lower mechanical stress to the feedstock due to the 
absence of applied shear stress during the atomization process. This is an important consideration 
in relation to the spray drying of large biological molecules which could be susceptible to 
deactivation under high shear forces. In order to evaluate the effect of shear stress on enzyme 
deactivation, the 10 wt.% solution was sprayed using both nozzles, without the application of heat. 
Activity measurements show that there is negligible enzymatic inactivation occurring during 
spraying with the ultrasonic nozzle i.e. retained activity of 93.2%. Samples sprayed with the 2-
fluid nozzle retained 100% activity. 6.8 % loss of activity due to the mechanical stress or local 
heat at the tip of the ultrasonic nozzle is insignificant compared with 50-60 % loss after spray 
drying with the application of heat. Therefore, the deactivation of lysozyme sprayed via the 
ultrasonic nozzle cannot be totally attributed to mechanical stress.  Lee and co-workers have also 
investigated the effect of nozzle type on the bioactivity of catalase. They demonstrated through 
cold atomization experiments, that applied mechanical stress during atomization with both nozzles 
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is not a major source of enzymatic deactivation in catalase, previously (Schaefer and Lee, 2015a, 
Schaefer and Lee, 2015b). 
Ultrasonic vibrations generate heat which can potentially contribute to deactivation of 
lysozyme during spray drying and should be considered (Schaefer and Lee, 2015a). This 
hypothesis has previously been explored by other research groups (Schaefer and Lee, 2015b, 
Schaefer and Lee, 2015a). Figure 4.6 shows the thermal map of the ultrasonic nozzle during a 30-
minute working period. The initial operating temperature of the nozzle was approximately 30°C 
upon commencement of drying however when spraying with 1 watt of power for 30 minutes, a 




Figure 4.6; The thermal map of ultrasonic nozzle during cold spray drying at (a) 0 mins, (b) 6 mins, (c) 12 mins, (d) 18 
mins, (e) 24 mins, (f) 30 mins, and the 2-fluid nozzle during cold spray drying at (g) 0 mins, (h) 6 mins, (i) 12 mins, (j) 18 mins, 
(k) 24 mins and (l) 30 mins. 𝜀 is the refractive index of polished stainless-steel surface of nozzles which was set at 0.8. The scale 
bar on the right depicts the range of highest and lowest temperature detected by camera.  
 
Figure 4.6 shows that the highest temperature was recorded at the location of the ultrasonic 
transducer just above the tip of the ultrasonic nozzle. The heat produced by this nozzle may also 
contribute to the inactivation of lysozyme during spray drying. In contrast, no heat was generated 
during atomization with the 2-fluid nozzle due to the atomizing gas flow that cools the nozzle 
during the atomization process.  
123 
 
Moreover, both nozzles are suspended from a metallic holder into the drying chamber. The 
metallic holder heats up to temperatures similar to Tin which in turn increased the temperature of 
the stainless-steel body of the nozzle. This temperature increase in addition to the heat generated 
by ultrasonic vibrations leads to significantly higher overall operating temperatures for the 
ultrasonic nozzle.  
 
4.4.6 Effect of temperature 
Heat is a critical factor in the enzymatic deactivation of lysozyme. During the spray drying 
process atomized droplets experience different temperatures for different timescales, each of 
which potentially contributes to enzymatic deactivation. Figure 4.7 shows that temperatures at the 
first stage are similar to (𝑇 ≤ 𝑇𝑤𝑏) and at the second stage (𝑇𝑤𝑏 < 𝑇 < 𝑇𝑜𝑢𝑡). Thus, in order to 
study the effect of each temperature range, a series of forced deactivation experiments were 
conducted to determine the kinetics and activation energy required for deactivation at different 
conditions. 
 




In order to study the effect of Twb when the droplets’ surface is saturated with water, a series 
of solutions were prepared with 1 and 10 wt.% concentration of lysozyme. Samples were then 
heated in a water bath at Twb which was calculated using equation 3 for each sample outlined in 
the DOE i.e. 30, 35, 40, 45 °C. Aliquots of dissolved lysozyme were removed from the respective 
solution at 5-minute intervals over a period of 45 minutes duration. The samples were stored at 5 
°C for at least 24 hrs until further analyses.  
In the next phase, the effect of Tout on the deactivation kinetics of solid lysozyme was 
studied by heating as-received solid lysozyme powder in a water bath at pre-defined outlet 
temperatures of 60, 70, 80 and 90 °C for 60 minutes, with sample aliquots removed every 10 
minutes. As before samples were stored at 5 °C for at least 24 hrs until further analyses. The storage 
time of 24 hrs has been selected to ensure that only the irreversible deactivation of lysozyme is 
considered since lysozyme has the capacity to undergo both reversible and irreversible 
deactivation, simultaneously (Nohara et al., 1999). Moreover, the deactivation of lysozyme has 
been determined to be a first-order reaction (Nohara et al., 1999). Results show that lysozyme was 
thermally degraded to a greater extent in solid form and at Tout compared with solutions at Twb. No 
major deactivation was found in solutions that were heat-treated at Twb as reported in the literature 
(Matagne et al., 2000). This can be attributed to the reversible refolding of lysozyme happening in 
the presence of water (Nohara et al., 1999, Matagne et al., 2000).  
Alternatively, heating as-received solid lysozyme to higher temperatures (60-90 °C) led to 
deactivation at various scales depending on the heating time. In Figure 4.8(a), the slope of the 
linear fitted lines to the points of retained activity versus time provides the inactivation rate 
constant (k). The linear regression was used for fitting lines to find the k value at different 
temperatures. This should be done by care as the linearity of the points should be considered before 




Figure 4.8; (a) Logarithmic graph of retained activity versus time at different temperatures for solid samples of 
lysozyme heated to 60, 70, 80 and 90 °C up to 60 minutes, (b) Logarithmic graph of inactivation rate constant versus inverse 
absolute temperature. 
 
Table 4.2 shows the calculated k and D-values for each temperature. A constant increase of 
k at higher temperatures suggests faster inactivation rates while a decrease in the D-value reflects 
the faster inactivation of lysozyme at elevated temperatures. D-values are in the range of 247-287 
min for temperatures ranging from 60-90 °C.  
 
Table 4.2; Calculated inactivation rate constant and D-values for different temperatures. 
Temperature (°C) 60 70 80 90 
)1-(min k 0.00798 0.00882 0.00884 0.00931 
D-value (min) 287 267 261 247 
 
The deactivation process was also investigated in solutions at temperatures similar to the 
Twb however no deactivation of lysozyme was detected at these temperatures. This can potentially 
be attributed to the low Twb. Following the calculation of k, the Arrhenius equation was fitted to 
the logarithmic line of k versus the inverse of the absolute temperature. Using the fitted line, the 
inactivation energy Ea and pre-exponential factor A can be calculated to be 11.67 kJ.mol
-1 and 1.33, 
respectively. Knowledge of inactivation energy with respect to temperature and use of Arrhenius 
equation to predict the inactivation rate constant are of immense importance in deciding final spray 
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drying process conditions, specifically Tout. Therefore, performing forced deactivation studies in 
advance of drying is useful especially in the case of high-value biotherapeutics.   
Forced deactivation studies revealed the critical temperatures at different stages of drying 
that affect enzymatic deactivation during the spray drying process. Therefore, based on the 
observations made in this study, we propose a decision tree to assist in identifying the most 
appropriate strategies for spray drying large molecule APIs. This decision tree is outlined in Figure 
4.9. With respect to spray drying of large molecule APIs one must first consider the intended 
application and delivery mechanism. The second stage is to develop an understanding of molecule 
behaviour under possible sources of deactivation such as mechanical and thermal stresses. Forced 
deactivation studies are the most critical part of this approach and should be performed under the 
same conditions as the spray drying process i.e. Twb and Tout. Finally, the selection of the right type 
of excipient (if required) and desired particle size and morphology should be considered if a 
successful spray drying strategy is to be identified.  
 
 
Figure 4.9; Decision tree of spray drying of large molecule APIs which helps to rationalize our understanding of the 





This work introduces a systematic approach to studying the spray drying of lysozyme as a 
model large molecule API. If implemented for other large molecule APIs, the approaches and 
models developed herein can be used to better understand the interaction between formulation and 
process factors affecting large biomolecules during spray drying. The effect of feed rate, solid 
concentration, Tout and nozzle type on the physical properties e.g. PSD and residual moisture 
content and retained enzymatic activity were investigated using a full factorial DoE. In addition, 
potential sources of enzymatic inactivation during the spray drying process were examined through 
forced deactivation studies. Using a standard least-squares model, feed rate and solid concentration 
were shown to be the most statistically significant factors affecting PSD for both nozzles. Tout was 
the only statistically significant factor which was negatively correlated to retained activity of 
lysozyme sprayed with the 2-fluid nozzle. Alternatively, it was demonstrated that powders sprayed 
with the ultrasonic nozzle have ~50 % lower enzymatic activity after drying due to elevated nozzle 
operating temperatures. Finally, forced deactivation studies were employed for identifying the 
critical points of enzymatic deactivation within the spray drying process.  The approach of defining 
the critical factors affecting bioactivity using a DoE, performing forced deactivation studies and 
optimising the formulation and process accordingly, is proposed as a future model for assessing 
the suitability of large biomolecules and biopharmaceuticals to spray drying. 
 
4.6 References  
ABDUL-FATTAH, A. M., KALCINIA, D. S. & PIKAL, M. I. 2007. The challenge of drying method 
selection for protein pharmaceuticals: Product quality implications. Journal of Pharmaceutical 
Sciences, 96, 1886-1916. 
AMERI, M. & MAA, Y.-F. 2006. Spray Drying of Biopharmaceuticals: Stability and Process 
Considerations. Drying Technology, 24, 763-768. 
BATENS, M., MASSANT, J., TEODORESCU, B. & VAN DEN MOOTER, G. 2018. Formulating 
monoclonal antibodies as powders for reconstitution at high concentration using spray drying: 
Models and pitfalls. European Journal of Pharmaceutics and Biopharmaceutics, 127, 407-422. 
BERGMEYER, H. U. 1983. Methods of enzymatic analysis, Weinheim, Verlag Chemie. 
CHOI, S., ATTRI, P., LEE, I., OH, J., YUN, J.-H., PARK, J. H., CHOI, E. H. & LEE, W. 2017. Structural 
and functional analysis of lysozyme after treatment with dielectric barrier discharge plasma and 
atmospheric pressure plasma jet. Scientific Reports, 7, 1027. 
128 
 
CICERONE, M. T. & DOUGLAS, J. F. 2012. β-Relaxation governs protein stability in sugar-glass 
matrices. Soft Matter, 8, 2983-2991. 
DALMORO, A., BARBA, A. A. & AMORE, M. 2013. Analysis of Size Correlations for Microdroplets 
Produced by Ultrasonic Atomization. The Scientific World Journal, 2013, 7. 
DE LA TORRE, B. & ALBERICIO, F. 2018. The Pharmaceutical Industry in 2017. An Analysis of FDA 
Drug Approvals from the Perspective of Molecules. Molecules, 23. 
ELKORDY, A. A., FORBES, R. T. & BARRY, B. W. 2004. Stability of crystallised and spray-dried 
lysozyme. International Journal of Pharmaceutics, 278, 209-219. 
ESPACHS-BARROSO, A., VAN LOEY, A., HENDRICKX, M. & MARTÍN-BELLOSO, O. 2006. 
Inactivation of plant pectin methylesterase by thermal or high intensity pulsed electric field 
treatments. Innovative Food Science & Emerging Technologies, 7, 40-48. 
GHILZAI, N. M. K. 2006. Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery 
Systems. American Journal of Pharmaceutical Education, 70, 94. 
GRENHA, A., SEIJO, B. & REMUNAN-LOPEZ, C. 2005. Microencapsulated chitosan nanoparticles for 
lung protein delivery. European Journal of Pharmaceutical Sciences, 25, 427-437. 
HORN, J., SCHANDA, J. & FRIESS, W. 2018. Impact of fast and conservative freeze-drying on product 
quality of protein-mannitol-sucrose-glycerol lyophilizates. European Journal of Pharmaceutics 
and Biopharmaceutics, 127, 342-354. 
HOU, A., LI, L., HUANG, Y., SINGH, V., ZHU, C., PAN, X., QUAN, G. & WU, C. 2018. Fragmented 
particles containing octreotide acetate prepared by spray drying technique for dry powder 
inhalation. Drug Delivery and Translational Research, 8, 693-701. 
JI, S., THULSTRUP, P. W., MU, H., HANSEN, S. H., VAN DE WEERT, M., RANTANEN, J. & YANG, 
M. 2016. Effect of ethanol as a co-solvent on the aerosol performance and stability of spray-dried 
lysozyme. International Journal of Pharmaceutics, 513, 175-182. 
JI, S., THULSTRUP, P. W., MU, H., HANSEN, S. H., VAN DE WEERT, M., RANTANEN, J. & YANG, 
M. 2017. Investigation of factors affecting the stability of lysozyme spray dried from ethanol-water 
solutions. International Journal of Pharmaceutics, 534, 263-271. 
JMP®, V. S. I. I., CARY, NC, 1989-2019. 
LEE, G. 2002. Spray-Drying of Proteins. In: CARPENTER, J. F. & MANNING, M. C. (eds.) Rational 
Design of Stable Protein Formulations: Theory and Practice. Boston, MA: Springer US. 
MAA, Y.-F., NGUYEN, P.-A. T. & HSU, S. W. 1998. Spray-Drying of Air–Liquid Interface Sensitive 
Recombinant Human Growth Hormone. Journal of Pharmaceutical Sciences, 87, 152-159. 
MAA, Y. F., NGUYEN, P. A., SWEENEY, T., SHIRE, S. J. & HSU, C. C. 1999. Protein inhalation 
powders: Spray drying vs spray freeze drying. Pharmaceutical Research, 16, 249-254. 
MASTERS, K. 1990. Understanding and applying spray dryers in chemical processing. Powder Bulk Eng, 
4, 36-38. 
MATAGNE, A., JAMIN, M., CHUNG, E. W., ROBINSON, C. V., RADFORD, S. E. & DOBSON, C. M. 
2000. Thermal unfolding of an intermediate is associated with non-arrhenius kinetics in the folding 
of hen lysozyme11Edited by C. R. Matthews. Journal of Molecular Biology, 297, 193-210. 
MILLER, R. S., HARSTAD, K. & BELLAN, J. 1998. Evaluation of equilibrium and non-equilibrium 
evaporation models for many-droplet gas-liquid flow simulations. International Journal of 
Multiphase Flow, 24, 1025-1055. 
MOAYYEDI, M., ESKANDARI, M. H., RAD, A. H. E., ZIAEE, E., KHODAPARAST, M. H. H. & 
GOLMAKANI, M. T. 2018. Effect of drying methods (electrospraying, freeze drying and spray 
drying) on survival and viability of microencapsulated Lactobacillus rhamnosus ATCC 7469. 
Journal of Functional Foods, 40, 391-399. 
MOORKENS, E., MEUWISSEN, N., HUYS, I., DECLERCK, P., VULTO, A. G. & SIMOENS, S. 2017. 
The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. 
Frontiers in Pharmacology, 8, 314. 
129 
 
MUMENTHALER, M., HSU, C. C. & PEARLMAN, R. 1994. Feasibility study on spray-drying protein 
pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. 
Pharmaceutical Research, 11, 12-20. 
NOHARA, D., MIZUTANI, A. & SAKAI, T. 1999. Kinetic study on thermal denaturation of hen egg-
white lysozyme involving precipitation. Journal of Bioscience and Bioengineering, 87, 199-205. 
RODRIGUES, M. A., LI, J., PADRELA, L., ALMEIDA, A., MATOS, H. A. & DE AZEVEDO, E. G. 
2009. Anti-solvent effect in the production of lysozyme nanoparticles by supercritical fluid-assisted 
atomization processes. The Journal of Supercritical Fluids, 48, 253-260. 
SCHAEFER, J. & LEE, G. 2015a. Arrhenius activation energy of damage to catalase during spray-drying. 
International Journal of Pharmaceutics, 489, 124-130. 
SCHAEFER, J. & LEE, G. 2015b. Post-chamber inactivation of catalase powder during spray drying in 
bench-top machines. Powder Technology, 277, 231-236. 
SEVILLE, P. C., LI, H.-Y. & LEAROYD, T. P. 2007. Spray-Dried Powders for Pulmonary Drug Delivery. 
Critical Reviews in Therapeutic Drug Carrier Systems, 24, 307-360. 
VEHRING, R. 2008. Pharmaceutical particle engineering via spray drying. Pharmaceutical research, 25, 
999-1022. 
WANG, W. 2000. Lyophilization and development of solid protein pharmaceuticals. International Journal 
of Pharmaceutics, 203, 1-60. 
WANG, W. & ROBERTS, C. J. 2013. Non-Arrhenius protein aggregation. The AAPS journal, 15, 840-851. 
ZIAEE, A., ALBADARIN, A. B., PADRELA, L., FAUCHER, A., O'REILLY, E. & WALKER, G. 2017. 
Spray drying ternary amorphous solid dispersions of ibuprofen – An investigation into critical 
formulation and processing parameters. European Journal of Pharmaceutics and 
Biopharmaceutics, 120, 43-51. 
ZIAEE, A., ALBADARIN, A. B., PADRELA, L., FEMMER, T., O'REILLY, E. & WALKER, G. 2019. 
Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental 




5 Chapter Five: Co-authored (non senior author) contributions  
5.1 Particle engineering of excipients: A mechanistic investigation into the 
compaction properties of lignin and [co]-spray dried lignin 
In this work, lignin was spray dried with sodium lauryl sulphate (SLS) with the purpose of 
improving its compaction properties. The physicochemical properties of spray dried formulations 
were studied and compared to as-received lignin and lactose which was used as a reference 
excipient. Single component tablets from individual powders were prepared and the mechanical 
properties of these powders were investigated by analysing force-displacement curves recorded 
during tableting, using a series of compaction equations. Moreover, the performance of these 
excipients in binary blends containing an active pharmaceutical ingredient (API) was investigated. 
A positive effect of SLS on the mechanical properties and bulk level properties of the spray dried 
formulations was observed. Spray dried formulations containing SLS showed superior flow 
properties to pure spray dried lignin while retaining similar particle size distributions. Spray dried 
formulations containing up to 10 w/w% SLS also showed superior compactibility in binary blends 
to as-received materials at porosity levels relevant for immediate release tablets. This study 
highlights the importance of understanding the compaction mechanics of single-component 
powders as a means of predicting their behaviour in multi-component blends. 
This work has been published in International Journal of Pharmaceutics and can be viewed in the 
Appendix section H.   
 
5.2 Co-crystal polymorphic control by nanodroplet and electrical 
confinement 
A comparative study of the effect of three different solvent-based methods of 
electrospraying (ES), SD and supercritical CO2 SD (SCCSD) on the control of polymorphism in 
the carbamazepine-saccharin (CBZ-SAC) cocrystal system was performed. It was shown that the 
polymorphic control of the co-crystal carbamazepine–saccharin (CBZ–SAC) metastable form II 
was achieved by nano-droplet confinement in tandem with droplet surface charging induced by 
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ES the precursor solution. In this case, the polymorphic exclusivity was shown for the first time 
for this system to be independent of solvent selection.   
This work has been published in the journal of CrystEngComm and can be viewed in the Appendix 
section I.   
 
5.3 Impact of polymeric excipient on cocrystal formation via hot-melt 
extrusion and subsequent downstream processing 
Pharmaceutical cocrystals have gained increasing interest due to their potential to modify 
the physicochemical properties of drugs. Herein, a 1:1 cocrystal of ibuprofen (IBU) as a BCS class 
II active pharmaceutical ingredient (API) and nicotinamide as coformer was produced using a hot-
melt extrusion (HME) process. The effect of process parameters such as barrel temperature and 
screw speed were studied. It was shown that the addition of polymeric excipient such as soluplus 
(Sol) decreases the cocrystallization temperature by enhancing the interaction between API and 
coformer. In order to study the effect of cocrystallization on the tableting properties of IBU-NIC 
cocrystal, 5 different formulations of pure IBU, IBU-NIC cocrystal, IBU-NIC physical mixture, 
IBU-NIC-Sol physical mixture and IBU-NIC-Sol cocrystal were tableted by a compaction 
simulator. Tabletability, compactibility and compressibility were investigated. The sample with 
IBU-NIC-Sol cocrystal formulation outperformed all the other formulations in terms of 
tabletability, compactibility and compressibility. Interestingly, this sample was even superior to 
the IBU-NIC cocrystal sample which verified the advantageous effect of the presence of an 
excipient. Moreover, dissolution test confirmed a noticeable increase in the dissolution of not only 
the cocrystal samples but even the physical mixtures of IBU and NIC compared with pure IBU. 
This work has been published in International Journal of Pharmaceutics and can be viewed 
in the Appendix section J.   
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6 Chapter Six: Conclusions  
Spray drying (SD) has been used as a versatile, one-step process of drying across many 
sectors such as dairy, food, ceramics and pharma. Its compatibility with continuous processing 
methodologies places it in a unique position for not only drying but also, formulating new 
compositions, engineering new particles and stabilizing pharmaceuticals and biopharmaceuticals. 
The urgent need for improved solubility/dissolution rate of BCS class II APIs in order to bring 
newly developed and high efficacy drugs to market can only be addressed by innovative 
formulation strategies. This is something that can only be achieved by gaining a comprehensive 
understanding of the interplay between formulation and process parameters of the spray drying 
process.  
Moreover, considering the increasing share of biopharmaceuticals in the emerging drugs 
market, novel formulation approaches such as drying (e.g. spray drying, freeze-drying) are 
required for improving the stability of highly concentrated large molecule APIs. However, 
considering the relatively high temperature and shear stress applied during the SD process, 
complex interplay of operating conditions and formulation parameters need to be well understood.  
In chapter two, SD was used for improving the dissolution rate and stability of IBU as a 
BCS class II API using DoE approach to comply with the current quality by design (QbD) 
standard. It was shown that the formation of fully amorphous IBU was only formulation 
dependant, whereas physicochemical properties were highly modifiable. The increased dissolution 
rate of IBU in ASDs was firstly attributed to its amorphous form, and secondly, the presence of 
Kollidon VA 64 as an amphiphilic excipient. The presence of HPMCP-HP55 as an insoluble 
excipient in gastric fluid, and high antiplasticizing effect in combination with Kollidon VA 64 
(high solubility in both polar and nonpolar solvents) led to the formation of a highly stable and 
soluble ASD with stability of more than a year at room temperature. Solid-State Nuclear Magnetic 
Resonance spectroscopy (ssNMR) was introduced as a method for analysing the presence of 
amorphous IBU in ASDs. It was shown that the crystalline IBU has no interaction with polymeric 
excipients, whereas amorphous IBU has contributed to hydrogen bonding (i.e. difference in 
chemical shift between IBU in ASD form and bulk IBU) with Kollidon VA 64.  
To further investigate the effect of processing technique on the formation of ASDs, chapter 
three is dedicated to preparing and analysing ASDs with three solvent-based processing 
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techniques; SD, electrospinning (ES) and rotary evaporation (RE). The study was performed using 
IBU as a BCS class II API. It was shown that despite the huge difference in the drying mechanism 
of these methods, the formation of ASD is solely formulation dependant. However, assessing the 
quality of prepared ASDs (i.e. homogeneity) via Principle component analysis (PCA) Raman 
spectroscopy indicated a significant difference between samples produced by each of the three 
processing techniques. Results showed a significant level of inhomogeneity in samples prepared 
via ES. The homogeneity of ASDs is critical for their stability over long term storage as the large 
clusters of API may act as nucleation sites for crystalline API. Therefore, preparing ASDs with 
different techniques in addition to qualitative analysis of homogeneity is the recommended 
approach for developing successful ASDs.  
Chapter four of this thesis is focused on developing a rational approach for SD of 
biopharmaceuticals by investigating lysozyme as a model large molecule API. While lysozyme 
was the model API, the primary aim of this work was to develop and methodical and informative 
approach to better understand the interaction between formulation and process factors affecting 
large biomolecules during the spray drying process. A full factorial DoE was used to study the 
effect of feed rate, solid concentration, Tout and nozzle type on the physicochemical properties e.g. 
particle size distribution and residual moisture content and retained enzymatic activity. In addition, 
potential sources of inactivation during the spray drying process (e.g. type of nozzle, temperature) 
were examined through forced deactivation studies. A thorough consideration should be made for 
selection of the equipment configuration as for instance in the case of lysozyme, spraying via 
ultrasonic nozzle led to ~50 % less enzymatic activity compared with 2-fluid nozzle. Moreover, 
forced deactivation studies were used to model the loss of activity of lysozyme over the range of 
outlet temperatures (Tout) and wet-bulb temperature (Twb). The approach of defining the critical 
factors affecting bioactivity using a DoE, performing forced deactivation studies and optimising 
the formulation and process accordingly, is proposed as a future roadmap for assessing the 
suitability of large biomolecules and biopharmaceuticals to spray drying. 
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7 Chapter Seven: Future Directions  
The application of SD for preparing ASDs and stabilizing large molecule APIs has been 
reported in the literature and applied practically for commercially available drugs. The continued 
emergence of more complex drugs through R&D production pipelines requires a comprehensive 
understanding of the interplay between process and formulation factors and their effect on the final 
properties of products.  SD is not only a way to formulate APIs but can also be critically important 
for engineering the physical properties of powders such as flow properties, micronization of 
particles and engineering the morphology of the particles. 
To further develop the ideas presented in this thesis, the author suggests the following 
studies: 
1. Use of different types of nozzles such as ultrasonic and 3-fluid to study the effect of 
these atomization techniques specifically on morphological and powder flow properties 
of the powders. Specifically, investigate the potential use of the particle engineering 
approach of each of these nozzles for preparing powders for specialized applications 
such as pulmonary delivery. Also, encapsulating drugs via 3-fluid nozzle can lead to 
developing appropriate formulations for applications such as transdermal drug delivery 
or controlled release of drugs. The comparison of the properties of the materials 
developed via each of these strategies would be highly beneficial in selecting the 
appropriate formulating approach.  
2. All the spray drying runs in this thesis have been done using a BUCHI B-290 lab scale 
spray dryer. However, in order to transfer the proposed applications and processes from 
lab scale to manufacturing scale, a comprehensive scale-up strategy is required. Test 
runs on a pilot-scale spray dryer and subsequent adaptation to large scale is the current 
approach in industry which could be implemented on the strategies and materials 
developed in this thesis to further investigate their scalability.  
3.  Pulmonary delivery of large and small molecule APIs is the preferred route of 
administration over other drug delivery forms such as subcutaneous injection which is 
the most common route for delivering proteins such as insulin. A few pulmonary 
delivered large molecule APIs have reached the market; however, they suffered of low 
sale numbers mostly due to technological problems. Exubera developed by Pfizer for 
135 
 
insulin delivery was one of the first examples that the main reasons of its failure have 
been explained in the first chapter of this thesis. Therefore, there is a good potential for 
further investigation of SD of large molecule APIs for the purpose of pulmonary 
delivery. Preparing variable dose formulations for dry powder inhalers (DPI) for more 
personalised medicine, specifically at high dosages is a challenge that needs to be 
overcome.  
4. The application of SD for particle engineering of excipients is another research theme 
that impacts the field of orally and pulmonary administered APIs. An example of using 
SD in combination with a surfactant/s to manipulate the morphology of lignin carriers 
to enhance its flowability and compressibility properties has been shown in one of the 
author’s publications. A similar strategy can be applied to carriers used for pulmonary 
delivery applications as long as the limitation in particle size (2-5 µm) are followed.  
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8 Appendix A: Supplementary Data for Chapter Two 
 
Figure 8.1; Final particle size [D50] of the spray dried samples. 
 
 
Figure 8.2; DSC thermograms of the PXRD-crystalline spray dried samples. The percentage of crystallinity of the 




Figure 8.3; Atomic structure of ibuprofen 
 
 
Table 8.1; Peak assignments and 13C NMR chemical shifts of bulk ibuprofen and ibuprofen in samples 1 and 4, as 
determined by simulation of the 13C CP/MAS NMR spectra. 
 δiso / ppm 
Assignment Bulk Sample 1 Sample 4 
C1 183.0 183.0 177.9a 177.2a 
C7 142.0 142.0 
139.8a 140.0a 
C4 137.2 137.2 
C5, C6, C8, 
C9 
≈127-132 ≈127-132 - ≈127-132 
C10 45.8 45.7 - - 
C2 44.0 44.0 - - 
C11 32.4 32.3 - - 
C13 24.9 24.9 - - 
C12 21.9 21.8 - - 
C3 15.3 15.2 - - 





9 Appendix B: Supplementary Data for Chapter Three 
 
Figure 9.1; Powder X-ray diffraction (PXRD) patterns of IBU-HPMCAS samples prepared by Electrospinning (ES), 
Rotary Evaporation (RS) and Spray Drying (SD) after 9 months storage at room temperature in closed vials. 
 
 
Figure 9.2; Powder X-ray diffraction (PXRD) patterns of IBU-HPMCP-HP55 samples prepared by Electrospinning 


















Figure 9.5; SEM images of electrospun samples: (a) 1:9 IBU:HPMCP-HP55 (red circle shows beads on string 
morphology), (b) 3:7 IBU:HPMCP-HP55 (red rectangle shows the needle-like crystal of IBU), (c) 5:5 IBU:HPMCP-HP55, (d) 
7:3 IBU:HPMCP-HP55, (e) 9:1 IBU:HPMCP-HP55. 
 
 
Figure 9.6; SEM images of electrospun samples: (a) 1:9 IBU:HPMCAS, (b) 3:7 IBU:HPMCAS, (c) 5:5 IBU:HPMCAS, 
(d) 7:3 IBU:HPMCAS, (e) 9:1 IBU:HPMCAS. 
 





Figure 9.7; SEM images of rotary evaporated samples: (a) 1:9 IBU:HPMCP-HP55, (b) 3:7 IBU:HPMCP-HP55, (c) 
5:5 IBU:HPMCP-HP55, (d) 7:3 IBU:HPMCP-HP55, (e) 9:1 IBU:HPMCP-HP55. 
 
 
Figure 9.8; SEM images of rotary evaporated samples: (a) 1:9 IBU:HPMCAS, (b) 3:7 IBU:HPMCAS, (c) 5:5 





Figure 9.9; SEM images of spray dried samples: (a) 1:9 IBU:HPMCP-HP55, (b) 3:7 IBU:HPMCP-HP55, (c) 5:5 
IBU:HPMCP-HP55, (d) 7:3 IBU:HPMCP-HP55, (e) 9:1 IBU:HPMCP-HP55. 
 
 
Figure 9.10; SEM images of spray dried samples: (a) 1:9 IBU:HPMCAS, (b) 3:7 IBU:HPMCAS, (c) 5:5 





Figure 9.11; FTIR spectra of samples produced via rotary evaporation (RE) using HPMCAS (a) and HPMCP-HP55 
(b) as excipient. 
 
 










Figure 10.1; Schematic representation of a two-fluid nozzle; the feedstock meets atomizing air at the tip of the nozzle 
and breaks up into droplets (Ziaee et al., 2019). 
 
 
Figure 10.2; Schematic representation of ultrasonic nozzle; the liquid feedstock breaks up into droplets at the tip of the 







Figure 10.3; Normal plot of screening the critical factors affecting D50 of spray dried powder via 2-fluid nozzle 
showing that feed rate and solid concentration are the most significantly effective factors, (b) actual versus predicted plot D50 of 




Figure 10.4; (a) Normal plot of screening the critical factors affecting retained activity of spray dried powder via 2-
fluid nozzle showing that Tout is significantly effective factor, (b) actual versus predicted plot of retained activity of spray dried 






Figure 10.5; (a) Normal plot of screening the critical factors affecting retained activity of spray dried powder via ultrasonic 
nozzle showing that Tout is significantly effective factor, (b) actual versus predicted plot of retained activity of spray dried 
powder via ultrasonic nozzle based on the fitted least squares model shows the good quality of the fit with R2=0.84. 
 
 
Figure 10.6; Normal plot of screening the critical factors affecting D50 of spray dried powder via ultrasonic nozzle 
showing that feed rate and solid concentration are the most significantly effective factors, (b) actual versus predicted plot D50 of 






Figure 10.7; PXRD of spray dried lysozyme via 2-fluid nozzle per DoE. No crystallinity could be detected in samples. 
The samples spray dried via ultrasonic nozzle were amorphous as well.  
 
ZIAEE, A., ALBADARIN, A. B., PADRELA, L., FEMMER, T., O'REILLY, E. & WALKER, G. 2019. 
Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental 
process optimization approaches. European Journal of Pharmaceutical Sciences, 127, 300-318. 
 
 
 
 
 
 
